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CHAPTER I
Introduction
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Scope of this thesis
This thesis focuses on the use of chemical genetics to study two different aspects of
membrane biology, (a) the mechanisms underlying cellular lipid transport and (b) the
intersection between endocytic and exocytic traffic. The broad goals of chemical genetics are to
find novel chemical tools to study biological systems and to identify novel molecular players
therein. A key advantage of small molecules is their ability to rapidly and reversibly interfere
with biology which qualifies them as ideal reagents to study the dynamics of complex processes
(1, 2).
Cellular cholesterol homeostasis is maintained at the level of synthesis and catabolism of
cholesterol, and through regulation of cellular lipid import and -export. Lipids can be acquired
from the extracellular environment by receptor-mediated endocytosis of specialized carriers,
such as low-density lipoproteins (LDL), or by dedicated surface membrane transport proteins
(3). LDL-receptor mediated endocytosis moves LDL particles into endosomal/lysosomal
compartments where cholesterol and other lipids are transferred into the cell proper,
concomitantly with the degradation of the lipoprotein (4). In contrast, surface membrane lipid
transporters directly transfer lipids between extracellular ligands and the cell surface bilayer
independent of cellular endocytic activity. The transport mechanisms of two lipid transport
proteins, Scavenger Receptor, Class B, type I (SR-BI), and ABCA1 (ATP Binding Cassette
transporter A1), are investigated in the first part of this thesis. Both transporters play critical
roles in lipoprotein metabolism, atherosclerosis and cardiovascular disease (5, 6).
The second part of this thesis describes a study of the mechanisms of intracellular
trafficking. For a multicellular organism to function properly, it is imperative that cells
coordinate their activities. Careful modulation of exocytic- and endocytic traffic allows cells to
communicate with each other via controlled surface expression of membrane proteins, and via
the secretion and internalization of soluble molecules. The information that these soluble
molecules carry can be interpreted in autocrine, paracrine or endocrine fashion. Because many
molecules need to be directed (and restricted) to their appropriate intracellular location following
their cellular synthesis or acquisition from the outside world, controlling cellular trafficking also
ensures the preservation of the identity of subcellular compartments. Finally, to fulfill their
metabolic needs, cells use intracellular trafficking pathways to take up nutrients, and other
molecules they cannot synthesize, from the outside world (3). Experiments described in the
second part of this thesis aspire to characterize molecular elements that regulate both endocytosis
and exocytosis. This line of research experiments is motivated by a desire to deepen our
understanding of the basic machinery of cellular traffic.
Part I, Cholesterol Homeostasis
An overview
Cholesterol is indispensable for numerous cellular functions, including cell signaling,
protein modification and synthesis of a variety of biologically active molecules such as steroid
hormones and bile acids. In addition, cholesterol performs a structural role in cellular
membranes. This puts a strict demand on the maintenance of cholesterol homeostasis, which can
be accomplished by controlling cholesterol synthesis and -metabolism, and by bi-directional
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cholesterol transport between cells and dedicated carriers, called lipoproteins
1
, in the circulation
(3).  
Synthesis of cholesterol is a multi-step process carried out by a large number of enzymes
that reside either in the cytosol or at the membrane of the endoplasmic reticulum. Because excess
of cellular cholesterol can be toxic (e.g. (7)), cells have the capacity to reduce cholesterol levels
by negative feedback mechanisms that put a brake on cholesterol synthesis, and by storing
cholesterol in lipid droplets in the form of cholesteryl esters. In addition, lipid transport proteins
can donate (excess) cellular cholesterol to extracellular carriers such as high-density lipoproteins
(HDL). Conversely, when cholesterol levels are low, cells may respond by increasing cholesterol
synthesis or acquisition of cholesterol from HDL, LDL and other lipoproteins in the circulation.
This requires specialized surface LDL-receptors to internalize low-density lipoproteins into a
lysosomal compartment, where cholesterol is made available to the cell upon degradation of the
lipoprotein. Other membrane receptors (e.g. SR-BI) act as lipid transport proteins to transfer
lipids from lipoproteins to cells without the concomitant internalization of receptors or
lipoproteins (3). The role of endocytosis in lipid transport mediated by SR-BI is investigated in
chapter IV of this thesis. The precursors of LDL (very low density lipoproteins or VLDL) and
HDL (pre-!-HDL, see below) are assembled in the liver and mature in the circulation to the final
product (6). A more detailed description of lipoprotein metabolism is beyond the scope of this
thesis.
Genetic- and environmental (high fat, western-style diet; sedentary lifestyle) factors can
have a severe impact on cholesterol homeostasis, potentially leading to the development of life-
threatening diseases such as atherosclerosis and cardiovascular disease (CVD). Indeed, many
genetic disorders have been identified that alter expression and/or activity of lipoprotein
receptors, as is the case with LDL-R (in familial hypercholesterolemia) (8), lipid transporters
(such as ABCA1 in Tangier Disease (9-12), ABCG5 and ABCG8 in sitosterolemia (13-15)),
apolipoproteins (e.g. in familial defective apolipoprotein B-100 (16)), or enzymes involved in
cholesterol synthesis or metabolism (17). A famous risk factor associated with cholesterol-
related diseases is the level of HDL and LDL in the plasma. HDL is also known as good
cholesterol because high levels of this lipoprotein inversely correlate with the chance of
developing atherosclerosis and CVD. As detailed below, this has subsequently been attributed to
the role of HDL in reverse cholesterol transport. In contrast, high LDL levels predispose for the
development of these diseases. LDL is referred to as bad cholesterol because, paradoxically, its
beneficial function as a cholesterol-delivery vehicle can unintentionally wreak havoc during an
inflammatory response in the arterial system, which may lead to activation of specialized cells
called macrophages. These cells develop the capacity to vigorously internalize cholesterol from a
modified (oxidized) form of LDL, which arises when plasma LDL levels are high. Consequently,
these macrophages transform into lipid-laden foam cells, marking the beginning of what could
become an atherosclerotic plaque. A growing plague progressively reduces the blood flow
through the vasculature, thereby depriving tissues from oxygen and nutrient (ischemia). If the
plaque grows to a size that severely or completely occludes the arteries that serve the heart or the
                                                 
1
  Lipoproteins are spherical assemblies of a lipid core and an outer shell composed of characteristic apolipoproteins
and lipids, which differ from those within the core. Different classes of lipoproteins are recognized based on their
protein components and lipid content, and hence the density of the particle. For instance, apoA-I is the most
prominent apolipoprotein in HDL, and apoB the sole protein found in LDL. The location of the lipids in the
lipoprotein depends on their physico-chemical properties; amphipatic phospholipids and unesterified cholesterol are
found in the outer shell and triglycerides and cholesteryl esters are located in the core.
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brain, or when a blood clot forms upon rupture of the plaque, a heart attack or a stroke may
result. LDL levels thus positively correlated with the chance of developing arteriosclerosis and
cardiovascular disease (3).
Scavenger Receptor, class B, type I (SR-BI)
SR-BI was identified as the first authentic cell surface receptor and lipid transporter for
high-density lipoproteins (18). In a process called selective uptake
2
 (19-21), SR-BI transfers
lipids from extracellular HDL (18) or LDL (22, 23) to cells. Cholesteryl esters are important
lipids to be transported, but other lipids (unesterified cholesterol, phospholipids, triglycerides)
and hydrophobic molecules (!-tocopherol) can be transferred too (24-31). Unlike lipid uptake
from LDL via the LDL-receptor (4), SR-BI mediated selective uptake does not require
degradation of the lipoprotein (18) or endocytosis of the receptor-lipoprotein complex (see
chapter IV of this thesis and (32)).
SR-BI is predicted to have two transmembrane domains and short intracellular N- and C-
terminal tails (33). Due to heavy glycosylation, the apparent molecular mass of this 57kDa
protein is about 82kDa (34). Genetic and chemical genetic analysis (chapter II of this thesis) and
a functional comparison to the SR-BI family member CD36 have shown that binding of
lipoproteins to the extracellular portion of SR-BI is required, but not sufficient, for selective
uptake to occur (35-37). Thus, SR-BI mediated selective uptake is a two-step process, which
demand a so-called productive binding of HDL to the receptor followed by the physical lipid
transfer to the cell (35, 38).
True to its name, SR-BI is able to recognize a variety of molecules, such as proteins (e.g.
apoA-I (39-41)), lipids (anionic phospholipids) (42, 43) and carbohydrates (lipopolysacharides
[LPS] (44), advanced end-linked glycan [AGE] modified proteins (45)). A physiological
relevance has been assigned for the interaction with lipoproteins, (e.g. HDL, LDL, chylomicrons
(46) and see (6)), but for others, including apoptotic cells (42, 47) and hepatitis C virus (48), this
remains to be established.
Reverse cholesterol transport
In murine experimental models, genetic manipulation of SR-BI expression levels has
demonstrated an important role for SR-BI and HDL in reverse cholesterol transport (RCT), a
process believed to offer protection against atherosclerosis and cardiovascular disease (49-56). In
reverse cholesterol transport, cholesterol is moved from extra-hepatic tissues to the liver. In
addition, cholesterol can also be transported to steroidogenic tissues. RCT avoids accumulation
of pathological levels of cholesterol in peripheral tissues, such as arterial macrophages. The first
step of reverse cholesterol transport is efflux of cellular unesterified cholesterol, potentially
mediated by ABC proteins (57) (as will be further explained in a following section), to spherical
HDL (!-HDL) bound to non-hepatic cells. In the circulation, HDL is subsequently remodeled by
a variety of enzymes, such as lecithine cholesteryl acyl transferase (LCAT), which catalyzes the
conversion of unesterified cholesterol to cholesteryl esters (58).
SR-BI mediated selective uptake of HDL cholesteryl esters and other lipids occurs
predominantly in the liver and steroidogenic tissues (testis, ovaria, adrenal gland), the tissues that
express the highest levels of SR-BI (59). Steroidogenic tissues hydrolyze cholesteryl esters to
produce cholesterol, which is used to synthesize steroid hormones. In the liver, a portion of the
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 Although SR-BI independent selective uptake pathways exist, this thesis will refer to selective uptake as SR-BI
mediated selective uptake.
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cholesteryl esters is stored in lipid droplets, secreted into the bile after conversion to bile acids,
or reused for biogenesis of nascent HDL and other lipoproteins. In addition to SR-BI mediated
selective uptake, a fraction of the cholesterol in HDL can be transferred to LDL in the form of
cholesteryl esters by cholesteryl ester transfer protein (CETP), which then can be delivered to the
liver via LDL-receptor mediated endocytosis (6, 60).
Cholesterol efflux from macrophages to HDL in the first phase of reverse cholesterol
transport is presumed to be facilitated by members of the ATP-binding cassette (ABC)
transporter family, of which ABCA1 (61) and, more recently, ABCG1 and ABCG4 have
received the most attention (57). In this context, it is worth mentioning that SR-BI can also
mediate efflux (as well as selective uptake) of unesterified cholesterol (but not cholesteryl esters)
from cells to HDL, LDL and other non- lipoproteins carriers (24, 38, 62). This efflux pathway
may represent either a net efflux or an exchange process at steady state, depending on the
direction of the cholesterol concentration gradient between cells and lipoprotein particles (63).
Although the physiological relevance of SR-BI dependent lipid efflux is largely unknown, there
is speculation that SR-BI could be responsible for the release of excess cholesterol from
macrophages to HDL. Consistent with this is the observation that targeted expression of SR-BI
in macrophages reduces the development of atherosclerotic lesions (56, 64). However, the role of
SR-BI in the macrophage appears to be complex. Indeed, in relevant mouse models the receptor
promotes formation of atherosclerotic lesions in young animals, presumably by increasing lipid
loading in macrophages as a result of cholesteryl ester selective uptake, but it counteracts plague
development later in life, perhaps by facilitating efflux of cellular cholesterol (65). These results
imply a need to balance the direction of lipid transport by SR-BI.
Physiological importance of SR-BI
By mediating selective uptake, SR-BI is a critical component in moving excess of lipids
from the periphery to the liver and steroidogenic tissues, where there is a use for it, thereby
avoiding atherosclerosis and CVD. In addition, as a consequence of its role in facilitating
selective uptake, SR-BI is crucial in controlling both metabolism and structure of HDL (18, 60).
Maintenance of the HDL pool is required to ensure that sufficient lipid carriers are available for
reverse cholesterol transport, and to carry out additional anti-atherogenic activities. For instance,
HDL reduces pro-inflammatory LDL oxidation and promotes the release of anti-inflammatory
nitric oxide (NO). Indeed, HDL binds molecules with anti-oxidant properties such as the enzyme
paraoxonase and !-tocopherol, the biologically active form of vitamin E (28, 30). Paraoxonase
reduces the lipid-peroxidation level of pro-atherogenic modified LDL lipoproteins, whose uptake
by macrophages otherwise promotes formation of atherosclerotic lesions (66, 67). Binding of
HDL to SR-BI leads to the production of the anti-inflammatory signaling molecule NO by eNOS
(endothelial Nitric Oxide Synthase) (68). NO stimulates relaxation of the endothelial wall,
facilitating circulation of the blood. Nitric oxide is also known to reduce the risk of arterial
plaque formation by modulating leukocyte and platelet adherence to the endothelium (69). The
molecular mechanisms of SR-BI and HDL mediated eNOS activation are somewhat
controversial. SR-BI mediated lipid selective uptake is believed to stimulate localization of
eNOS to caveolae (70). Here, eNOS activity is induced by HDL associated lysophospholids (71)
and/or estradiol (72) via stimulation of signaling cascades that rely on protein- and lipid kinases
(73), synthesis of ceramide lipids (74) and/or mobilization of intracellular Ca
2+
 (69). Further
anti-atherogenic activities ascribed to SR-BI are based on the increase in expression of genes
involved in adhesion and transendothelial migration of monocytes in SR-BI null mice, which is
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speculated to be caused by alterations in cholesterol homeostasis. This has led to the proposal
that the receptor may control inflammatory responses in aortic vessels (75).
In addition to the effects on arteriosclerosis and cardiovascular disease, the physiological
significance of SR-BI is further highlighted in female fertility (49) and reticulocyte maturation
(76), which are both compromised in SR-BI deficient mice. This may be related to changes in
lipoprotein metabolism and, consequently, in cellular cholesterol levels (76, 77). Contrary to
expectation, infertility cannot be explained by insufficient production of steroid hormones in the
ovaries, such as progesterone, because this appears to be adequate (49).
The cellular mechanism of SR-BI mediated selective uptake
 Although a wealth of information is available on the physiological effect of SR-BI in
various disease models and on lipoprotein metabolism, and on the details of lipoprotein binding,
a physical and biochemical understanding of the lipid transport mechanism is limited.
It is now generally accepted that binding of lipoproteins to SR-BI is necessary for
selective uptake to occur. Williams, Phillips and colleagues hypothesized that SR-BI forms a
channel through which lipids are transported from the lipoprotein into the cell (78). An
alternative model by Krieger and co-workers proposes that lipid transfer is dependent on hemi-
fusion of lipids in the outer shell of HDL and the outer leaflet of the plasma membrane, allowing
for movement of core cholesteryl-esters into the surface membrane (35). There is speculation
that oligomerization of SR-BI is required for selective uptake to occur (79).
Mice deficient in SR-BI show changes in lipoprotein profiles, most notably an increase in
the size and lipid- and protein composition of HDL particles (50). This has led to the idea that
transfer of lipids from HDL reduces the physical size of the lipoprotein, which is considered to
be sufficient to reduce the apparent affinity of SR-BI for HDL, allowing for the release of the
lipoprotein (38, 80-83). This liberates the receptor for another round of selective uptake with a
newly incoming lipoprotein.
 Genetic- and chemical genetic approaches have been applied to understand the
relationship between lipoprotein binding, lipid transfer and other activities of SR-BI. These
studies have demonstrated that lipoprotein binding is required for lipid transport to occur, and
that both processes are tightly coupled (35-37). Differences exist between HDL and LDL with
regard to binding to SR-BI (84). Suggestions that SR-BI needs to form a special membrane
microenvironment at the surface to facilitate selective uptake (85) have recently been discredited
(86). Furthermore, the mechanisms of SR-BI mediated selective uptake and efflux may share
similarities, but they do not need to be identical. Indeed, cholesterol efflux is less sensitive to
certain chemical inhibitors targeting SR-BI activity (37), and genetic mutations in SR-BI reduce
cholesterol efflux more pronounced than selective uptake (79). Finally, the exploitation of yet a
different set of SR-BI mutants has indicated that cholesterol efflux to HDL may differ from
efflux to non-lipoprotein acceptors (86).
It is clear from in vitro reconstitution experiments in liposomes that SR-BI supports
selective cholesteryl-ether (a non-hydrolyzable analogue of cholesterol-esters) uptake without
the need for accessory proteins or specialized lipid environments (87). However, this does not
preclude that other factors may modulate the efficiency of SR-BI dependent lipid transport in
vivo. Indeed, hepatic lipase (88) and lipoprotein lipase (89) are reported to facilitate cellular
selective uptake, but this seems to be independent of SR-BI (although for a different view on
hepatic lipase see (90)).
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Cellular location of SR-BI mediated selective uptake
Currently, it is uncertain whether (cholesteryl ester) selective uptake from HDL requires
endocytosis of the lipoprotein. Selective uptake was originally assumed to be a cell surface
event, without the need for internalization or degradation of the receptor or the lipoprotein (as
observed for lipid uptake from LDL via the LDL-receptor pathway (4)). This statement is based
predominantly on electron microscopic- and biochemical analysis showing a lack of internalized
HDL particles in a variety of primary and immortalized cell lines, and on the observation that
selective uptake is accompanied by very little degradation of HDL (18-20, 91-93). By depleting
cells of ATP, it was recently shown that endocytosis of HDL is not needed for SR-BI mediated
uptake of fluorescent cholesterol analogues from HDL. However, it was suggested that this may
be different for the transfer of esterified cholesterol (32). Finally, SR-BII, an alternative splice
form of SR-BI that differs only in the short C-terminal intracellular segment (94), efficiently
internalizes HDL particles into an intracellular environment that appears not to be optimal
equipped for lipid transport (95). Together, these data suggest that SR-BI mediated selective
uptake occurs at the cell surface.
In sharp contrast to this ‘cell surface model’, Silver and co-workers have proposed that
SR-BI mediated selective uptake occurs intracellularly (96). This is supported primarily by their
observation that a (small amount) of fluorescently labeled HDL is endocytosed in primary
hepatocytes and cell lines expressing recombinant SR-BI (96), and on experiments which show
that a reduction in HDL recycling is associated with diminished selective uptake in ob/ob mice
(97). Indeed, it had been shown before that HDL particles can be internalized by a variety of
cells, but these studies did not examine a possible involvement of SR-BI (98-105), and SR-BI-
independent endocytic pathways for HDL are recognized too (e.g. via the cubulin-megalin
receptor pathway (106-108)). In this thesis, a functional link is investigated between SR-BI
mediated selective uptake of cholesteryl esters and endocytosis of lipoproteins. The results
presented in chapter IV suggest that selective uptake from HDL or LDL carried out by SR-BI
occurs at the cell surface and does not require endocytosis of the lipoproteins.
Intracellular components of SR-BI mediated lipid transport
Cholesteryl esters transferred to the cell via SR-BI mediated selective uptake first enter a
reversible membrane pool, meaning that the lipids can be shuttled back to HDL (19-21), and
subsequently move into an irreversible pool (109, 110). One study has proposed that the lipids
are irreversibly incorporated in a soluble, non-membranous, cytosolic complex consisting of the
cholesterol-chaperone caveolin, cyclophilin A, cyclophilin 40 and Annexin II before entering an
internal membrane compartment(s) of unknown identity (111). In favor of a role for
caveolin/caveolae in lipid transport is the observation that SR-BI and caveolin-1 are found by
immunofluorescence and biochemistry in the same subcellular fraction (34). However, a
confounding fact is cells that do not express caveolin support efficient SR-BI mediated lipid
transport, suggesting that the caveolin protein is dispensable (112, 113). This is substantiated by
recent high-resolution electron microscopy analysis showing that SR-BI and caveolin are
juxtaposed, but not colocalized, in specialized membrane structures (91). Still other reports claim
that caveolin is a negative regulator of selective uptake by SR-BI (114). Clearly, a more
thorough study is required to fully comprehend the role of caveolin in SR-BI mediated lipid
transport.
It is not unlikely that the mechanistic details of SR-BI activity depend on the cellular
context, and this may at least in part account for the apparent contradictory results on the role of
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caveolin. An example is offered by studies of PDZKI knock-out mice. PDZK1 is a scaffold
protein that post-translationally stabilizes hepatic SR-BI (115). It binds the C-terminal
intracellular domain of the receptor (116). In PDZKI deficient mice, hepatic SR-BI levels are
undetectable, and HDL levels and -metabolism are affected consequently in a manner similar to
animals that do not express SR-BI. Importantly, the effect of PDZK1 deficiency on SR-BI
expression is a cell-type specific phenomenon, because the steady-state level of SR-BI protein is
only decreased in the liver and not in steroidogenic tissues, the other major site of SR-BI
expression (115).
Events downstream of the initial selective uptake step have been probed with chemical
reagents. These studies revealed for instance that HDL and LDL-born cholesteryl esters are
hydrolysed by neutral hydrolases in a compartment of unknown identity (117).
 ABCA1
ABCA1 is a member of the family of ATP Binding Cassette (ABC) transporters, which is
characterized by the ability to transport small molecules (xenotoxins, endogenous metabolites,
lipids) across cellular membranes in an ATP dependent fashion (118). ABCA1 is a full
transporter, meaning that it consists of twelve transmembrane helices, two large extracellular
loops and two intracellular Walker A/B motifs responsible for ATP-hydrolysis (12, 119, 120).
Several ABC proteins, including ABCA1 (9-12), ABCA7 (121-123), ABCG5 and ABCG8 (13-
15), ABCG1 and ABCG4 (57) and ABCB11 (124) have been implicated in cholesterol
homeostasis and/or cellular lipid transfer.
The physiological importance of ABCA1 became apparent in Tangier disease patients,
who suffer from neuropathies, splenomegaly, hepatomegaly, ocular abnormalities,
hypocholesteremia and cardiovascular disease (125). Similar to ABCA1 null mice (126-128),
these patients accumulate cholesterol in peripheral macrophages in many of the affected organs
and they have almost undetectable levels of serum HDL (9-12). The latter is the opposite finding
of SR-BI deficient mice, which display an increase in the size of HDL, and a change in lipid and
protein composition of this lipoprotein (50).
The absence of HDL in ABCA1 deficient individuals is consistent with the essential role
of this lipid transporter in the early steps of hepatic HDL biogenesis in the liver, which
synthesizes and secretes apoA-I (the precursor to HDL), and consequently in reverse cholesterol
transport. At the cell surface (but see below for alternative views), ABCA1 catalyzes with low
efficiency the efflux of phospholipids and cholesterol to lipid-free or lipid-poor apoA-I (12, 129-
131). Consensus is emerging that apoA-I is required to bind to ABCA1 (120, 132) and the
surrounding membrane (133) to facilitate lipid transport. It is speculated that ABCA1 needs to
rearrange the membrane into a special microenvironment for apoA-I to bind (133-136). The
lipidated products, called pre-!-HDL, arising from ABCA1 mediated efflux are further
remodeled in the circulation into mature, spherical "-HDL particles (137-140). These particles
serve as acceptors for cholesterol efflux by peripheral tissues and transport excess of lipid to SR-
BI expressing tissues for selective uptake.
While SR-BI and ABCA1 share the ability to transfer lipids from cells to extracellular
carriers, they have mutually exclusive preferences for lipid acceptors. Thus, SR-BI mediates
cholesterol efflux to spherical HDL, but not to apoA-I, and the opposite is true for ABCA1 (12,
24, 38, 62, 129-131, 141). SR-BI binds HDL on the apoA-I moiety (41), but the structural or
conformational determinants on apoA-I that are crucial for interaction differ from those
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necessary for productive interactions with ABCA1 (38, 39, 142). Another difference is that
unlike SR-BI, ABCA1 cannot accommodate cellular lipid import. Notwithstanding these
differences, the fact that both SR-BI and ABCA1 transport lipids between cells and (different
forms of) lipoproteins has catalyzed the research outlined in Chapter III of this thesis, where the
use of small molecule inhibitors has led to the proposal that SR-BI and ABCA1 may share
similar mechanisms of lipid transport.
Similar to SR-BI, the location of ABCA1 mediated lipid efflux is an unresolved issue.
Focus has been aimed at two different, not necessarily exclusive, subcellular locations, being the
cell surface (12, 120, 133, 143-146), and the endo-lysosomal system accessed by apoA-I via
ABCA1-mediated endocytosis (143, 147-150). A third model proposes that at least part of the
newly synthesized apoA-I is lipidated intracellularly in the liver by ABCA1 independent
pathways before being secreted into the extracellular space (151, 152).
In addition to its role in HDL biogenesis, ABCA1 is thought to facilitate transport of
lipids in the initial phase of reverse cholesterol transport, from macrophages in the arterial wall
to HDL (9-11, 128). However, because of the very low levels of free apoA-I in the circulation
(153), and the fact that ABCA1 is unable to transfer lipids to mature HDL (141), this has been a
controversial scenario. Indeed, targeted expression of ABCA1 in macrophages appears to have
only a minor impact on the size of the HDL pool in the circulation (154). An alternative proposal
for the atheroprotective function of ABCA1 in peripheral macrophages is to control the
recruitment of monocytes into the vascular wall (155, 156). One intriguing possibility is that the
newly discovered ABCG1 and ABCG4 proteins, and not ABCA1, may be responsible for
removal of excess lipids to spherical HDL particles in peripheral tissues (57).
Part II: Intracellular vesicular trafficking
Cellular communication, maintenance of cellular compartmentalization and transport of
nutrients all require delivery of molecules to the appropriate addresses. The cell has developed
different trafficking pathways that operate separately, sequentially or in parallel to ensure that
traffic jams do not occur and faulty delivery is avoided. The prevalent route of trafficking
depends on vesicles, but (poorly characterized) vesiculo-tubule based pathways are recognized
too (157). Some of these sorting routes are cell-type specific, such as the basolateral sorting
mechanisms along the exocytic trajectory of polarized cells (158).
Vesicular trafficking requires sequestration of select cargo into designated coated
vesicles. Nascent coated vesicles bud from the membrane, after which the coat is shed and the
naked vesicle moves to its specific destination, sometimes directed by actin- or microtubule
tracts. Fusion with the acceptor membrane releases the vesicular cargo into the correct
subcellular compartment (157).
Coated vesicle-based trafficking
Transport pathways can be discriminated based on whether they rely on coats to form
vesicles, and if so, what class of coat proteins is employed. Four different, well-studied, coated
vesicle species exist: clathrin-, COPI-, COPII- and caveolin-based vesicles (157).
The basic mechanistic steps of these coat-operated traffic routes are similar (coat
formation, vesicle budding and detachment, coat release, fusion with acceptor membrane), but
the molecular details differ. Cargo (soluble and membrane proteins, lipids) is selected by specific
cargo receptor proteins, often based on recognition of specific molecular tags (peptide sequences,
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carboydrate groups) presented by the cargo. The cargo receptors physically tether their load to
coat proteins in the growing coated vesicle, sometimes at designated subcellular locations (e.g.
exit sites at the endoplasmic reticulum [ER] (159)). Coat proteins nucleate the formation of
membrane vesicles from a planar membrane by recruitment of other coat components. The
unique combination of coat protein and cargo receptors defines the nature of the transport
pathway and its destination (157).
Clathrin coated vesicles are employed in endocytosis and exocytosis to transport soluble
and transmembrane proteins, of which a subset collects cargo from the extracellular milieu.
Endocytosed material is either recycled back to the surface or targeted to the endo-lysomal
system. Clathrin vesicles are also used at the trans-golgi network (TGN) to sort exocytic cargo to
the endo-lysosomal compartment or to the basolateral cell surface (157, 158). Recent advances in
single molecule tracking by fluorescence microscopy have for the first time visualized the early
events in clathrin-mediated endocytosis (160).
In the exocytic trajectory, COPII vesicles bud from the ER and shuttle newly synthesized
proteins to the Golgi-apparatus. COPI based vesicles move material in the opposite direction, at
least in part to retrieve mistargeted proteins from Golgi back to the ER. In addition, COPI
vesicles may also guide forward transport between the Golgi cisternae (157) (an alternative view
is that intra-Golgi movement does not require vesicle transport, but relies on maturation of the
different Golgi cisternae (161)) Some toxins, such as cholera toxin, hijack the COPI-retrograde
route to gain access to the ER from the Golgi apparatus after they enter the cell. Recently, a
chemical genetic study has shown that cholera toxin still can access the ER when the Golgi-
apparatus is chemically destroyed, demonstrating the existence of alternative retrograde
trafficking routes (162).
In addition to cargo receptors, a large variety of other proteins are specifically associated
with the different coated vesicle species. They fulfill important roles in recruitment of the
ligands, coat formation, detachment of the coated vesicle from the membrane and the final step
of uncoating. Coats are strictly required for vesicle formation. Upon detachment of the vesicle
from the membrane, coat proteins are released as individual subunits and recycled for a new
round of vesicle formation (157). At least a subset of the resulting naked vesicles is attached by
motor proteins to cellular networks of actin (for short range transport) or microtubules (for
trafficking over long distances) for transport through the cytosol to the correct destination (163,
164). Different classes of vesicles utilize distinct motor proteins. At the acceptor site, docking
proteins, including SNAREs, catalyze fusion of the vesicle with the acceptor membrane,
allowing release of the vesicular content into the appropriate subcellular compartment (157).
The regulation of intracellular trafficking is not limited to protein-protein interactions.
Important roles are set aside for lipids. For instance, the local synthesis and concentration of
phospoinositol-4,5-bisphosphate is required to dock cargo receptors for clathrin-based vesicles at
the cell surface (157). Changes in the levels of membrane cholesterol are also reported to
influence trafficking (165), once again underscoring the importance of maintaining cellular
cholesterol homeostasis.
Lipid rafts and caveolae
Coat structures named caveolae, made of the coat protein (and cholesterol chaperone)
caveolin, have been suspected for a long time to guide cellular trafficking, but few cargo proteins
have been identified. There is evidence that caveolae guide transcytosis of albumin in endothelial
cells (e.g. (166)) and certain viruses may use this pathway to enter the cell (167-170). In addition
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to their role in trafficking, caveolae are also thought to function as signaling scaffolds (171), for
instance as described before for the case of eNOS signaling.
Cholesterol and sphingholipids can be tightly packed in lipid rafts in the membrane.
Although somewhat controversial, rafts are proposed to mediate apical sorting from the TGN to
the cell surface (172) and endocytosis of a particular class of post-translationally modified
proteins tagged with either glycosylphosphatidylinositol (GPI), palmitoyl, dual acyl chains or
cholesterol (173). Similar to caveolae, rafts are proposed to function as platforms for intracellular
signaling, by limiting the lateral diffusion of membrane-associated receptor proteins (174).
A chemical link between the exocytic- and the endocytic pathway
Coated-vesicle dependent exocytosis shares many similarities with coat-dependent
endocytic transport. To further characterize these similarities, small molecule inhibitors of
exocytosis (175, 176) were used to search for molecules that regulate both endocytic- and
exocytic traffic (Chapter V of this thesis). This has led to the discovery of a novel class of
inhibitors that block intracellular transport by preventing Vacuolar-ATPase mediated proton
translocation into the endocytic compartment, and possibly the Golgi (177). Indeed, precise
regulation of intracellular pH is a prerequisite for proper intracellular transport as detailed in the
following section.
The role of pH homeostasis in membrane traffic
The maintenance of the intracellular pH is a key requirement for optimal intracellular
traffic, as well as many other biological processes, including kidney function and bone
resorption. An acidic pH in endosomes is required for dissociation of cargo from receptor, which
allows for recycling of receptors to the cell surface. Similarly, pH regulation in the Golgi
compartment is needed for proper sorting of molecules to the surface, to lysosomes, and for
secretion. The proton pumping activity of Vacuolar proton-translocating ATPases (V-ATPases)
ensures proper pH homeostasis in these compartments. V-ATPases also regulate proton release
from the plasma membrane, thereby affecting the cytoplasmic acid balance (178). Although the
significance remains to be established, it is noteworthy that V-ATPases have been found to
associate with clathrin-coated vesicles (179, 180).
Vacuolar ATPases are composed of two multi-subunit sectors, named Vo and V1. ATP
hydrolysis by the peripheral V1 domain is required for the membrane integral Vo domain to
translocate protons over the membrane against their concentration gradient (178). Not
surprisingly, small molecule inhibitors for the Vo complex abolish many V-ATPase dependent
processes, such as surface receptor recycling (177, 181) and transport through the Golgi and
Trans-Golgi network (177, 182-184). Although speculative, inefficient exocytosis under alkaline
conditions has been attributed to the inability of transport vesicles to fuse with the acceptor
compartment during Golgi-transit (182).
Part III: chemical genetics
The concept of the chemical genetic approach is to screen diverse libraries of chemical
compounds for their ability to interfere with biology on a molecular, cellular or organismal level.
Chemical genetics aspires to find new tools to dissect biology and to use these chemicals in the
search for novel molecular components that operate in the process under scrutiny. An important
consideration for the choice of small molecules is that they are ideally suited to study the
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dynamics of complex processes, due to the fact that in many cases they act within minutes, and
their effects are often reversible. While their value is beyond doubt, classic genetic and RNA-
interference based approaches to study the role of a particular gene (product) may induce
(unwanted) cellular responses to the introduction or deletion of the foreign gene (product). It is
therefore not inconceivable that secondary downstream effects, rather than the biology of the
gene of interest, end up being investigated. This can be avoided with the use of fast acting small
molecules (1, 2).
Historically, small molecules have proven to be invaluable to the study of biology, in
combination with biochemical, cell biological and physiological experimentation. An additional
advantage of small molecule screens is the possibility of discovering novel medicinal drugs. One
of the most famous examples is the fortuitous discovery of the antibiotic penicillin from
Streptomyces sp. by Alexander Fleming in 1929 (185). Cyclosporin A and FK506 helped
elucidate the mechanisms for T-cell activation and graft-versus-host disease (186). The natural
product taxol was found to posses anti-tumor activity and is a used to study microtubule
polymerization (187). Histone deacetylase inhibitors are useful reagents to dissect gene
regulation, chromatin and microtubule dynamics (188) and aging (189), and they are under
consideration for treatment of neurodegenerative diseases (190-192). Brefeldin A (193),
illimaquinone (194) and macrolide antibiotics (195) have been exploited to probe the basic
mechanisms of cellular trafficking pathways and cellular entry of pathogens. Many of these
chemicals were isolated from natural sources such as sponges, fungi or plants based on a
particular pharmacological activity. This strategy was partly born out of necessity, because the
synthesis of large collections of chemicals was at the time not feasible or not available, at least
for academia (196). While the use of (focused) synthetic libraries is the most widespread today,
natural- and natural-like products have regained popularity, partly from the thinking that nature,
over the course of evolution, could have already invented and optimized by trial-and-error small
molecules with potential experimental value (197, 198).
Reverse chemical genetics
Reverse chemical genetics encompasses the development of high-throughput chemical
screens focused on a designated molecular target, protein-protein interactions or enzymatic
activity, considered to be important for a particular biological or pathological process. In analogy
with reverse genetics, chemicals are selected to specifically interfere with a known gene-
product(s), and subsequently used to probe the importance of that gene-product in a biological
system. Sometimes, chemical libraries with specific functional groups are designed, as is the case
with nucleotide analogues (199, 200). Successive rounds of derivatization of the lead compound
are aimed to obtain a highly potent compound that is able to penetrate the cellular membrane
bilayer, does not display cytotoxicity (unless desired), is not readily degraded and still retains its
desired biological activity. This is done sometimes with the knowledge at hand of the three-
dimensional structure of a protein (complex) that revealed an interaction- or enzymatic site, or
some other ‘drugable’ pocket (200). Thus, the advantage of the reverse chemical genetic
approach is that by design the target of the small molecule is known. However, it often remains a
gamble whether the chemical will have the desired effect in vivo, or a potential use in therapeutic
settings (1, 2, 201).
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Forward chemical genetics: shoot first, ask later
A solution to this conundrum is offered by recent developments in high-throughout
screening methodology. Perhaps the most important factor was the realization that the use of
phenotypic screens could potentially overcome the hurdle of finding small molecules that display
activity in vivo. The immediate pay-off is that in this forward chemical genetic approach, ‘hit’
compounds are selected based on an interesting biological phenotype they induce in complex
systems such as cell extracts, intact cells or whole organisms. This is analogous to the
identification of novel genes in forward genetic screens in which cells are generated with a
desired phenotype by, for instance, chemical mutagenesis. As mentioned earlier, one of the two
goals of chemical genetics is to identify novel molecular entities that participate in a biological
process. Unfortunately, chemical target identification has met very limited success and often
requires significant efforts in secondary assays and/or follow-up chemistry to overcome the
notorious low affinity of the small molecules discovered (1, 2). This problem will be discussed
more extensively in Chapter VI of this thesis.
Phenotypic high-throughput screens can be of quantitative nature (fluorescence,
chemiluminescence, colorimetric, densitometric). The value of this approach is that by design the
potency of the ‘hit’ compound is revealed (e.g. (37)), an important parameter to select the most
useful chemicals, especially when target identification is being considered. But perhaps one of
the biggest impacts in screening technology has been made by the development of automated
(fluorescence) microscopy. Together with multi-parameter analysis and powerful computer
algorithms, this has created the possibility of chemical profiling the spatial and temporal effect of
small molecules on cellular- or subcellular behavior in a quantitative manner (202-204). Indeed,
the classification of exocytosis inhibitors by the nature of their perturbation, e.g. blocking ER-
versus-Golgi exit, could only be achieved because the design of the microscopy-based screen
enabled the recognition of the subcellular compartment where traffic was arrested (175, 176).
From the screen it became instantaneously apparent that the effect of at least some of these
chemicals was reminiscent of well-characterized inhibitors of trafficking, which accelerated the
elucidation of the molecular mechanisms underlying the block (175, 177). Arguably, one of the
more exciting applications of microscopy-based phenotypic screening is to probe the biology of
intact organisms, highlighted in a study of the ontogeny of the neural and cardiovascular system
in zebra fish (205).
The evolution in the biological approach towards phenotypic screens came hand-in-hand
with changes in the design of chemical libraries. The ‘old’ synthetic libraries are synthesized
with the idea to stick close to molecules that worked in the past. For instance, adenosine analog
libraries were designed to find novel protein kinase inhibitors (200). More recently, libraries
have been engineered largely from a ‘chemistry-centric’ perspective, with the emphasis on
creating collections that cover a large, chemical space, but that are not necessarily designed to be
optimal biological agents (206). Natural product libraries are thus regaining popularity (207,
208). In addition, a relatively new and focused approach of diversity-oriented synthesis (DOS)
has emerged, in which a synthetic blue print of a natural small molecule is used as a scaffold to
construct a library of (natural-like) products with diverse functional groups (198, 209, 210).
Outline of this thesis
This thesis exploits the chemical genetics approach to study two different aspects of
membrane biology, (a) cellular lipid transport and (b) vesicular trafficking.
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Chapter II of this thesis describes the development of a cell-based quantitative high-
throughput screen for SR-BI mediated selective uptake from HDL. The small molecule inhibitors
identified, named BLTs because they Block Lipid Transport, were used to study the relationship
between HDL binding and selective lipid uptake, and to investigate the mechanisms of selective
uptake and lipid efflux.
The lipid transporters SR-BI and ABCA1 have structurally nothing in common, but they
do share the ability to mediate efflux of lipids to (different) lipoprotein carriers. Small molecule
inhibitors of SR-BI (BLTs) and ABCA1 (glyburide) were thus exploited to probe for the
possibility that these two proteins use similar mechanisms of lipid transport (Chapter III).
 Chapter IV addresses the cellular location of SR-BI mediated selective uptake with the
use of BLTs and inhibitors of endocytic traffic.
 In Chapter V, novel small molecule inhibitors of secretory traffic (175, 176) are used to
identify elements which act as regulators of both the endocytic and the exocytic pathway.
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The high-density lipoprotein (HDL) receptor, scavenger receptor,
class B, type I (SR-BI), mediates both the selective uptake of lipids,
mainly cholesterol esters, from HDL to cells and the efflux of
cholesterol from cells to lipoproteins. The mechanism underlying
these lipid transfers is distinct from classic receptor-mediated
endocytosis, but it remains poorly understood. To investigate
SR-BI’s mechanism of action and in vivo function, we developed a
high-throughput screen to identify small molecule inhibitors of
SR-BI-mediated lipid transfer in intact cells. We identified five
compounds that in the low nanomolar to micromolar range block
lipid transport (BLTs), both selective uptake and efflux. The effects
of these compounds were highly specific to the SR-BI pathway,
because they didn’t interfere with receptor-mediated endocytosis
or with other forms of intracellular vesicular traffic. Surprisingly, all
five BLTs enhanced, rather than inhibited, HDL binding by increas-
ing SR-BI’s binding affinity for HDL (decreased dissociation rates).
Thus, the BLTs provide strong evidence for a mechanistic coupling
between HDL binding and lipid transport and may serve as a
starting point for the development of pharmacologically useful
modifiers of SR-BI activity and, thus, HDL metabolism.
The high-density lipoprotein (HDL) receptor, scavenger re-ceptor, class B, type I (SR-BI), plays an important role in
controlling the structure and metabolism of HDL (1, 2). Studies
in mice have shown that alterations in SR-BI expression can
profoundly influence several physiologic systems, including
those involved in biliary cholesterol secretion, female fertility,
red blood cell development, atherosclerosis, and the develop-
ment of coronary heart disease (3–11). SR-BI controls HDL
metabolism by mediating the cellular selective uptake of cho-
lesteryl esters and other lipids from plasma HDL (1, 2). During
selective uptake (12–14), HDL binds to SR-BI, and its lipids,
primarily neutral lipids such as cholesteryl esters in the core of
the particles, are transferred to the cells. The lipid-depleted
particles subsequently are released back into the extracellular
space. Although the mechanism of SR-BI-mediated selective
lipid uptake and the subsequent intracellular transport of these
lipids have only just begun to be explored (2, 15, 16), they clearly
differ fundamentally from the pathway of receptor-mediated
endocytosis via clathrin-coated pits and vesicles used by the
low-density lipoprotein (LDL) receptor to deliver cholesterol
esters from LDL to cells (17). SR-BI also can mediate cholesterol
eff lux from cells to HDL, although the physiological significance
of SR-BI-mediated lipid efflux to lipoproteins is uncertain (18).
To generate reagents that can provide new insight into the
mechanism of SR-BI-mediated selective lipid transfer, we have
performed a high-throughput screen of a chemical library to
identify potent small molecule inhibitors of SR-BI-mediated
lipid transport. We report here five chemicals that block lipid
transport, BLT-1–BLT-5, and describe their effects on SR-BI
activity in cultured cells. All five BLTs inhibited SR-BI-mediated
selective lipid uptake from HDL and efflux of cellular choles-
terol to HDL. One of these, BLT-1, was particularly potent,
inhibiting lipid transport in the low nanomolar concentration
range. Unexpectedly, all five BLTs enhanced HDL binding to
SR-BI by increasing the binding affinity. Thus, the BLTs provide
strong evidence for the mechanistic coupling between HDL
binding and lipid transport and should prove helpful in the
analysis of the mechanism of action and function of SR-BI.
Methods
Lipoproteins and Cells. Human HDL was isolated and labeled with
125I (125I-HDL); 1,1!-dioctadecyl-3,3,3!,3!-tetramethylindocar-
bocyanine perchlorate (DiI, Molecular Probes; DiI-HDL); or
[3H]cholesteryl oleyl ether ([3H]CE, [3H]CE-HDL) (1, 19–22).
LDL receptor-deficient Chinese hamster ovary cells (ldlA-7)
that express low levels of endogenous SR-BI (23), ldlA-7 cells
stably transfected to express high levels of murine SR-BI
(ldlA[mSR-BI]) (1), Y1-BS1 murine adrenocortical cells that ex-
press high levels of SR-BI after induction with adrenocortico-
tropic hormone (ACTH) (24), monkey kidney BS-C1 cells (25),
and HeLa cells (26) were maintained as previously described.
High-Throughput Screen. On day 0, ldlA[mSR-BI] cells were plated
at 15,000 cells per well in clear bottom, black wall, 384-well black
assay plates (Costar) in 50 !l of medium A (Ham’s F12 supple-
mented with 2 mM L-glutamine, 50 units/ml penicillin!50 !g/ml
streptomycin, and 0.25 mg/ml G418) supplemented with 10%
FBS (medium B). On day 1, cells were washed once with medium
C [medium A with 1% (wt!vol) BSA and 25 mM Hepes, pH 7.4,
but no G418] and refed with 40 !l of medium C. Compounds
(16,230 from the DiverSet E, ChemBridge Corp., San Diego)
dissolved in 100% DMSO were individually, robotically ‘‘pin’’
transferred (40 nl) by a pin-based compound transfer robot
(http://iccb.med.harvard.edu) to the wells to give a nominal
concentration of 10 !M (0.01% DMSO). After 1 h of incubation
at 37°C, DiI-HDL (final concentration of 10 !g of protein per
ml) in 20 !l of medium C was added. Two hours later, f luores-
cence was measured at room temperature ("2 min per plate)
with an Analyst plate reader (rhodamine B dichroic filter;
excitation, 525 nm; emission, 580 nm; Molecular Devices), both
before removing the incubation medium (to test for autofluo-
rescence and quenching) and after the medium removal and four
washes with 80 !l of PBS!1 mM MgCl2!0.1 mM CaCl2 to
determine cellular uptake of DiI. All compounds were sampled
in duplicate on different plates, and each screen included ldlA-7
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and ldlA[mSR-BI] cells in the presence or absence of a 40-fold
excess of unlabeled HDL, but with no added compounds, as
controls.
Assays. For the assays, all media and buffers contained 0.5%
DMSO and 0.5% BSA to maintain compound solubility. Cells
were preincubated with BLTs for 1 h (or 2.5 h for transferrin,
epidermal growth factor, and cholera toxin uptake experiments),
and all of the experiments were performed at 37°C unless
otherwise noted. Detailed characterization of the BLTs and their
effects was performed with compounds whose identities and
purities were confirmed by LC-MS.
Lipid uptake from HDL, cholesterol efflux to HDL, and HDL binding assays.
Assays for the uptake of lipids from DiI-HDL and [3H]CE-HDL,
efflux of [3H]cholesterol from labeled cells, and 125I-HDL
binding were performed as described (1, 18, 20). In some
experiments, values were normalized so that 100% of control
represents activity in the absence of compounds and 0% repre-
sents activity determined in the presence of a 40-fold excess of
unlabeled HDL or, for Y1-BS1 cells, in the presence of a 1:500
dilution of the KKB-1 blocking antibody (generous gift from
Karen Kozarsky, Glaxo!SmithKline Beecham, King of Prussia,
PA) (20). The amounts of cell-associated [3H]cholesteryl oleyl
ether are expressed as the equivalent amount of [3H]CE-HDL
protein (ng) to permit direct comparison of the relative amounts
of 125I-HDL binding and [3H]CE uptake.
The rates of HDL dissociation from cells were determined by
incubation of the cells with 125I-HDL (10 !g of protein per ml,
2 h, 37°C) with and without BLTs. Then either the medium was
replaced with the same medium in which a 40-fold excess of
unlabeled HDL was substituted for the 125I-HDL, or a 40-fold
excess of unlabeled HDL was added to the labeled incubation
medium. The amounts of cell-associated 125I-HDL then were
determined as a function of time. The two methods gave similar
results.
Fluorescence microscopic analysis of intracellular trafficking and cytoskel-
etal organization. Receptor-mediated endocytosis of Alexa-594-
labeled transferrin or FITC-labeled epidermal growth factor
(Molecular Probes) by HeLa cells (27) and uptake of Alexa-
594-labeled holo-cholera toxin (kind gift of Wayne Lencer,
Children’s Hospital Boston and Harvard Medical School) by
BSC-1 cells were detected by fluorescence microscopy. The
intracellular transport of the temperature-sensitive glycoprotein
of vesicular stomatitis virus (VSV-Gts045), fused at its carboxyl
terminus to enhanced GFP (VSV-Gts045-EGFP) from the en-
doplasmic reticulum to the plasma membrane, after a shift from
40 to 32°C for 2 h, was determined by fluorescence microscopy
(Y. Feng, S. Yu, T. Lasell, A. Jadhav, E. Macia, P. Chardin, P.
Melancon, M. Roth, T. Mitchison, and T.K., unpublished data).
The effects of the compounds on the distribution of actin using
rhodamine-labeled phalloidin and tubulin using the FITC-
labeled DM1" monoclonal antibody (Sigma) in ldlA[mSR-BI]
cells were determined as described (25) by fluorescence micros-
copy using an air #63 objective (Nikon).
Flow cytometric analysis of SR-BI cell surface expression. Cells were
incubated for 3 h (medium C) with or without BLTs at their
IC95CE concentrations and harvested with PBS containing 2 mM
EDTA and compounds, and the levels of SR-BI surface expres-
sion in unfixed cells were determined at 4°C by flow cytometry
with the KKB-1 antibody (19).
Results
High-Throughput Screening for Inhibitors of SR-BI-Mediated Selective
Lipid Uptake.Cellular uptake and accumulation of the fluorescent
lipophilic dye DiI from DiI-labeled HDL (DiI-HDL) is a reliable
surrogate for SR-BI-dependent selective uptake of the cho-
lesteryl esters in HDL (1). To identify small molecule inhibitors
of SR-BI-mediated selective lipid uptake, we screened 16,320
compounds representing the DiverSet E of the ChemBridge
library collection for their abilities to block the cellular uptake
of DiI from DiI-HDL. The compounds were tested at a nominal
concentration of 10 !M in a 384-well plate assay using
ldlA[mSR-BI] cells that express a high level of mSR-BI (1). Fig.
1 shows results from a representative assay plate along with
controls (no compounds, addition of excess unlabeled HDL or
use of untransfected ldlA-7 cells). Compounds that quenched
(Q) or enhanced the intrinsic f luorescence of DiI-HDL were not
examined further. Approximately 200 compounds that repro-
ducibly blocked DiI uptake in a first round of screening were
retested. Five of the most effective with IC50DiIs in the micro-
molar range or lower (Fig. 2A) were designated BLT-1–BLT-5
and further characterized. Strikingly, the most potent of these,
BLT-1 and BLT-2, inhibited in the nanomolar range and are
structurally related (Table 1). Inhibition of DiI uptake did not
require de novo protein synthesis, because pretreatment of cells
for 30 min with 100 !g!ml cycloheximide did not diminish their
inhibitory effects (data not shown). Finally, there were essen-
tially no effects of the BLTs on the low background level of
uptake of DiI or [3H]CE by untransfected ldlA-7 cells expressing
minimal amounts of SR-BI (data not shown).
The IC50CEs for inhibition of uptake of the more physiologic
lipid [3H]cholesteryl oleyl ether ([3H]CE) from [3H]CE-HDL by
ldlA[mSR-BI] cells were similar to those for DiI uptake (Fig. 2B
and Table 1). The inhibition of [3H]CE uptake was reversible (1
h of incubation with compounds followed by a 3- to 6-h washout
period and a subsequent 2-h incubation with [3H]CE-HDL, data
not shown). Moreover, the compounds also blocked the uptake
of [3H]CE by Y1-BS1 adrenocortical cells that express high levels
of SR-BI (24) (Table 1), indicating that the inhibitory effects by
the compounds are not cell-type specific. Experiments in which
the cells or the labeled HDL were preincubated with the
compounds indicated that the cells, rather than the HDL, were
the target of the compounds (data not shown).
Inhibition of Selective Lipid Uptake by BLTs Is Specific. We examined
the specificity of BLT inhibition by testing the effects of the BLTs
on several other cellular properties at concentrations that inhibit
Fig. 1. High-throughput screen for inhibitors of SR-BI-mediated DiI uptake
from DiI-HDL. Example of a fluorescent readout obtained from a single
384-well plate during the first round of the high-throughput screen. SR-BI-
expressing ldlA[mSR-BI] cells were plated into 384-well plates, and the effect
of compounds ("10 !M) on the uptake of DiI from DiI-HDL (10 !g of protein
per ml) was determined by using a high-speed fluorescence plate reader.
Columns 1–20 show results (fluorescence in arbitrary units) from 16 indepen-
dent wells per column (different colored symbols) from a single plate, repre-
senting a total of 320 compounds. Controls without compounds are wells
containing ldlA[mSR-BI] cells in the absence or presence of a 40-fold excess of
unlabeled HDL, or containing untransfected ldlA-7 cells (very low SR-BI ex-
pression). Wells containing an inhibitory compound named BLT-1 and wells
with compounds that quenched DiI-HDL fluorescence (Q) are indicated.
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[3H]CE uptake by 95% (IC95CE) (Fig. 3). None of the BLTs
disrupted the integrity of the actin and tubulin networks. They
also did not inhibit the uptake or alter the intracellular distri-
bution of the fluorescently labeled endocytic receptor ligands
transferrin and epidermal growth factor. The BLTs also failed to
inhibit the uptake of fluorescently labeled cholera toxin from the
cell surface to perinuclear regions through a pathway believed to
depend in part on cholesterol- and sphingolipid-rich lipid rafts
(28). Moreover, BLTs did not interfere with the secretory
pathway, as assessed by analysis of the transport of VSV-Gts045-
EGFP. Thus, BLTs do not induce general defects in clathrin-
dependent and -independent intracellular membrane trafficking
or in the organization of the cytoskeleton and are, by these criteria,
specific inhibitors of SR-BI-dependent lipid uptake.
BLTs Inhibit SR-BI-Mediated Cholesterol Efflux from Cells to HDL. In
addition to mediating selective lipid uptake from HDL, SR-BI
can facilitate the efflux of unesterified, or free, cholesterol (FC)
from cells to HDL particles (18). To determine whether the
BLTs could inhibit this SR-BI-mediated lipid transport activity,
we labeled cells with [3H]cholesterol and measured its eff lux to
unlabeled HDL in the presence or absence of the BLTs (Fig. 2C
and Table 1). All BLTs inhibited SR-BI-mediated cholesterol
eff lux with relative potencies (IC50FCs) similar to those for
[3H]CE uptake; however, in the cases of BLT-3, BLT-4, and
BLT-5, the IC50FCs for eff lux were higher than those for uptake,
suggesting that the BLTs may have uncovered possible differ-
ences in the mechanisms of uptake and efflux. In ldlA[mSR-BI]
cells, the BLTs had little effect on the SR-BI-independent efflux
(not inhibited by the specific anti-SR-BI blocking antibody
KKB-1; ref. 20) (data not shown). Similarly, in untransfected
ldlA-7 cells expressing relatively low levels of endogenous SR-BI,
total and SR-BI-dependent (e.g., KKB-1-inhibitable) cholesterol
eff lux was substantially lower than in ldlA[mSR-BI] cells. The
BLTs were able to inhibit the low SR-BI-dependent cholesterol
eff lux in ldlA-7 cells, but they had no inhibitory effect on the
similarly low SR-BI-independent efflux (data not shown).
BLTs Do Not Change the Surface Expression of SR-BI. To determine
whether BLTs inhibited SR-BI function by reducing its cell
surface expression, we measured surface expression by using the
KKB-1 anti-mSR-BI antibody (20) and flow cytometry. Fig. 4
shows that, after 3 h of incubation at their IC95CEs (correspond-
ing to 1!M for BLT-1 and BLT-2 and 50!M for BLT-3–BLT-5),
the BLTs did not alter the expression of mSR-BI on the surfaces
of ldlA[mSR-BI] cells.
BLTs Enhance Binding of HDL to SR-BI. We initially expected that the
BLTs would function by inhibiting HDL binding to SR-BI.
However, when cells were incubated with a subsaturating con-
centration of either [3H]CE-HDL or 125I-labeled HDL (125I-
HDL) (10 !g of protein per ml) and increasing amounts of
compound (Fig. 5), the decreases in [3H]CE uptake (solid lines,
no symbols, data from Fig. 2B) and [3H]cholesterol eff lux
(dashed lines, data from Fig. 2C) were accompanied by corre-
sponding increases in 125I-HDL binding (Fig. 5, solid lines). The
concentration dependence of 125I-HDL binding was determined
in the presence or absence of BLTs at their IC95CE concentra-
tions (Fig. 6 and Table 1). The BLTs did not substantially alter
the number of binding sites (Bmax), but rather induced small, yet
significant, increases in the affinity of SR-BI for HDL (lower
apparent Kd). Furthermore, the BLTs reduced the rates of
dissociation of 125I-HDL from SR-BI (Table 1), indicating that
the tighter binding induced by the BLTs was due, at least in part,
to a decrease in the dissociation rate.
Discussion
In this study, we report the discovery and characterization of
BLT-1–BLT-5, small molecules that inhibit the transfer of lipids
between HDL and cells mediated by the HDL receptor SR-BI.
BLTs inhibited both cellular selective lipid uptake of HDL
cholesteryl ether and efflux of cellular cholesterol to HDL. The
inhibitory effects of the BLTs were specific, because they
required SR-BI and they did not interfere with several clathrin-
dependent and -independent endocytic pathways, the secretory
pathway, or the actin or tubulin cytoskeletal networks. Strikingly,
inhibition of lipid transfer by BLTs was accompanied by en-
hanced HDL binding affinity (reduced dissociation rates).
Fig. 2. Concentration dependence of the inhibition by BLTs of SR-BI-
mediated lipid transfer between HDL and cells. ldlA[mSR-BI] cells were incu-
bated with the indicated concentrations of BLTs, and their effects on DiI
uptake fromDiI-HDL (A), [3H]CE uptake from [3H]CE-HDL (B), and the efflux of
[3H]cholesterol from cells to HDL (C) were determined. The 100% of control
values were 50.6 ng of HDL protein equivalents per well (384-well plates) (A)
and3,908ngofHDLproteinequivalents permgof cellular protein (B). InC, the
data were normalized such that the maximum amount of [3H]cholesterol
transferred from cells to HDL in the absence of compounds (55.7% of total)
was set to 100%. The 0% value corresponds to the efflux of [3H]cholesterol
transferred from ldlA[mSR-BI] cells toHDLwithout BLTs and in the presence of
saturating inhibitory amounts of the specific anti-SR-BI blocking antibody
KKB-1 (15% of total) (20). The efflux of [3H]cholesterol from ldlA-7 cells
measured in the absence or presence of KKB-1 was 15% and 10% of total
cellular [3H]cholesterol, respectively.
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BLTs and other inhibitors or activators of SR-BI should be
useful for the analysis of the molecular and cellular mechanisms
of SR-BI activity and the study of the physiologic functions of
SR-BI by its pharmacologic manipulation in vivo. Our studies
with the BLTs support a two-step mechanism of SR-BI activity,
productive binding followed by lipid transfer (19, 29), and
suggest that these two steps may be mechanistically linked
because they result in coordinated decreases in lipid transfer and
increases in binding affinity. They also suggest that there may be
differences in the mechanisms of SR-BI-mediated lipid uptake
and cholesterol eff lux (20, 30), because the IC50 values for
uptake and efflux for each of three BLTs (BLT-3–BLT-5)
differed.
The mechanistic coupling of HDL binding and lipid transport
observed here is consistent with the productive binding model
for SR-BI interaction with HDL (29). A number of studies have
explored the influence of the protein composition of HDL
particles on binding and lipid transfer (26, 29, 31–33). They
showed that variations in the structure!composition of HDL
particles could affect the efficiency of selective uptake or efflux
relative to lipoprotein binding and thus support the concept of
productive binding. In addition, CD36, a close homolog of
Table 1. Effects of BLTs on SR-BI activity
n
BLT-1,
mean $ SD
BLT-2,
mean $ SD
BLT-3,
mean $ SD
BLT-4,
mean $ SD
BLT-5,
mean $ SD
No BLT,
mean $ SD
IC50, !M
DiI-HDL uptake
[3H]CE-HDL uptake
3 0.06 $ 0.04 0.35 $ 0.18 0.51 $ 0.15 2.0 $ 1.0 7.1 $ 3.7 — —
ldlA[mSR-BI] cells 6 0.11 $ 0.08 0.24 $ 0.1 2.3 $ 1.5 3.9* $ 0.76 13.8* $ 8.5 — —
Y1-BS1 cells 2 0.38† 0.41† 1.7† 4.4† 8.0† — —
[3H]cholesterol efflux 3 0.15 $ 0.09 0.47 $ 0.23 17.2 $ 4.0 54.9 $ 35.2 75.3 $ 40.1 — —
125I-HDL binding 3 0.088 $ 0.05 0.25 $ 0.13 46.5 $ 49.3 24.9 $ 14.8 18.0 $ 3.7 — —
Binding parameters
Apparent Kd, !g!ml%1 3 4.7 $ 0.05 6.0 $ 6.0 8.0 $ 4.0 8.9 $ 2.3 12.0 $ 1.6 16.6 $ 1.5
Koff, min%1 2 0.06† 0.062† 0.08† 0.082† 0.079† 0.11†
Bmax, % 95.8 $ 10.1 93.0 $ 20.5 85.8 $ 15.8 79.9 $ 15.9 92.1 $ 36.8 100.0 $ 18.4
All experiments were with ldlA[mSR-BI] cells except where noted.
*n & 5.
†SD is not applicable.
Fig. 3. Effects of BLT-1 on intracellular membrane trafficking and cytoskeletal organization. Cells were incubated for 3 h in the absence (Upper) or presence
(Lower) of 50 !M BLT-1, and epifluorescence light microscopy was used to monitor the following cellular activities: clathrin-dependent endocytosis of
fluorescently labeled transferrin (A and B; HeLa cells) and epidermal growth factor (C and D; HeLa cells); clathrin-independent endocytosis of fluorescently
labeled cholera toxin (E and F; BSC-1 cells); and transport of the temperature-sensitive fluorescent membrane protein VSV-Gts045-EGFP from the endoplasmic
reticulum to the cell surface (G and H; BSC-1 cells). In addition, the intracellular distributions of the actin cytoskeleton (I and J; ldlA-[mSRBI] cells visualized with
rhodamine-labeled phalloidin) and the tubulin network (K and L; BSC-1 cells visualized with fluorescently labeled antibodies specific to "-tubulin) were
determined. BLT-1 and the other BLTs (data not shown) had no effects on any of these cellular properties or activities.
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SR-BI, mediates high-affinity HDL binding but not efficient
lipid transfer (19, 34). Thus, HDL binding per se to a member of
this superfamily of receptors is not sufficient for efficient lipid
transport; rather, the binding must be productive. That is, SR-BI
and HDL must bind in a precisely aligned fashion, have the
capacity to undergo appropriate conformational changes on
binding, or both.
BLTs might block productive binding by inducing (or prevent-
ing) interactions between HDL and its receptor, or interfering
with critical conformational changes such that lipid transfer
could not occur. A direct consequence of these altered interac-
tions could be the tighter HDL binding observed when the cells
were treated with BLTs. Alternatively, the BLTs might not
interfere with productive binding and lipid transfer, but rather
might simply inhibit dissociation of HDL from SR-BI, thereby
preventing the multiple rounds of HDL binding, lipid transfer,
dissociation of the smaller lipid-depleted particle, and binding of
a new HDL particle that are required for efficient selective
uptake. If this were the case, in the presence of BLTs the initially
bound HDL particles would competitively inhibit the binding of
other particles. Another possibility is that direct BLT inhibition
of the lipid transfer step might prevent the size reduction of HDL
that accompanies selective uptake. Previous studies have shown
that larger, lipid-rich HDLs bind more tightly to SR-BI than
smaller, relatively lipid-poor HDLs (33, 35). Thus, BLT inhibi-
tion of the lipid transfer step would lead to larger HDL particles
bound more tightly to SR-BI at steady state, resulting in a slower
dissociation rate and apparently higher binding affinity. Finally,
it seems unlikely that the BLTs would inhibit lipid transfer
step(s) occurring distally to the receptor itself [e.g., between the
Fig. 4. Cell surface expression of SR-BI. ldlA[mSR-BI] and ldlA-7 cells were
treated for 3 hwith orwithout BLTs at their corresponding IC95CE concentrations
(1!MforBLT-1andBLT-2and50!MforBLT-3–BLT-5) followedbydetermination
of surface expression levels of SR-BI by flow cytometry. A–C show histograms of
the surface expression for ldlA[mSR-BI] cells without BLTs, ldlA[mSR-BI] cells with
1 !M BLT-1, and ldlA-7 cells without BLTs, respectively. D summarizes the results
in ldlA[mSR-BI] cells for all five BLTs, with the value determined without com-
pounds set to 100%. n, number of independent determinations.
Fig. 5. Effects of BLTs on SR-BI-mediated cholesterol ether uptake from HDL, cellular cholesterol efflux to HDL, and HDL binding. The effects of the indicated
concentrations of BLTs on SR-BI-mediated uptake of [3H]CE from [3H]CE-HDL (solid lines, no symbols), efflux of [3H]cholesterol from cells to HDL (dashed lines),
or binding of 125I-HDL to cells (solid lines, symbols) were determined by using ldlA[mSR-BI] cells. To simplify comparisons, we define the lowest observed [3H]CE
uptake and [3H]cholesterol efflux values (from Fig. 2) as 0% and the values in the absence of BLTs as 100%. The 100% control value for the 125I-HDL binding in
the absence of BLTs was 403 ng of HDL protein per mg of cell protein.
Fig. 6. Effects of BLT-1 on the concentrationdependenceof 125I-HDLbinding
to ldlA[mSR-BI] cells. The binding of 125I-HDL to ldlA[mSR-BI] cells was deter-
mined in duplicate at the indicated concentrations of HDL in the presence
(blue) or absence (black) of 1 !M BLT-1 (IC95CE). Each value was corrected for
binding of 125I-HDL in the presence of 40-fold excess of unlabeled HDL to ldlA
[mSR-BI] cells in the presence of BLT-1.
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plasma membrane and internal cellular compartments signifi-
cantly downstream from the association between HDL and
SR-BI (16)], given the strong inverse correlation between the
effects of BLTs on binding and lipid transport. Future identifi-
cation of the molecular target(s) of the BLTs, whether SR-BI or
other proteins or lipids, should provide insights into the mech-
anisms underlying the activities of both the BLTs and SR-BI.
Experiments with SR-BI-deficient or SR-BI-overexpressing
mice have provided important insights into SR-BI function and
potential roles of SR-BI and HDL metabolism in pathophysiol-
ogy, including female infertility, aberrant red blood cell devel-
opment, and cardiovascular disease (6, 7, 10, 15). BLTs and other
small molecules isolated by using the approach described here
may prove helpful in further studying the physiology of these
systems. In this regard it is noteworthy that BLT-1 has been
shown to interfere with the early stages of brain development in
zebrafish (36). It may be worthwhile to explore the potential role
of disrupted lipid metabolism in this system. Given the wide-
spread consequences of genetically manipulating SR-BI expres-
sion in mice, pharmacologic manipulation may have potential
therapeutic value.
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CHAPTER III
Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol
transport by the small molecules BLT-4 and glyburide
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Cross-inhibition of SR-BI- and ABCA1-mediated
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Abstract Scavenger receptor class B type I (SR-BI) and
ABCA1 are structurally dissimilar cell surface proteins that
play key roles in HDL metabolism. SR-BI is a receptor that
binds HDL with high affinity and mediates both the selec-
tive lipid uptake of cholesteryl esters from lipid-rich HDL
to cells and the efflux of unesterified cholesterol from cells
to HDL. ABCA1 mediates the efflux of unesterified choles-
terol and phospholipids from cells to lipid-poor apolipo-
protein A-I (apoA-I). The activities of ABCA1 and other
ATP binding cassette superfamily members are inhibited by
the drug glyburide, and SR-BI-mediated lipid transport is
blocked by small molecule inhibitors called BLTs . Here, we
show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-
urea] (BLT-4), blocked ABCA1-mediated cholesterol efflux
to lipid-poor apoA-I at a potency similar to that for its inhi-
bition of SR-BI (IC50
 
! 55–60 
 
!M). Reciprocally, glyburide
blocked SR-BI-mediated selective lipid uptake and efflux
at a potency similar to that for its inhibition of ABCA1 (IC50
 
!275–300
 
!M). As is the case with BLTs, glyburide in-
creased the apparent affinity of HDL binding to SR-BI.
The reciprocal inhibition of SR-BI and ABCA1 by BLT-4
and glyburide raises the possibility that these proteins may
share similar or common steps in their mechanisms of lipid
transport.—Nieland, T. J. F., A. Chroni, M. L. Fitzgerald, Z.
Maliga, V. I. Zannis, T. Kirchhausen, and M. Krieger. Cross-
inhibition of SR-BI- and ABCA1-mediated cholesterol trans-
port by the small molecules BLT-4 and glyburide 
 
J. Lipid
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Supplementary key words scavenger receptor class B type I • ATP
binding cassette transporter A1 • blockers of lipid transport
Cholesterol and cholesteryl ester movement into and
out of cells mediated by lipoproteins and cell surface pro-
teins such as scavenger receptor class B type I (SR-BI) and
ABCA1 plays an important role in cellular and whole body
lipid metabolism and can profoundly influence the risk
of atherosclerosis and coronary heart disease (1–8). The
pathologic consequences of naturally arising or experi-
mentally induced disruptions in the SR-BI and ABCA1
genes clearly demonstrate that these lipid transport pro-
teins serve physiologically important, yet dramatically dis-
tinct, purposes in HDL metabolism (1, 2).
SR-BI, a member of the CD36 superfamily of proteins,
is a 509 residue glycoprotein (apparent mass of 82 kDa)
containing two predicted transmembrane helices adjacent
to very short N- and C-terminal cytoplasmic domains, with
the bulk of the protein consisting of a large extracellular
loop (3, 4). Alterations in SR-BI expression can influence
profoundly several physiologic processes, including biliary
cholesterol secretion, female fertility, red blood cell matu-
ration, and the development of atherosclerosis and coro-
nary heart disease (5–7, 9–14). SR-BI tightly binds large,
spherical, cholesteryl ester-rich HDL particles, primarily
via its major apolipoprotein, apolipoprotein A-I (apoA-I),
but lipid-free apoA-I is a poor ligand (15). SR-BI mediates
the selective uptake of HDL cholesteryl esters (16–19)
and other lipids (3, 20, 21) into cells, after which the lipid-
depleted particles dissociate from the cells. The mecha-
nism of selective lipid uptake differs markedly from that
of the classic coated pit-mediated endocytic uptake of LDL
receptors (22). The binding of native spherical HDL par-
Abbreviations: ABC, ATP binding cassette; apoA-I, apolipoprotein
A-I; BLT, small molecules that block lipid transport; COE, cholesteryl
oleyl ether; DSP, dithiobis (succinimidyl propionate); Kd, dissociation
constant; SR-BI, scavenger receptor class B type I; SUR, sulfonylurea re-
ceptor.
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Nticles or reconstituted apoA-I/phospholipid/cholesterol
disks to SR-BI also results in the efflux of unesterified cho-
lesterol from cells to the particles (23–25), but the physio-
logical significance of this activity has not yet been deter-
mined.
ABCA1, a member of the ATP binding cassette (ABC)
superfamily of proteins, has a structure strikingly different
from that of SR-BI. ABCA1 is a much larger protein (
 
!200
kDa) that contains 12 membrane-spanning helices, two cy-
toplasmic ATP binding domains, and two large extracellu-
lar loops (2, 26, 27). It mediates the transfer of unesteri-
fied cholesterol and phospholipids from cells to lipid-
poor apoA-I (28–31), which can subsequently mature into
spherical, cholesteryl ester-rich HDL particles (32–35).
These mature HDLs are poor acceptors for ABCA1-medi-
ated cholesterol efflux (36). Mutations in ABCA1 are the
underlying cause of Tangier disease, which is character-
ized by the virtual absence of spherical, cholesteryl ester-
rich HDL particles in the plasma and an accumulation of
cholesterol in peripheral macrophages (28, 37–39). Mice
with targeted homozygous inactivating mutations in the
ABCA1 gene exhibit phenotypes similar to those of hu-
man Tangier patients (40–42). In contrast, SR-BI-deficient
mice (homozygous null mutations) have increased levels
of abnormally large lipid-rich HDL particles in their
plasma (43). The differences in the structures of SR-BI
and ABCA1 suggest that they use different mechanisms to
transfer lipids between cells and HDL. This is supported
by experiments showing that the structural or conforma-
tional determinants on apoA-I that are crucial for its inter-
action with ABCA1 (e.g., apoA-I’s C terminus) appear to
differ from those necessary for productive interactions
with SR-BI (15, 24, 44). However, their common abilities
to mediate cholesterol efflux from cells led us to probe
their activities using small molecules that had previously
been shown to inhibit their lipid transport activities.
These included small molecules that block lipid transport
(BLTs) mediated by SR-BI (45) and the drug glyburide
(29, 31, 46–51), which blocks ABCA1-mediated choles-
terol efflux.
Glyburide (also called glybenclamide; Fig. 1A) is a sulfo-
nylurea that has received wide attention in clinical settings
as a potent drug for the treatment of non-insulin-depen-
dent diabetes mellitus (52). Glyburide binds tightly to and
inhibits sulfonylurea receptors 1 and 2 (SUR1 or SUR2),
members of the ABC superfamily of proteins that form
the SUR subunit of the ATP-sensitive potassium channel.
SUR1 and SUR2 are responsible for the binding and hy-
drolysis of ATP and effectively control the closing of the
channel and the regulation of insulin release. The dissoci-
ation constant (Kd) for glyburide binding to SUR1, which
apparently involves association with its transmembrane
domains, is in the low nanomolar range [reviewed in ref.
(53)]. Glyburide also inhibits the activities of other ABC
proteins (54–56), including ABCA1. Inhibition of ABCA1
by glyburide has been reported to occur in the concentra-
tion range of 100–1,000 
 
!M (29, 31, 46–51).
By using a high-throughput chemical library screen, we
recently identified five small molecules (BLT-1 to BLT-5)
that in the low nanomolar to micromolar range block
lipid transport (selective uptake from and efflux to HDL)
mediated by SR-BI (45). Unexpectedly, they enhance
rather than decrease the apparent affinity of HDL bind-
ing to SR-BI.
Here, we report that 1-(2-methoxy-phenyl)-3-naphtha-
len-2-yl-urea (BLT-4) (Fig. 1B) blocks ABCA1-mediated
cholesterol efflux to lipid-free apoA-I. The other BLTs did
not inhibit ABCA1 activity. Conversely, glyburide pre-
vented SR-BI-mediated selective lipid uptake from and
cholesterol efflux to HDL. Similar to the BLTs, glyburide
enhanced the affinity of HDL binding to SR-BI. The
concentrations at which glyburide inhibited SR-BI- and
ABCA1-mediated lipid efflux were similar (IC50
 
! 275–
300
 
!M), as were those for BLT-4, but BLT-4 was the more
potent inhibitor (IC50
 
! 55–60 
 
!M). The reciprocal or
cross-inhibition of these two lipid transport proteins by
BLT-4 and glyburide raises the possibility that there may
be similarities in at least one step of the mechanisms of
SR-BI- and ABCA1-mediated lipid transport
EXPERIMENTAL PROCEDURES
Stock solutions of BLTs (Chembridge Corp.) and glyburide
(Sigma) were prepared in 100% DMSO and diluted into the as-
say medium immediately before use. Dithiobis (succinimidyl pro-
pionate) (DSP; from Pierce Biotechnology, Inc.), which contains
thiol-sensitive bonds, was dissolved in dimethyl sulfoxide and
then diluted to 250 
 
!M with PBS immediately before use.
Lipoproteins and cells
Human HDL (density of 
 
!1.09–1.16 g/ml) and recombinant
lipid-free human apoA-I were isolated and labeled with either
125I (125I-HDL or 125I-apoA-I) or [3H]cholesteryl oleyl ether
([3H]COE, [3H]COE-HDL) (3, 19, 25, 44, 57, 58). LDL receptor-
deficient Chinese hamster ovary cells that express low levels of en-
dogenous SR-BI (ldlA-7) (59), ldlA-7 cells stably transfected to ex-
press high levels of murine SR-BI (ldlA[mSR-BI]) (19), and HEK293-
EBNA-T human embryonic kidney (HEK) cells (27) were main-
tained in culture as previously described. All assay media contained
0.5% or 0.29% (v/v) DMSO and 0.5% (w/v) BSA (fatty acid-free
form in efflux assays), and all experiments were conducted at 37
 
"C.
Fig. 1. Chemical structures of glyburide (A) and 1-(2-methoxy-
phenyl)-3-naphthalen-2-yl-urea (BLT-4) (B).
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1Lipid transport and binding assays
All data presented are representative of results from two or
more independent experiments.
SR-BI. Assays for the uptake of [3H]COE from [3H]COE-
HDL, efflux of [3H]cholesterol from labeled cells, and 125I-HDL
binding were performed using ldlA[mSR-BI] cells and control
untransfected ldlA-7 cells as previously described (19, 23, 25).
We also determined the SR-BI-mediated efflux of [3H]choles-
terol from HEK293-EBNA-T cells transiently transfected with an
SR-BI expression plasmid (19), as described for ABCA1 below.
On the day of the assay, cells were preincubated for 1 h at 37
 
"C in
assay medium (Ham’s F12, 0.5% BSA, 0.5% DMSO, and 25 mM
HEPES, pH 7.4) containing compounds at the indicated concen-
trations. Subsequently, the cells were incubated for an additional
2 h with the same concentration of small molecules and with the
indicated concentrations of 125I-HDL (binding), [3H]COE-HDL
(uptake), or unlabeled HDL (efflux). 125I-HDL saturation bind-
ing assays were performed as previously described, in which a 40-
fold excess of unlabeled HDL was included in some of the incu-
bations to permit the correction for nonspecific binding (19,
45). Analysis of saturation binding curves was performed using
GraphPad Prism3 software from GraphPad Software, Inc. (San
Diego, CA).
For some experiments, the values presented were normalized
so that 100% of control represents activity in the absence of com-
pounds. In Figs. 2 and 3B, 0% activity was defined as the activity
determined in the presence of a 1:800 dilution of the anti-SR-BI
blocking antibody KKB-1 (25), a generous gift from Karen Kozar-
sky. In other experiments, the 0% values were defined as the
amount of activity either in ldlA-7 control cells in the presence of
drugs (Fig. 4C) or in ldlA[mSR-BI] cells in the presence of a
40-fold excess of unlabeled HDL (Fig. 5). The amount of cell-
associated [3H]COE is expressed as the equivalent amount of
[3H]COE-HDL protein (nanograms) to permit direct compari-
son of the relative amounts of 125I-HDL binding and [3H]COE
uptake (60).
ABCA1. ABCA1-dependent efflux of [3H]cholesterol was
measured using HEK293-EBNA-T cells transiently transfected
with either an ABCA1 pcDNA1 expression vector or the empty
pcDNA1 vector control, as previously described (44, 61). On day
0, HEK293-EBNA-T cells were plated at 200,000 cells/well on 24-
well poly-d-lysine-coated plates (Becton Dickinson) in medium A
[DMEM containing high glucose and 10% (v/v) fetal calf serum
without antibiotics]. On day 1, cells were transfected with either
the ABCA1 vector or an “empty” vector control using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
suggestions. The media were removed 16 h later, and cells were
incubated for 24 h in medium A supplemented with 0.5 
 
!Ci/ml
1,2[3H]cholesterol (Perkin-Elmer). The cells were then washed
twice with DMEM (high glucose) and incubated for 1 h in assay
medium [DMEM (high glucose) supplemented with 0.2% fatty
acid-free BSA, 0.5% DMSO, and 25 mM HEPES, pH 7.4]. The
cells were then pretreated with the indicated concentrations of
small molecules in the assay medium for 1 h at 37
 
"C and then in-
cubated with the same concentrations of compounds in the pres-
ence or absence of 10 
 
!g/ml lipid-free recombinant human
apoA-I for an additional 4 h to permit the efflux of cellular cho-
lesterol. The supernatant was harvested and clarified by centrifu-
gation (5 min, 6,000 g), the cells were lysed in 0.1 M NaOH, and
radioactivity in both fractions was measured by liquid scintilla-
tion counting.
Cholesterol efflux was defined as the amount of radioactivity
in the extracellular media at the end of the 4 h incubation di-
vided by the total amount of cellular radioactivity in the media
plus cells (the percentage efflux). The apoA-I-dependent efflux
is defined as the difference between the efflux values deter-
mined for incubations in medium that did or did not contain
lipid-free apoA-I. The ABCA1- and apoA-I-dependent efflux is
defined as the difference between the apoA-I-dependent efflux
values determined using cells that express the ABCA1 transgene
(HEK[ABCA1]) and the empty vector controls (HEK[control]).
Efflux values are presented as the percentage of total cellular
1,2[3H]cholesterol present in the cells at the beginning of the 4 h
incubation.
The IC50 values are those concentrations of the compounds
that caused a half-maximal inhibition of lipid transport mediated
by either ABCA1 or SR-BI.
Cross-linking assay of apoA-I binding to ABCA1
The binding assays were conducted as described by Wang et
al. (62) with minor modifications. HEK293-EBNA-T cells were
plated as described above on 12-well poly-d-lysine-coated plates
and 3 days later were transfected with plasmids when the cells
were
 
!95% confluent, as described above. On day 4, the cells
were preincubated in DMEM (high glucose) and 0.2% (w/v)
fatty acid-free BSA with the indicated amounts of compounds at
37
 
"C for 1 h before incubation at 37
 
"C for 1 h with 2 
 
!g/ml
125I-apoA-I and the indicated compounds in the presence or
absence of a 30-fold excess of unlabeled apoA-I. Cells were
then washed, reversibly cross-linked with DSP (2 ml/well), and
washed again as previously described (62). For immunoprecipi-
tation, cell lysates prepared in buffer RI [50 mM Tris, pH 7.6, 150
mM NaCl, 0.25% sodium deoxycholate, 1% Nonidet P-40] con-
taining a protease inhibitors mixture (Roche Molecular Bio-
chemicals GmbH), and 1 mM phenylmethylsulfonyl fluoride
were subjected to centrifugation at 1,000 g in a microcentrifuge
for 10 min. The supernatant was collected and precleared with
10
 
!l of GammaBind G Sepharose beads for 1 h at room temper-
ature with rotation. Polyclonal anti-ABCA1 antibody (50 
 
!g) di-
rected against the C terminus of ABCA1 (61) was added to the
preabsorbed cell lysates and incubated with rotation at room
temperature for 2 h. Twenty microliters of GammaBind G Sepha-
rose beads was then added, and the incubation with rotation was
continued at room temperature for 1 h. The samples were sub-
jected to a brief centrifugation, and the pellets were washed
three times with cold buffer RI at room temperature. The bound
proteins were eluted from the beads by incubation and boiling in
Laemmli sample buffer in the presence of 5% 
 
#-mercaptoetha-
nol, which also serves to break the DSP-mediated cross-links be-
tween apoA-I and ABCA1. The eluted proteins were fractionated
by 12% SDS-polyacrylamide gel electrophoresis, and the radioac-
tivity in the dried gels was analyzed using a PhosphorImaging
STORM860 system (Molecular Dynamics, Inc., Sunnyvale, CA)
and ImageQuant software.
Determination of ABCA1 expression levels
To determine the effect of the compounds on the cell surface
expression of ABCA1, we used previously described quantitative
assays for cell surface ABCA1 that detects a FLAG tag inserted
in the first large extracellular loop of ABCA1 (27). In brief,
HEK293-EBNA-T cells on 24-well plates were transfected with a
FLAG-ABCA1 cDNA or empty vectors as described above. The
media containing DNA and lipofectamine were removed 1 day
after transfection, and 1 day later the cells were exposed for 5 h
at 37
 
"C to assay medium [DMEM (high glucose) supplemented
with 0.2% fatty acid-free BSA, 0.5% DMSO, and 25 mM HEPES,
pH 7.4] with or without 150 
 
!M BLT-4 or 500 
 
!M glyburide. The
cells were then chilled on ice for 10 min, and cell surface
ABCA1-FLAG expression was measured as described by Fitzger-
ald et al. (27).
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Total cellular ABCA1 expression was measured by immunoblot
analysis using a polyclonal antibody as previously described (61).
Transfected cells were treated for 5 h at 37
 
"C with 500 
 
!M glyburide
or 150 
 
!M BLT-4 in assay medium [DMEM (high glucose) supple-
mented with 0.2% fatty acid-free BSA, 0.5% DMSO, and 25 mM
HEPES, pH 7.4] and subsequently lysed in a hypotonic buffer (250
mM sucrose, 10 mM HEPES, pH 7.4, and 1 mM EDTA) supple-
mented with a protease inhibitor mini-cocktail containing EDTA
(Roche). Nuclei and cell debris were removed by centrifugation
(800 g for 10 min). The amount of protein was measured in the
postnuclear supernatants by the method of Bradford (63) and 15
 
!g of each sample were separated by 6% SDS-PAGE and transferred
to nitrocellulose membranes. The membranes were processed for
antibody staining, and ABCA1 was detected using an enhanced
chemiluminescence system (Pierce) as previously described (61).
Measurement of total cellular cholesterol and cholesteryl 
ester levels by TLC
HEK, ldlA7, and ldlA[mSR-BI] cells were labeled with [3H]cho-
lesterol as described above for cholesterol efflux assays. After incu-
bation for 5 h with or without 500 
 
!M glyburide or 150 
 
!M BLT-4,
the cells were lysed (lysis buffer: 50 mM Tris, pH 7.6, 150 mM
NaCl, 0.25% sodium deoxycholate, and 1% Nonidet P-40) for 30
min at room temperature. A mixture of 2:1 chloroform-methanol
(v/v) containing unlabeled lipids (200 
 
!g/
 
!l cholesterol and 200
 
!g/
 
!l cholesteryl oleate) was added to the lysate as an internal
standard. The organic phase of the resulting mixture was evapo-
rated under nitrogen, dissolved in 75 
 
!l of chloroform, and frac-
tionated by TLC using ITLC SA plates (Pal Corporation) using
petroleum ether-ether-acetic acid (85:15:1). Spots containing cho-
lesteryl ester, cholesterol, and origin spots were cut out, and radio-
activity was measured by liquid scintillation counting.
Synthesis of BLT-4
Naphthyl isocyanate (Sigma-Aldrich) was dissolved in ethyl
acetate and N-methyl-pyrrolidinone (Sigma-Aldrich) and then
cooled to 0
 
"C. 2-Anisidine was added drop-wise by syringe over
10 min. Solid naphthyl isocyanate (1.00 g, 5.92 mmol) was dis-
solved in 45 ml of anhydrous 1:2 N-methyl pyrrolidinone-ethyl
acetate (Acros Organics) under a nitrogen atmosphere and
cooled to 0
 
"C. 2-Anisidine (900 
 
!l, 7.32 mmol) was added drop-
wise by syringe over 10 min and the reaction was stirred, first at
0
 
"C for 2 h and then for an additional 2 h at room temperature.
The reaction was quenched by the addition of 100 ml of 0.1 N
HCl and extracted three times with 50 ml of dichloromethane.
The pooled organic fractions were dried over anhydrous potas-
sium carbonate, concentrated by rotary evaporation, and puri-
fied by flash chromatography using silica gel 60 (EMD Pharma-
ceuticals) equilibrated in 2:1 (v/v) hexane-ethyl acetate. BLT-4
was eluted with 1:1 (v/v) hexane-ethyl acetate and lyophilized
with a final yield of 22%. The product was more than 95% pure
as determined by liquid chromatography-mass spectrometry and
NMR spectroscopy. The 1H-NMR resonance frequencies for BLT-4
are as follows: (d6-Me2SO):
 
$ 3.89 (3H, s), 6.90 (1H, td, J 
 
% 1.5
Hz, 1.5 Hz), 6.96 (1H, td, J 
 
% 1.5, 5.5 Hz), 7.02 (1H, dd, J 
 
% 7,
1.5 Hz), 7.34 (1H, T, J 
 
% 8 Hz), 7.44 (3H, m), 7.77 (1H, s), 7.79
(1H, s), 7.81 (1H, d, J 
 
% 4 Hz), 7.84 (1H, s), 8.12 (1H, d, J 
 
% 2
Hz), 8.17 (1H, dd, J 
 
% 1.5, 6.5 Hz), 8.30 (1H, s), 9.52 (1H, s).
RESULTS AND DISCUSSION
Effects of BLTs on ABCA1-mediated [3H]cholesterol 
efflux to apoA-I
To determine if SR-BI- and ABCA1-mediated choles-
terol efflux share common features, we examined the ef-
fects of BLTs on ABCA1-mediated cholesterol efflux from
HEK293 cells transiently transfected with either an ABCA1-
expression vector (HEK[ABCA1]) or an empty vector
control (HEK[control]).
Cholesterol efflux was measured from cells labeled with
unesterified [3H]cholesterol for 24 h, followed by a 1 h
preincubation with the BLT. This was followed by a 4 h in-
cubation with the BLT in the presence or absence of 10
 
!g of protein per milliliter of lipid-free apoA-I, which
served as an acceptor for cholesterol efflux. The amounts
of [3H]cholesterol in the incubation media and the
amounts remaining associated with the cells were mea-
sured, and efflux was expressed as the percentage of cellu-
lar [3H]cholesterol released into the medium during the
4 h incubation. Figure 2 shows that the ABCA1-mediated
[3H]cholesterol efflux to apoA-I (closed bars) was not in-
Fig. 2. Effects of BLTs on ABCA1- and scavenger receptor class B
type I (SR-BI)-dependent efflux of [3H]cholesterol to extracellular
acceptors. HEK293-EBNA-T cells were transiently transfected with
either an ABCA1 expression vector or the control pcDNA1 vector.
One day after transfection, the cells were labeled for 24 h with
[3H]cholesterol and then preincubated for 1 h at 37"C in assay me-
dium containing 0.5% (v/v) DMSO with or without the indicated
concentrations of BLTs. After the preincubation, the cells were in-
cubated for an additional 4 h at 37"C with the same concentrations
of BLTs in the presence or absence of 10 !g/ml lipid-free recombi-
nant human apolipoprotein A-I (apoA-I) to measure cholesterol ef-
flux. The amounts of [3H]cholesterol transferred from the cells to
the medium and the values for ABCA1- and apoA-I-dependent ef-
flux were determined as described in Experimental Procedures
(closed bars). The control efflux values (percentage of cellular cho-
lesterol released into the medium) measured in the absence of
BLTs were as follows: HEK[ABCA1] with apoA-I, 7.4%; HEK
[ABCA1] without apoA-I, 4%; HEK[control] with apoA-I, 1.7%;
HEK[control] without apoA-I, 1%. The 100% control value deter-
mined in the absence of BLTs for ABCA1- and apoA-I-dependent ef-
flux was 2.7% [calculated as (7.4-4)&(1.7-1)%]. Error bars repre-
sent the range of duplicate determinations. In independent
experiments, SR-BI-mediated and HDL-dependent [3H]cholesterol
efflux was determined in [3H]cholesterol-labeled ldlA[mSR-BI]
cells (open bars). Cells were preincubated with the indicated
amounts of BLTs for 1 h and then incubated for 2 h at 37"C with
500 !g of protein per milliliter of HDL and the same concentra-
tions of BLTs in the presence or absence of a 1:800 dilution of the
anti-SR-BI blocking antibody KKB-1 (25). The 100% of control
value represents efflux in the absence of compound (50% of initial
cellular radiolabeled cholesterol for efflux to HDL), and the 0% of
control value represents efflux in the presence of HDL and the
KKB-1 antibody (1:800 dilution) (12% of initial cellular radiola-
beled cholesterol). There was no effect of the compounds on efflux
to HDL in the presence of KKB-1. Error bars represent standard de-
viations from triplicate measurements.
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1hibited by BLT-1 (10 !M), BLT-3 (150 !M), or BLT-5 (150
!M), at concentrations that inhibit SR-BI-mediated [3H]
cholesterol efflux to HDL from ldlA[mSR-BI] cells, a cell
line stably transfected with murine SR-BI (open bars)
(45). At these concentrations, all three BLTs inhibited
cholesterol efflux to HDL from HEK cells transfected with
a cDNA construct encoding murine SR-BI, indicating that
HEK cells are not intrinsically resistant to BLT-1, BLT-3,
and BLT-5 (data not shown). Because the structures of
BLT-1 and BLT-2 are very similar (45), we did not test BLT-2
in these studies. In contrast to the other BLTs, BLT-4 (Fig.
1B) at a concentration of 150 !M inhibited ABCA1- and
apoA-I-dependent efflux by !90%, approximately the
same extent of its inhibition of cholesterol efflux observed
for SR-BI-mediated efflux to HDL (Fig. 2) from trans-
fected ldlA-7 (45) or HEK293 (data not shown) cells.
Figure 3A shows the concentration dependence of
BLT-4-mediated inhibition of [3H]cholesterol efflux. HEK
[ABCA1] and HEK[control] cells were labeled with [3H]
cholesterol and incubated with or without lipid-free apoA-I
and the indicated concentrations of BLT-4. As described
previously (28, 29, 44, 61, 64), we found that [3H]choles-
terol efflux depended on the expression of ABCA1 and
the presence of apoA-I as an acceptor in the incubation
medium. As the concentration of BLT-4 increased, there
was a substantial inhibition of efflux from HEK[ABCA1]
cells incubated with apoA-I, but there was little or no in-
hibition of the relatively low background efflux from
HEK[ABCA1] cells in the absence of apoA-I or from
HEK[control] cells either with or without apoA-I. Figure
3B shows that the ABCA1- and apoA-I-dependent [3H]
cholesterol efflux, calculated as described in Experimen-
tal Procedures, was inhibited by BLT-4 with an IC50 of !60
!M. This value is similar to that for its inhibition of SR-BI-
dependent [3H]cholesterol efflux to HDL (IC50 ! 55 !M;
Fig. 3B) (45).
The shared sensitivities to BLT-4 suggest that there may
be similarities in the mechanisms by which BLT-4 inhib-
ited ABCA1- and SR-BI-mediated cellular cholesterol ef-
flux. The inability of BLT-1, BLT-3, and BLT-5 to inhibit
ABCA1 raises the possibility that the mechanisms by which
they block SR-BI activity may differ from that of BLT-4, al-
though additional studies will be required to directly ad-
dress this question.
Effects of the ABCA1 inhibitor glyburide
on SR-BI-mediated [3H]cholesterol efflux to HDL
The inhibition of ABCA1-mediated cholesterol efflux
by BLT-4 prompted us to determine if the ABCA1 inhibi-
tor glyburide (29, 31, 46–51) (Fig. 1A) could block SR-
BI-mediated [3H]cholesterol efflux to HDL. Figure 4
compares the concentration dependence of glyburide’s
inhibition of ABCA1-mediated [3H]cholesterol efflux to
apoA-I (A, C) with its effects on SR-BI-mediated [3H]cho-
lesterol efflux to HDL (B, C).
As expected from previous studies (29, 31, 48–50), gly-
buride inhibited ABCA1-mediated [3H]cholesterol efflux
from HEK[ABCA1] cells to apoA-I (10 !g protein/ml)
with an IC50 of !300 !M (Fig. 4A), and it had little effect
on the low background efflux in the absence of ABCA1
transgene expression, in the absence of apoA-I, or both.
This IC50 value is substantially greater than that for BLT-4
(!60 !M). Thus, BLT-4 was a more potent inhibitor of
ABCA1 than was glyburide.
Strikingly, glyburide’s effects on SR-BI-mediated efflux
were virtually identical to those on ABCA1-mediated ef-
flux. Figure 4B shows that glyburide inhibited SR-BI-medi-
ated [3H]cholesterol efflux from ldlA[mSR-BI] cells to
HDL (500 !g protein/ml) with a IC50 of !275 !M, and it
had little effect on the low background efflux in the ab-
sence of SR-BI transgene expression (ldlA-7 control cells),
in the absence of HDL, or both. Figure 4C, which com-
pares directly glyburide’s inhibition of ABCA1- and apoA-
I-dependent cholesterol efflux and its inhibition of SR-BI-
and HDL-dependent cholesterol efflux, shows that the
drug is equally potent in inhibiting these cell surface
transport proteins.
We also found that lipid-free apoA-I (10 !g protein/ml)
was a poor acceptor of SR-BI-mediated [3H]cholesterol ef-
flux compared with HDL (500 !g protein/ml) [2% vs.
61%, respectively; also see ref. (36)]. The low level of
lipid-free apoA-I-dependent [3H]cholesterol efflux from
Fig. 3. Concentration dependence of the inhibition of ABCA1-
and SR-BI-mediated [3H]cholesterol efflux by BLT-4. A: [3H]cho-
lesterol efflux from HEK[ABCA1] (closed symbols) or HEK[con-
trol] (open symbols) cells was determined in the presence
(squares) or absence (triangles) of 10 !g/ml lipid-free recombi-
nant human apoA-I and the indicated concentrations of BLT-4 as
described in the legend to Fig. 2 and Experimental Procedures. Val-
ues are expressed as the percentage of cellular [3H]cholesterol re-
leased into the medium after a 4 h incubation at 37"C. B: The effect
of BLT-4 on ABCA1-mediated and apoA-I-dependent [3H]choles-
terol efflux (closed squares) was calculated from the data in A as
described in the legend to Fig. 2 and Experimental Procedures. In
an independent experiment, SR-BI-mediated and HDL (500 !g
protein/ml)-dependent [3H]cholesterol efflux (open circles) was
determined as described in the legend to Fig. 2 and Experimental
Procedures. The maximum efflux in the absence of BLT-4 (60% of
total cellular cholesterol) was set to 100% (the 0% of control was
19%).
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ldlA[mSR-BI] and untransfected ldlA-7 control cells (!2%)
was insensitive to glyburide (data not shown). It is thus un-
likely that glyburide’s ability to affect SR-BI’s activity
has complicated the interpretation of previous studies
of ABCA1 activity, because those studies used lipid-free
apoA-I as an acceptor of glyburide-sensitive cholesterol ef-
flux.
We and others have found that the concentration of gly-
buride required to inhibit ABCA1 is substantially higher
than its reported in vitro Ki for other ABC proteins, such
as SUR1/2 [reviewed in ref. (53)]. It is possible that the
inhibition of ABCA1-mediated cholesterol efflux by gly-
buride is a secondary consequence of high concentrations
of glyburide interfering with other cellular processes, in-
cluding features of cellular cholesterol metabolism. We
were unable to detect glyburide inhibition of cholesterol
esterification (thin layer chromatographic assay) or of the
total cellular cholesterol levels in either HEK cells or
ldlA[mSR-BI] cells loaded with [3H]cholesterol (data not
shown). Thus, at least some aspects of cellular cholesterol
metabolism appear to be unaffected by high-dose gly-
buride treatment under the conditions used in these ex-
periments. We previously have shown that BLT-4 is a rela-
tively specific inhibitor in that it does not affect multiple
membrane transport processes, such as clathrin-depen-
dent endocytosis, lipid-raft-dependent endocytosis, and
the protein secretory pathway, nor does it have a detect-
able impact on the integrity of the actin and microtubular
networks (45). As was the case with glyburide, BLT-4 did
not appear to inhibit cholesterol esterification or to alter
total cellular cholesterol levels in either HEK cells or
ldlA[mSR-BI] cells loaded with [3H]cholesterol (data not
shown).
Effects of glyburide on SR-BI-mediated [3H]COE uptake 
from [3H]COE-HDL and 125I-HDL binding
Previous studies have shown a close relationship be-
tween SR-BI-mediated binding to HDL with both SR-BI-
mediated cholesterol efflux to HDL and selective lipid up-
take from HDL (24, 57, 65–68). We tested the effects of
glyburide on these two additional activities of SR-BI. Fig-
ure 5 shows that glyburide suppressed SR-BI-mediated
[3H]COE uptake from [3H]COE-HDL by ldlA[mSR-BI]
cells (IC50 ! 150 !M). Flow cytometric analysis of the sur-
face expression of SR-BI established that the effects of gly-
buride (at concentrations of '500 !M) on SR-BI’s activi-
ties were not attributable to a reduction in the steady-state
level of SR-BI on the cell surface (data not shown).2 Thus,
glyburide inhibited both lipid transport activities of SR-BI,
selective uptake and cholesterol efflux, as is the case for
the BLTs (45).3
BLTs 1–5 increase the affinity of 125I-HDL binding to
SR-BI at 37"C (lower apparent Kd) (45). The decreased
apparent Kd values are attributable, at least in part, to
decreased dissociation rates and are not accompanied
by substantially altered maximal binding values. Figure
5 shows that increasing concentrations of glyburide in-
Fig. 4. Concentration dependence of the inhibition of ABCA1-
and SR-BI-mediated [3H]cholesterol efflux by glyburide. A:
[3H]cholesterol efflux from HEK[ABCA1] (closed symbols) or
HEK[control] (open symbols) cells was determined in the pres-
ence (squares) or absence (triangles) of 10 !g/ml lipid-free re-
combinant human apoA-I and the indicated concentrations of
glyburide as described in Experimental Procedures. B: [3H]choles-
terol efflux from SR-BI-expressing ldlA[mSR-BI] (closed symbols)
or control ldlA-7 (open symbols) cells was determined in the pres-
ence (circles) or absence (triangles) of 500 !g of protein per milli-
liter of HDL and the indicated concentrations of glyburide as
described in the legend to Fig. 3B. C: ABCA1-mediated and apoA-I-
dependent [3H]cholesterol efflux (closed squares) was calculated
from the data in A as described in Experimental Procedures. SR-BI-
mediated and HDL-dependent [3H]cholesterol efflux (open circles)
was calculated from the data in B. Efflux to HDL in ldlA[mSR-BI]
cells in the absence of compound, and in ldlA-7 cells in the pres-
ence of compound, was used to set the 100% and 0% of control
values, respectively. There was a small, KKB-1-inhibitable effect of
glyburide on cholesterol efflux to HDL in ldlA-7 cells, which repre-
sents the efflux mediated by the low levels of endogenous SR-BI
that is expressed in these cells.
2 When ldlA[mSR-BI] or ldlA7 cells were treated with a very high
concentration of glyburide (1 mM) for a total of 3 h, we observed mor-
phological changes (e.g., changes in the appearance of the nucleus)
and occasionally signs of toxicity as measured by trypan blue exclusion.
3 Glyburide at a concentration of 1 mM has been reported to pre-
vent specific ABCA1- and apoA-I-dependent phospholipid (phosphati-
dylcholine) efflux from cells, determined as the difference in phospho-
lipid efflux from ABCA1-expressing cells measured in the presence
and absence of apoA-I in the extracellular medium (29). We also ob-
served this inhibition at very high doses of glyburide (500 !M and
higher). However, we found in our experiments that the glyburide-
induced decrease in specific apoA-I-dependent phospholipid efflux was
largely attributable to an increase in ABCA1-mediated efflux to the
apoA-I-free medium rather than to a substantial decrease in efflux to
the apoA-I containing medium (data not shown).
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creased the binding of 125I-HDL (10 !g protein/ml) to
ldlA[mSR-BI] cells in a manner that was correlated in-
versely with its inhibition of lipid transport (Figs. 4 and 5).
The increased binding of 125I-HDL to SR-BI observed at a
subsaturating concentration of 125I-HDL appeared to be
attributable, at least in part, to a glyburide-induced in-
crease in the affinity of SR-BI for 125I-HDL without a sub-
stantial change in the maximal binding values (Fig. 6).
For the 125I-HDL concentrations used in these experi-
ments [a relatively broad density range (23)], the appar-
ent Kd values were 26.2 ( 3.7 !g protein/ml in the ab-
sence of glyburide and 4.7 ( 0.7 !g protein/ml in the
presence of 250 !M glyburide. Thus, the effects of the
ABCA1 inhibitor glyburide on SR-BI’s activities were simi-
lar to the activities of the BLTs: increased HDL binding
and decreased lipid transport.
Effects of BLT-4 and glyburide on apoA-I binding
to ABCA1
The increase in affinity of SR-BI for HDL induced by
BLT-4 [see also ref. (45)] and glyburide prompted us to
examine the binding of apoA-I to ABCA1. Figure 7 shows
a representative assay that involved incubating ABCA1-
expressing cells with 125I-apoA-I, treating the cells with a
cleavable cross-linking agent (DSP), immunoprecipitating
cross-linked complexes with anti-ABCA1 antiserum, and
then detecting the coprecipitated 125I-apoA-I after break-
ing the cross-links and fractionating the samples by SDS-
PAGE (62). As expected, there was no detectable binding
of 125I-apoA-I to control cells transfected with empty vec-
tor (no ABCA1). Both glyburide [250–1,000 !M; see also
ref. (62)] and BLT-4 (150 !M) effectively blocked the
binding of 125I-apoA-I to ABCA1 at concentrations that in-
hibit ABCA1-mediated cholesterol efflux to apoA-I (Figs.
2–4). We did not detect a decrease in either the cell sur-
face levels or the total protein levels of ABCA1 in cells
treated under similar conditions with either compound
(data not shown). Thus, glyburide and BLT-4 inhibition of
125I-apoA-I binding to ABCA1 cannot be explained by de-
creases in either cell surface or total levels of ABCA1. The
inhibition of apoA-I binding to ABCA1 by glyburide and
BLT-4 contrasts their abilities to enhance the affinity of
HDL binding to SR-BI.
It is possible that the reciprocal inhibition of SR-BI and
ABCA1 by the structurally distinct small molecules BLT-4
and glyburide was simply a coincidence of multiple inde-
pendent activities of these compounds. An alternative,
more appealing explanation is that, despite the very dif-
ferent structures and physiologic functions of SR-BI and
Fig. 5. Effects of glyburide on SR-BI-mediated [3H]cholesteryl
oleyl ether ([3H]COE) uptake from [3H]COE-HDL and 125I-HDL
binding. SR-BI-expressing ldlA[mSR-BI] or control ldlA-7 cells were
preincubated with the indicated concentrations of glyburide, and
then the uptake of [3H]COE from [3H]COE-HDL (10 !g protein/
ml) (closed circles) or the binding of 125I-HDL (10 !g protein/ml)
(open circles) was determined in the presence or absence of a 40-
fold excess of unlabeled HDL (duplicate incubations). The specific
values (difference between the values in the absence and presence
of excess HDL) were normalized such that the value in the absence
of glyburide was set to 100%. The 100% of control values (nano-
grams of HDL protein per milligram of cell protein) for ldlA[mSR-
BI] cells were as follows: [3H]COE uptake, 1,962; 125I-HDL binding,
198. The 100% of control values for ldlA-7 cells were as follows:
[3H]COE uptake, 289; 125I-HDL binding, 21.
Fig. 6. Effects of glyburide on the concentration dependence of
125I-HDL binding to SR-BI-expressing cells. SR-BI-expressing
ldlA[mSR-BI] cells were preincubated in the absence (closed
squares) or presence (open squares) of 250 !M glyburide and then
incubated for 2 h at 37"C with the same amount of glyburide and
the indicated concentrations of 125I-HDL in the presence (single in-
cubations) or absence (duplicate incubations) of a 40-fold excess of
unlabeled HDL. The specific binding values are shown.
Fig. 7. Effects of BLT-4 and glyburide on 125I-apoA-I binding to
ABCA1. HEK293-EBNA-T cells were transiently transfected with ei-
ther an ABCA1 expression vector (ABCA1) or a control pcDNA1
vector (No ABCA1). One day after transfection, the cells were pre-
incubated for 1 h at 37"C in assay medium with the indicated con-
centrations of BLT-4 or glyburide. The binding of 125I-apoA-I (2
!g/ml, 1 h, 37"C) in the presence or absence of a 30-fold excess of
unlabeled apoA-I and the indicated concentrations of inhibitors
was measured using a dithiobis (succinimidyl propionate) cross-
linking assay as described in Experimental Methods. Bound 125I-
apoA-I was fractionated by SDS-PAGE and detected in the gels us-
ing a PhosphorImaging STORM860 system (top), and the relative
amounts of 125I-apoA-I in the lanes were determined using Im-
ageQuant software (bottom). Values shown in the lower portion of
the figure are representative of two independent experiments per-
formed in duplicate. Error bars represent the ranges of duplicate
determinations.
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ABCA1, some features of their mechanisms of lipid trans-
port may have similarities or even share common steps
that are sensitive to BLT-4 and glyburide. This explanation
is supported by the observation that the potencies (IC50)
for glyburide inhibition of SR-BI and ABCA1 are virtually
identical, as they are for BLT-4.
The molecular targets of BLT-4 and glyburide responsi-
ble for their inhibition of SR-BI- and ABCA1-mediated
lipid transport activities have not yet been identified, and
they need not be the same. However, these lipid transport
proteins themselves are obvious candidates. Glyburide
and BLT-4 might bind to either the same or distinct sites
on each protein. It is also possible that the direct targets
of these inhibitors are not the transporters themselves
but rather some other protein(s) or lipids (e.g., a specific
membrane domain). It is noteworthy that, even though
the structures of glyburide and BLT-4 (with the exception
of the methoxyphenyl and the urea functionalities) differ
(Fig. 1), they both can inhibit the activities of several ABC
proteins. BLT-4 inhibits ethidium bromide efflux from
Staphylococcus aureus mediated by NorA, a member of the
ABC superfamily (69), as well as ABCA1 activity (this
study). Glyburide, which was originally identified as a
drug that binds to and inhibits the ABC subunit (SUR) of
the ATP-sensitive K)ATP channels, can interfere with path-
ways involving the ABC proteins cystic fibrosis trans-
membrane regulator (54), bile salt export pump (56),
and multidrug resistance P-glycoprotein (55), as well as
ABCA1 (29, 31, 46–51). It is possible that the target of the
inhibitory activities of both drugs could be a cell surface
or intracellular ABC transporter(s) other than ABCA1
that may directly or indirectly influence lipid transport
mechanisms mediated by both SR-BI and ABCA1.
Despite the similar abilities of either glyburide or BLT-4
to inhibit lipid transport mediated by ABCA1 and SR-BI,
there are several striking differences in the mechanisms
by which these transporters function. Lipid-free apoA-I
binds preferentially to ABCA1, and along with pre#-apoA-I
it is the preferred cholesterol acceptor from ABCA1 rela-
tive to spherical, lipid-rich HDL particles (32–36). In con-
trast, spherical, lipid-rich HDL particles are the preferred
ligands for SR-BI (15). The effects of glyburide and BLT-4
on ligand binding also highlight the differences between
these transporters. Both inhibitors block ligand binding
to ABCA1, whereas they enhance the ligand binding affin-
ity of SR-BI. Additional studies will be required to eluci-
date the mechanisms underlying the complex effects of
these inhibitors on these key cholesterol transporters.
In summary, we have identified BLT-4 as a new and rela-
tively potent inhibitor of ABCA1. We also show that gly-
buride is a heretofore unrecognized inhibitor of SR-BI.
The reciprocal inhibition of these transport proteins by
BLT-4 and glyburide raises the possibility that the mecha-
nisms of lipid transport by SR-BI and ABCA1 might possi-
bly involve another ABC transporter.
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Abstract
The scavenger receptor class B, type I (SR-BI) mediates the cellular selective uptake of cholesteryl esters and other lipids from high-
density lipoproteins (HDL) and low-density lipoproteins (LDL). This process, unlike classical receptor-mediated endocytosis, does not result
in lipoprotein degradation. Instead, the lipid depleted particles are released into the medium. Here we show that selective lipid uptake
mediated by murine SR-BI can be uncoupled from the endocytosis of HDL or LDL particles. We found that blocking selective lipid uptake
by incubating cells with the small chemical inhibitors BLT-1 or BLT-4 did not affect endocytosis of HDL. Similarly, blocking endocytosis by
hyperosmotic sucrose or K+ depletion did not prevent selective lipid uptake from HDL or LDL. These findings suggest that mSR-BI-
mediated selective uptake occurs at the cell surface upon the association of lipoproteins with mSR-BI and does not require endocytosis of
HDL or LDL particles.
D 2005 Elsevier B.V. All rights reserved.
Keywords: High-density lipoprotein; Low-density lipoprotein; Scavenger receptor; Scavenger receptor class B, type I; Endocytosis; BLT
1. Introduction
The high-density lipoprotein (HDL) receptor SR-BI
(scavenger receptor class B, type I) plays an important role
in the metabolic control of HDL [1]. SR-BI mediates the
selective uptake of cholesteryl esters [2] and other lipids [3–
6] from HDL particles by cells, and it also facilitates the
transfer of cholesterol from cells to HDL or to other
acceptors present in the extracellular environment [7–9]. In
addition, SR-BI binds to [10] and mediates selective lipid
uptake from LDL [11–14], although to a lesser extent than
from HDL. Results from in vitro experiments indicate that
liposomes containing SR-BI and no other proteins are
sufficient to sustain the selective transfer of cholesteryl
esters from HDL particles to these liposomes [15].
Intracellular lipoprotein degradation is not required for
selective lipid uptake in cells expressing SR-BI, because
subsequent to lipid depletion most or all the HDL [2,16–18]
or LDL particles [19–21] are released to the extracellular
space. Although this is consistent with lipid transfer
occurring at the cell surface, it does not rule out the
possibility that lipid transfer might occur in a specialized
endosomal compartment and thus depend on the internal-
ization of HDL or LDL complexed to SR-BI. The model of
endocytosis-independent selective lipid uptake is supported
by the in vitro liposome reconstitution experiments [15] and
electron microscopic images showing little or no intra-
cellular HDL in cultured murine adrenal cells [22] or in
steroidogenic tissues [23] that naturally exhibit high levels
of SR-BI-mediated selective uptake. It is also supported by
the observation that the transfer of fluorescently labeled-
cholesterol from HDL to cells expressing SR-BI was not
affected by ATP depletion, which blocked HDL internal-
ization [24]. The alternative model of endocytosis-depend-
1388-1981/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbalip.2005.02.007
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ent selective lipid uptake is supported by reports showing
that the extent of HDL cycling between the cell surface and
intracellular compartments is directly correlated with the
efficacy of selective uptake [25–27].
To distinguish between these two models, we took
advantage of distinct treatments that prevent either cellular
endocytosis or SR-BI-mediated selective lipid transport to
ask if the blockage of one pathway affects the other. We
found that exposure of cells expressing murine SR-BI
(mSR-BI) to BLT-1 or BLT-4, two potent small chemical
inhibitors of SR-BI-dependent selective lipid uptake [28],
did not interfere with the low level of internalization of
HDL mediated by mSR-BI. The transient treatment of
cells to block endocytosis with hyperosmotic sucrose
[29,30] or the depletion of intracellular potassium
[30,31] prevented the low levels of mSR-BI-mediated
internalization of HDL and LDL, but did not inhibit mSR-
BI-mediated selective uptake from these lipoproteins.
Taken together, these results show that lipoprotein internal-
ization is not a requisite for efficient mSR-BI-mediated
lipid transport.
2. Materials and methods
2.1. Chemicals
Stock solutions of BLT-1 (Chembridge Corp.) and BLT-4
[32] were prepared in 100% DMSO and diluted into the
appropriate assay media immediately prior to use. The final
concentration of DMSO in the media was 0.5% (v/v). The
control assay media contained 0.5% DMSO without BLT.
2.2. Lipoproteins
Human HDL and LDL were isolated and labeled with
Alexa Fluor 568 (Molecular Probes) (Alexa-HDL and
Alexa-LDL), 125I (125I-HDL), 1,1V-dioctadecyl-3,3,3V,3V-
tetramethylindodicarbocyanine 4-chlorobenzenesulfonate
(DiD, Molecular Probes) (DiD-HDL and DiD-LDL), and
[3H]cholesteryl oleyl ether ([3H]CEt, [3H]CEt-HDL and
[3H]CEt-LDL) as described [2,10,33–35]. LDL was labeled
with [3H]CEt according to the [3H]CEt-HDL labeling
procedure [2].
2.3. Cells
LDL receptor deficient Chinese hamster ovary cells that
express low levels of endogenous SR-BI (ldlA-7, [36]) and
ldlA-7 cells that were stably transfected to express high
levels of murine SR-BI (ldlA[mSR-BI]) [2] were grown in
Ham’s F12 culture medium supplemented with 5% (v/v)
fetal bovine serum (FBS), 100 Ag/ml each of penicillin and
streptomycin and 500 Ag/ml G418 (for ldlA[mSR-BI] cells).
Y1-BS1 adrenal cells were grown in an RMPI culture
medium (Gibco BRL) supplemented with 10% fetal bovine
serum and 100 Ag/ml each of penicillin and streptomycin.
The expression of endogenous SR-BI was induced by
treating the Y1-BS1 cells for 24 h in the same medium
supplemented with 0.1 AM adrenocorticotropic hormone
(ACTH, Sigma) [37].
2.4. General assay conditions
Prior to the assay, cells were grown for 2 days on glass
coverslips (for microscopy experiments) or in regular 24-
well plates (for assays using radiolabeled lipoproteins). On
the day of the assay, cells were washed twice in the
appropriate culture medium supplemented with 0.5% bovine
serum albumin and 25 mM HEPES/KOH, pH 7.4 but
without serum, antibiotics or G418 (assay medium). For
experiments involving DiD-labeled lipoproteins, we used
Leibowitz medium (Gibco BRL) containing 0.5% bovine
serum albumin (BSA) and 25 mM HEPES/KOH, pH 7.4.
For control experiments, we used assay medium supple-
mented 0.5% DMSO.
2.5. Hypertonic sucrose treatment
Endocytosis was blocked by incubation with hypertonic
sucrose [29,30]. Briefly, cells were incubated at 37 8C for 30
min with 0.45 M sucrose in the appropriate assay medium.
Alexa-568, DiD, 125I- or [3H]CEt-labeled HDL or LDL was
then added for an additional incubation of 1 h at the same
temperature. During the last 20 min of the incubation, 50
Ag/ml of Alexa488-labeled human holotransferrin (Molec-
ular Probes) were added.
2.6. Potassium depletion
Endocytosis was blocked by potassium depletion
[30,31]. Briefly, cells were washed twice with PBS/1 mM
MgCl2/0.1 mM CaCl2 (PBS+) followed by one wash with
hypotonic medium (PBS+/H2O (1:3 v/v)) followed by a
brief 5–7 min incubation with the hypotonic medium. The
cells were then washed 5–8 times in a medium containing
150 mM NaCl/1 mM MgCl2/1 mM CaCl2/20 mM HEPES/
KOH pH 7.4/0.5% DMSO/0.5% BSA followed by a 30 min
incubation in the same medium. Alexa-568, DiD or 125I-
labeled HDL or LDL was then added for an additional
incubation of 1 h at the same temperature. During the last 20
min of the incubation, 50 Ag/ml of Alexa488-labeled human
holotransferrin (Molecular Probes) was added.
2.7. Preparation of cells for fluorescence microscopy
After exposure to Alexa-HDL or -LDL, cells were chilled
on ice for 10 min, washed three times with PBS+ and then
fixed for 1 h on ice with 4% (w/v) paraformaldehyde (PFA)
dissolved in PBS+(PBS-PFA). The PFA was quenched by
the addition of 50 mM NH4Cl for 5 min at room temperature
(RT). Following a wash with PBS+, the surfaces of the cells
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were stained at RT for 30 min with Alexa647-labeled
Concanavalin A (100 Ag/ml, Molecular Probes) in PBS+
containing 5% (w/v) BSA (PBS-BSA). The cells were then
washed in PBS-BSA, fixed again in PBS-PFA for 15 min at
RT and quenched as described above. We used the
lipophylic dye DiD instead of the more commonly used
dye DiI to avoid the excitation of DiI by the 488 nm spectral
laser line required to excite Alexa-488. After the exposure
of cells to DiD-labeled HDL or LDL, the medium
containing the fluorescent lipoproteins was removed and
each coverslip was placed in a live-cell imaging open
perfusion chamber at 37 8C containing hypertonic sucrose
or buffer A (for K+ depletion) to maintain the endocytic
block. Cells were imaged with a spinning disk confocal
microscope under the control of SlideBook 4 (Intelligent
Imaging Innovations). Three-dimensional image stacks were
recorded by sequential acquisition of optical sections along
the z-axis with steps of 0.25 Am.
2.8. Cellular binding, uptake, and degradation of radio-
labeled HDL and LDL
Assays of the uptake of [3H]CEt from [3H]CEt-HDL or
[3H]CEt-LDL, and the cellular degradation and binding of
125I-HDL and 125I-LDL (all at 10 Ag protein/ml) were
performed in ldlA[mSR-BI] cells and control untransfected
ldlA-7 cells as described [2]. The amounts of cell-associated
[3H]cholesteryl ether are expressed as the corresponding
amounts of protein (ng) in the [3H]CEt-labeled lipoprotein
to permit a direct comparison of the relative amounts of 125I-
HDL or 125I-LDL binding and [3H]CEt uptake [38].
Statistical analysis was performed with Graphpad Prism 3
software from Graphpad Software, Inc. (San Diego).
2.9. Flow cytometric analysis of mSR-BI surface expression
The surface expression of mSR-BI in ldlA[mSR-BI] and
ldlA7 cells was determined using the polyclonal anti-SR-BI
antibody KKB1 [33] as described [28].
3. Results
3.1. The inhibition of mSR-BI-mediated selective lipid
uptake by BLTs does not prevent the endocytosis of HDL
It was previously shown that the expression of SR-BI
results in the specific binding of HDL to the cell surface [2]
and in the internalization of relatively little HDL [25–
27,39]. These observations were confirmed by experiments
using three-dimensional confocal fluorescence microscopy.
In these experiments, stably transfected cells expressing
high levels of mSR-BI (ldlA[mSR-BI] cells, [2]) were
exposed for 1 h at 37 8C to HDL fluorescently labeled on its
protein moiety with Alexa-568 (Alexa-HDL). Control
untransfected ldlA-7 cells that express very little mSR-BI
[36] exhibited little binding or endocytosis of the fluo-
rescently labeled lipoprotein (Fig. 1A, circumscribed areas
demarcate the inside of the cell). The colocalization of
Alexa-HDL with the fluorescently labeled plasma mem-
brane marker Concanavalin A demonstrated that in
ldlA[mSR-BI] cells the majority of the HDL was bound at
the cell surface (Fig. 1D, F). Only a small portion of the
Alexa-HDL was found in endocytic compartments, visual-
ized by colocalization with Alexa 488-transferrin internal-
ized by receptor-mediated endocytosis (Fig. 1E) [40].
We have previously identified a set of small molecule
inhibitors named BLTs that block SR-BI-mediated selective
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Fig. 1. Effects of BLT-1, hypertonic sucrose treatment and cellular
potassium depletion on mSR-BI-mediated endocytosis of HDL.
ldlA[mSR-BI] cells and ldlA-7 cells were incubated for 30 min with the
control medium (A–F), 1 AM BLT-1 (G–I), hypertonic sucrose medium (J–
L) or medium lacking potassium (M–O). The cells were then incubated for
another 60 min with Alexa568-HDL (10 Ag protein/ml) followed by the
addition of Alexa488-transferrin (TF) (50 Ag/ml) during the last 20 min of
incubation. All the incubations were performed at 37 8C. Cells were
transferred to 4 8C, fixed and incubated with Alexa647-Concanavalin A
(ConA) to label the external cell surfaces. The cells were imaged using
three-dimensional fluorescence confocal microscopy and representative
confocal sections are shown. The white lines circumscribe the cell interior.
Similar results were obtained using unlabeled HDL visualized with the
polyclonal antibody 5F6 (specific for the major HDL protein apoA-I,
University of Ottawa Heart Institute) in PFA fixed cells permeabilized with
0.1% saponin (not shown).
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lipid uptake from HDL but do not block the entry of
transferrin, EGFF or cholera toxin [28]. To test whether
BLTs block selective uptake by preventing HDL internal-
ization, we incubated the mSR-BI expressing cells with
BLT-1, which is the most potent inhibitor. We found, as
expected [28], a 83% decrease in the selective uptake of
[3H]cholesteryl ether ([3H]CEt) from [3H]CEt-HDL and a
two-fold increase in cell-associated 125I-HDL (not shown).
Under these conditions in which selective lipid transfer was
blocked, we observed an increase in the amount of Alexa-
HDL bound at the cell surface, and a small increase in the
amount of internalized Alexa-HDL (Fig. 1G). Similar
results were obtained when cells were treated with 50 AM
BLT-4 (not shown). These results suggest that the inhibition
of selective lipid uptake by the BLTs is not a consequence of
a block in the SR-BI-mediated endocytosis of the HDL
particles.
3.2. The inhibition of HDL endocytosis does not prevent
mSR-BI-mediated selective lipid uptake
The second approach we used to determine if lipoprotein
internalization is required for mSR-BI-mediated selective
lipid uptake was to examine the effects on selective lipid
uptake of an acute block of endocytosis. A brief exposure of
ldlA[mSR-BI] cells to hyperosmotic sucrose [29,30] or
transient depletion of intracellular K+ [30,31] results in the
expected strong inhibition of receptor-mediated endocytosis
of Alexa-488 transferrin (Fig. 1K, N, compared to B, E and
H). Similarly, these perturbations interfered with the uptake
of Alexa-HDL particles (Fig. 1J, M, compared to D and G).
In contrast, the mSR-BI-dependent selective uptake of the
fluorescent lipid probe DiD from DiD-labeled HDL
particles to the cells was not affected (Fig. 2). Similar
results (not shown) were obtained using ACTH-treated Y1-
BS1 murine adrenal cortical cells [37] that normally express
mSR-BI. Combined, these qualitative results suggest that
blocking the internalization of HDL particles does not affect
noticeably mSR-BI-mediated selective lipid uptake. Inde-
pendent support for these observations was obtained by
following the effect of hypertonic sucrose treatment on the
cell association and degradation of 125I-HDL, and on the
selective uptake of [3H]CEt from [3H]CEt-HDL (Fig. 3A–
C). These experiments showed that in ldlA[mSR-BI] cells
under normal conditions most of the cell-associated 125I-
HDL, which represents both surface bound and internalized
lipoprotein, was dependent on mSR-BI expression as there
was little association in control ldlA-7 cells. Hypertonic
sucrose treatment decreased this association by ~30% (Fig.
3A). In addition, the low level of intracellular 125I-HDL
proteolysis, as measured by the generation of 125I-labeled
acid soluble degradation products released in to the medium,
was also reduced when the ldlA[mSR-BI] cells were treated
with hyperosmotic sucrose (Fig. 3B). This was presumably
due to the inhibition of HDL internalization, since the
amount of HDL at the cell surface as determined by
fluorescence microscopy of Alexa-HDL did not change
(Fig. 1), and the level of SR-BI at the cell surface as was not
altered (determined by flow cytometry, not shown). Taken
together, these results demonstrate that hyperosmotic
sucrose prevents the internalization of HDL mediated by
mSR-BI. Under these conditions of endocytic blockade,
however, the selective uptake of [3H]CEt from [3H]CEt-
HDL was not affected (Fig. 3C). Thus, mSR-BI-mediated
selective lipid uptake from HDL can occur independently of
HDL endocytosis and degradation.
3.3. Uncoupling of mSR-BI-mediated LDL endocytosis and
selective lipid uptake
Next, we asked if mSR-BI-mediated selective uptake
from LDL requires endocytosis of LDL particles. As shown
in Fig. 4A, there was virtually no surface binding or
internalization of Alexa568-LDL by control ldlA-7 cells,
which express essentially no SR-BI [2] or LDL receptor
[36]. In contrast, the expression of mSR-BI in ldlA[mSR-
BI] cells led to the intracellular accumulation of LDL
labeled on its protein moiety with Alexa568 (Alexa-LDL) in
an endosomal compartment (Fig. 4D), identified by the
colocalization with Alexa488-transferrin internalized
through the clathrin-mediated pathway (Fig. 4E). Further-
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Fig. 2. Effect of hypertonic sucrose treatment and cellular potassium
depletion on mSR-BI-mediated selective uptake of DiD from DiD-HDL.
ldlA[mSR-BI] cells were incubated for 30 min with the medium only (A,
B), hypertonic sucrose medium (C, D) or potassium-controlled medium (E,
F) followed by the addition of DiD-labeled HDL (DiD-HDL) (80 Ag
protein/ml final) for another 60 min. Alexa488-transferrin (TF) was added
during the last 20 min of incubation. All incubations were carried at 37 8C.
Cells were washed at room temperature and imaged without fixation by
confocal fluorescence microscopy. Representative sections are shown.
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more, the incubation of ldlA[mSR-BI] cells with 125I-LDL
results in a low level of lipoprotein degradation not
observed in the untransfected control ldlA-7 cells (Fig.
3E). Thus, mSR-BI mediates a low level of endocytosis and
degradation of LDL.
As was the case for HDL, hyperosmotic treatment of
ldlA[mSR-BI] cells also inhibited the mSR-BI-mediated
internalization (Fig. 4G) and degradation of LDL (Fig. 3E)
but did not interfere with mSR-BI-dependent selective
uptake of [3H]CEt from [3H]CEt-LDL (Fig. 3F) or of DiD
from DiD-LDL (Fig. 5). As expected, ldlA-7 cells did not
support selective uptake from [3H]Cet-LDL (Fig. 3F) or
DiD-LDL (not shown), nor cell association and degradation
of 125I-LDL (Fig. 3D, E). Based on these observations, we
suggest that the mSR-BI-mediated selective lipid uptake
from LDL also does not require lipoprotein endocytosis.
4. Discussion
In vitro and in vivo studies have established that the HDL
receptor SR-BI plays a key role in mediating the physio-
logically relevant cellular selective uptake of lipid from
lipoproteins, and thus controls the metabolism of HDL [1].
The detailed molecular mechanisms underlying selective
lipid uptake mediated by mSR-BI remain to be established.
One area of controversy regarding the mechanism of mSR-
BI-mediated selective lipid uptake has been the role of
receptor-ligand endocytosis. In the current study we have
shown that the inhibition of cellular lipoprotein endocytosis
by either hypertonic sucrose treatment or K+ depletion does
not prevent the mSR-BI-mediated selective uptake of lipids
(cholesterol ethers or the lipophilic dye DiD) from either
HDL or LDL. These results support our previous conclusion
Fig. 3. Effects of endocytic block by hypertonic sucrose on cell association and degradation of 125I-HDL and 125I-LDL and on selective uptake of [3H]CEt from
[3H]CEt-HDL or [3H]CEt-LDL. Cells (ldlA[mSR-BI] or ldlA-7) were incubated for 30 min with the control medium (!) or hypertonic sucrose medium (+)
followed by the addition for 60 min of 125I-HDL, 125I-LDL, [3H]CEt-HDL, or [3H]CEt-LDL (10 Ag protein/ml final) in the presence or absence of a 40-fold
excess of the respective unlabeled lipoproteins. The cells were washed and lysed to determine the total amounts of 125I-HDL (A) or 125I-LDL (D) associated
with the cells (this value represents lipoprotein both bound at the cell surface and internalized). Media were harvested and used to determine the extent of 125I-
HDL (B) or 125I-LDL (E) degradation. The selective transfer of [3H]CEt from the [3H]CEt-HDL (C) or [3H]CEt-LDL (F) to the cells was calculated by
subtracting the contributing amounts of [3H]CEt contained in the lipoproteins associated with the cells. The mean values and standard errors determined in 6
independent experiments are shown. P values are shown for ldlA[mSR-BI] samples only.
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that mSR-BI-mediated HDL binding and selective lipid
uptake are intrinsic properties of the receptor that do not
require the intervention of other proteins or traffic to specific
intracellular compartments [15]. Furthermore, we found that
the specific inhibition of mSR-BI-dependent lipid transport
by the small molecules BLT-1 and BLT-4 does not involve
the inhibition of HDL particle internalization mediated by
mSR-BI. Our results are consistent with previous electron
microscopic morphological studies that support the model
of HDL particle internalization independent SR-BI-medi-
ated lipid transport [22,23].
During the preparation of this manuscript, two reports
appeared supporting the proposal that SR-BI-mediated
lipid transport is independent of lipoprotein internalization.
In the first study, Maxfield and co-workers [24] reported
that the intracellular depletion of ATP in HepG2 cells
increased the efficiency of selective lipid uptake mediated
by human SR-BI from the HDL of the fluorescent
unesterified cholesterol analogue dehydroergesterol, even
though the endocytic uptake of HDL particles was
blocked. They noted, however, that the dehydroergesterol
intracellular trafficking pathway involved a rapid non-
vesicular mechanism that might differ from that of the
selective uptake of HDL’s cholesteryl esters (or cholesteryl
ether analogues). In the second study, Eckhardt et al. [41]
compared the selective uptake and endocytic activities of
mSR-BI and a naturally occurring murine splice variant
called SR-BII in non-polarized transfected cells. SR-BII
and SR-BI differ only in their short 45–47 amino acid C-
terminal cytoplasmic domains [42]. The steady state ratios
of the levels of intracellular-to-cell surface receptor and
associated HDL were substantially higher in the SR-BII
expressing cells, possibly due to SR-BII’s more rapid
endocytosis (and/or slower recycling to the cell surface).
Selective uptake by these receptors positively correlated
with their levels of surface expression, but not with the
levels of internalized HDL. Eckhardt et al. suggested that
these data support the model that most of the selective
uptake mediated by SR-BI occurred at the cell surface,
although their study did not rule out the possible require-
ment for a rapid cycle of endocytosis and recycling that
would result in a very small internal pool of SR-BI and its
ligand that is able to efficiently support selective uptake. It
remains possible that in some specialized cells (e.g.
mammary epithelial cells [43]) mSR-BI-mediated endocy-
tosis plays a role in lipid metabolism; however, in many, if
not all cases, it clearly is not required for efficient selective
uptake.
These reports, together with our study, demonstrate that
the endocytosis of HDL or LDL is not required for mSR-BI-
mediated selective uptake from these lipoproteins. Further-
more, our data strongly suggests that selective uptake occurs
at the surface of the cell.
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endocytosis of LDL. ldlA-7 and ldlA[mSR-BI] cells were treated with
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Chemical genetics seeks to identify small molecules that
afford functional dissection of cell biological pathways.
Previous screens for small molecule inhibitors of exocytic
membrane traffic yielded the identification and character-
ization of several compounds that block traffic from the
Golgi to the cell surface as well as transport from the
endoplasmic reticulum to the Golgi network [Feng et al.
Proc Natl Acad Sci USA 2003;100:6469–6474; Yarrow et al.
Comb Chem High Throughput Screen 2003;6:279–286;
Feng et al. EMBO Reports 2004: in press]. Here, we
screened these inhibitors for potential effects on endocy-
tic membrane traffic. Two structurally related sulfona-
mides were found to be potent and reversible inhibitors
of transferrin-mediated iron uptake. These inhibitors do
not block endoplasmic reticulum-to-Golgi transport, but
do disrupt Golgi-to-cell surface traffic. The compounds
are members of a novel class of sulfonamides that elevate
endosomal and lysosomal pH, down-regulate cell surface
receptors, and impair recycling of internalized transferrin
receptors to the plasma membrane. In vitro experiments
revealed that the sulfonamides directly inhibit adenosine
triphosphate (ATP) hydrolysis by the V-ATPase and that
they also possess a potent proton ionophore activity.
While maintenance of organellar pH is known to be a
critical factor in both endocytosis and exocytosis, the
precise role of acidification, beyond the uncoupling of
ligands from their receptors, remains largely unknown.
Identification of this novel class of sulfonamide inhibitors
provides new chemical tools to better understand the
function of organelle pH in membrane traffic and the
activity of V-ATPases in particular.
Key words: chemical genetics, membrane traffic, organ-
elle pH, sulfonamides
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Chemical genetics seeks to identify novel small molecules
that afford functional dissection of cell biological pathways
(1–3). Such compounds are useful as bioactive molecular
probes and allow further analysis of the relationship
between target processes or proteins within cells and
their cellular function. We have taken a chemical genetics
approach to identify small cell-permeable molecules that
block exocytosis (4,5). The exocytic or constitutive secre-
tory pathway encompasses vesicular movement of newly
synthesized membrane proteins and secretory compon-
ents from the endoplasmic reticulum (ER) to the Golgi
apparatus with final arrival at the cell surface (for resident
plasma membrane proteins) or export (for secreted pro-
teins). To identify small molecule inhibitors of this path-
way, we employed a medium-throughput screen based on
cell fluorescence imaging of a green fluorescent protein
(GFP)-tagged vesticular stomatitis virus glycoprotein
temperature-sensitive mutant (VSV-Gts045) which transits this
pathway in a well-defined and experimentally manipulable
fashion (4,5). This investigation led to the discovery of
Exo1(6B6) and Exo2(15E19), agents that block exit from
the ER (4), as well as five other compounds (16D20,
30N12, 4F17, 17G7, 16F19) that block exit from the
Golgi (5). To further examine the selectivity of these com-
pounds as inhibitors of specific steps of intracellular mem-
brane traffic, we undertook the present study to explore
their effects on the endocytic pathway.
The process of endocytosis brings extracellular material
and plasma membrane proteins into cells from their sur-
face through a series of membrane-bound compartments,
often referred to as early, sorting and recycling endo-
somes. Internalized material is sorted and ultimately dir-
ected from these endocytic organelles for degradation in
lysosomes or for return to the cell surface (recycling). Our
knowledge of the endocytic recycling pathway is largely
based on detailed analysis of the membrane traffic of
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transferrin (Tf). This serum iron-binding protein associates
with specific cell surface receptors to be internalized and
delivered to the endocytic pathway. These binding inter-
actions are facilitated at the extracellular pH of 7.4 with
high ligand binding affinity (Kd ! 1–5 nM) (6,7). Tf–TfR com-
plexes cluster into clathrin-coated pits to be delivered to
early endosomes. The pH of endosomes is lowered by an
ATP-dependent proton pump; under these conditions, the
release of iron from Tf is facilitated through its interactions
with Tf receptor (8). Unlike many other ligands, apoTf
(devoid of its cargo iron) remains bound to its receptor
and is therefore recycled back to the cell surface, where
it can be released for further rounds of iron delivery (9–11).
The vesicular movement of the Tf receptor through the
early sorting and recycling endosomal pathway is well-
defined (12).
In screening the small molecule inhibitors of exocytosis for
their effects on cellular iron assimilation through the Tf
cycle, we fortuitously identified a family of sulfonamide
compounds that blocked uptake of iron via the Tf receptor
pathway. Seven members of this family were character-
ized with IC50 values ranging from 0.1mM to greater than
250mM. Detailed study of one member, 16D10, revealed
that treatment with this compound increases the pH of
compartments of the endocytic pathway, thereby blocking
both the release of iron from Tf and recycling of Tf recep-
tors to the cell surface. Results from biochemical experi-
ments presented here demonstrate that a potential target
of the compounds is the V1 domain of vacuolar ATPases
(V-ATPases), which is responsible for pumping protons
into the lumen of a variety of organelles, including endo-
somes, lysosomes and the Golgi apparatus. In addition,
we found that members of the sulfonamide family can act
as proton ionophores in vitro. While it is well-established
that maintenance of organellar pH is a critical factor in
both endocytic and exocytic membrane traffic, the precise
role of acidification in these pathways remains largely
unknown. The novel class of sulfonamide inhibitors there-
fore provides new chemical tools to better understand the
function of organelle pH in membrane traffic and to study
functional aspects of V-ATPases in particular.
Results
Compounds that block Golgi to plasma membrane
traffic inhibit Tf-mediated iron uptake
In a recent high throughput screen of more than 10 000
chemicals from the DIVERSet E (ChemBridge Corp.,
San Diego, CA) for inhibitors of exocytosis, seven small
molecules were identified that reduced the delivery of
GFP-tagged VSV-Gts045 to the cell surface (4,5). Two com-
pounds, 6B6 and 15E19, now called Exo1 and Exo2,
respectively, were characterized to block exit from the
ER (4). Five others, 16D20, 30N12, 4F17, 17G7, and
16F19, did not affect VSV-Gts045 traffic from the ER to
the Golgi apparatus, but instead inhibited the membrane
protein’s exit from the Golgi to the cell surface (5). Struc-
tures of these seven small molecule inhibitors are shown
in Figure 1. When tested at 50mM, these compounds
reduced the amount of the viral glycoprotein delivered to
the cell surface with inhibitory potencies that ranged
between 95 and 30%, with 6B6> 15E19> 16D20–
16F19–30N12–4F17> 17G7 (Figure 2).
To examine the effect of this set of inhibitors on the
endocytic pathway, uptake of radioactive iron from Tf
was measured in the presence of 50mM of the com-
pounds. After association with its receptor at the cell sur-
face, Tf delivers iron to cells via the endocytic pathway. As
shown in Figure 3, none of the drugs affected cell-
associated 55Fe at 4 !C (open bars), a temperature that
blocks endocytosis of Tf. These data indicate that none of
the drugs permeabilizes cells or in any way promotes non-
endocytic uptake of iron from Tf. However, Tf-mediated
uptake of 55Fe at 37 !C (closed bars) was inhibited by 85%
to 5% with an order of potency 16D20–30N12–16F19>>
17G7> 4F17–15E19–6B6. This order of potency was
completely different from inhibition of VSV-G traffic and
confirms the selectivity of 6B6 (Exo1) and 15E19 (Exo2) to
inhibit ER-to-Golgi transport. In contrast, inspection of the
chemical features of two of the most potent inhibitors
of both exocytic and endocytic traffic, 30N12 and 16F19
(Figure 1), suggested a common structural basis for their
effects on both pathways. Based on the presumption that
these compounds might selectively target a cellular com-
ponent functioning in both the endocytic and exocytic
pathways, these compounds became a focus for further
investigation.
Inhibition of Tf-mediated iron uptake by 30N12 and
16F19 is dose-dependent and reversible
The dose–response of inhibition of Tf-mediated iron uptake
by 30N12 and 16F19 was determined. Both compounds
effectively blocked iron uptake in a dose-dependent man-
ner, with IC50 values of 0.1 and 2mM, respectively (Figure 4).
Moreover, inhibition by 30N12 and 16F19 was reversible
(Figure 5). In these experiments, cells were either first
treated with vehicle solvent (DMSO) followed by a 1-h
incubation with the inhibitor (open bars) or they were
treated with the compounds for 1 h, followed by a 4-h
recovery period with DMSO added (solid bars). Reversal
of the inhibition of Tf-mediated iron uptake under the latter
conditions also confirmed that there were no confounding
solvent effects of vehicle treatment, and that these com-
pounds were not toxic to cells.
Structurally related sulfonamides inhibit membrane
traffic
Based on the chemical structures of 30N12 and 16F19,
five other sulfonamide compounds were selected from the
ChemBridge DIVERSet E (Figure 6). The ability of mem-
bers of this family of sulfonamides to inhibit uptake of 55Fe
Sulfonamide Inhibitors of Membrane Traffic
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from Tf was determined in a series of dose–response
experiments that established IC50 values from 0.1mM
(30N12) to > 250mM (23H9). Inhibition studies of the ability
of these sulfonamide family members to block cell surface
delivery of VSV G protein revealed a similar range of IC50
values (data not shown). From the relative potency of the
compounds (30N12> 16L2–16F19–16D2> 16D10>>O-1
and 23H9), limited structure-activity information can be
deduced. In more potent compounds, the sulfonamide is
flanked by a single benzyl ring on the sulfonyl-group,
whereas bulkier aryl groups are tolerated on the amide
(e.g. 16F19). A converse configuration (23H9 vs. 16L2)
significantly impairs inhibitory potency. Chloro- and/or
nitroso substituents on the single benzyl ring off the
sulfonyl-group do not appear to affect the compound’s
action (e.g. 30N12 vs. 16L2). On the aryl group adjacent
to the amide, a halide is invariantly present in the para
position; elimination of this halide greatly reduces the
ability of the sulfonamide to inhibit both endocytosis and
exocytosis (O-1). For more detailed functional studies, we
focused on 16D10 since it has a structure representing the
most significant aspects of this class of compounds: both
chloro- and nitroso-groups are present on an aryl ring
adjacent to the sulfonyl-group and a halide is para to the
amide on a benzyl group, which itself is connected via an
amide linkage to a second benzyl ring. As a control for
some of these experiments, we employed O-1, which
lacks the halide and nitroso constituents and displays an
IC50 value for inhibition of
55Fe uptake that is one order of
magnitude greater than 16D10.
Figure 1: Chemical genetic
screening identifies compounds
that reduce exocytosis of GFP-
tagged VSV-Gts045 to the cell
surface. Structures of seven small
molecule compounds were
identified in a screen of >10000
chemicals from the ChemBridge
DIVERSet E library to block
secretion of VSV G. Screening
conducted by Y.F. (4,5).
Nieland et al.
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16D10 does not inhibit non-Tf bound iron (NTBI)
uptake or ER-to-Golgi traffic
To test whether the inhibition of iron assimilation was
linked to the Tf–Tf receptor (TfR)-dependent pathway, the
effect of 16D10 on NTBI uptake was examined. NTBI
uptake involves transport of the metal directly across the
cell surface in the absence of Tf, and does not depend on
endocytosis (13). As shown in Figure 7, NTBI uptake was
unaffected by the presence of 50mM 16D10. From these
data, we conclude that 16D10 does not act as a membrane
perturbant or iron chelator to disrupt Tf-mediated delivery
and cellular iron assimilation from this pathway. These
results also indicate that inhibition of Tf-mediated iron
uptake by the sulfonamide is unlikely to be caused by
cellular ATP depletion, since NTBI uptake is an energy-
requiring process (14). To further examine the selectivity
of 16D10, we took advantage of GFP-tagged VSV-Gts045 to
follow its movement by fluorescence microscopy. This
temperature-sensitive mutant accumulates in the ER until
cells are placed at permissive temperature (32 !C). Under
these conditions, most of the GFP-tagged protein is
observed in the Golgi apparatus after a 30-min incubation
(upper panels, Figure 8). Treatment of cells with inactive
O-1 or active 16D10 did not alter transport of the VSV G
Figure2: Inhibition of VSV-Gts045 exocytosis. To examine the
effects of chemicals shown in Figure 1, BSC1 cells were
transduced with adenovirus to express GFP-tagged VSV Gts045
and grown overnight at 40 !C. Prior to transfer to 32 !C, 50mM of
each compound was added to the media for 1 h. After 3 h
incubation at 32 !C, the amount of VSV Gts045 at the cell surface
was measured by incubating with monoclonal VSV-G antisera as
detailed in the Materials and Methods section. As a control for
nonspecific binding, cells were also treated with 10 mM brefeldin
A, a drug known to completely block transport to the cell surface.
After subtraction of background (measured in the presence of
brefeldin A), data were normalized to the total fluorescence signal
detected by GFP expression. Shown is the percentage of surface
VSV-G relative to the total GFP signal (n¼9;#SEM). Experiments
performed by Y.F.
Figure 3: Inhibitors of the exocytic pathway block 55Fe
uptake from Tf. HeLa cells were treated with 50mM of inhibitors
shown in Figure 1 for 4 h at 37 !C (solid bars) or 4 !C (open bars)
in the continued presence of 40nM 55FeTf. After washing, cells
were lysed with 0.1% Triton X-100 containing 0.1% NaOH
and cell-associated 55Fe was determined by liquid scintillation
counting. Results were normalized to protein concentrations to
determine pmol 55Fe/mg cell protein. The means of duplicate deter-
minations are shown from a single experiment with similar results
obtained on several occasions. Experiments were performed by
J.X.B and P.D.B.
Figure4: Dose–response to 16F19 and 30N12. Inhibition of
55Fe uptake from Tf was determined exactly as described for
Figure 1. HeLa cells were incubated with the concentrations of
inhibitors and the amount of 55Fe taken up by the cells was
normalized to control cells which were treated with vehicle
(DMSO) alone. Experiments performed by J.X.B and P.D.B.
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protein to this compartment. Longer incubation times (2 h)
resulted in the appearance of fluorescence at the cell
surface; however, the presence of 16D10 significantly
reduced traffic of the GFP-tagged protein to the plasma
membrane (lower left panel, Figure 8). The observation
that 16D10 does not block ER-to-Golgi transport is consist-
ent with previous results obtained for 30N12 and 16F19
(5) and bolsters the idea that the sulfonamides selectively
inhibit specific steps of membrane traffic involved in trans-
port to the cell surface.
16D10 reduces Tf endocytosis due to receptor down-
regulation
Endocytic uptake of Tf is initiated at the cell surface upon
receptor binding, with internalization by clathrin-coated
vesicles followed by delivery of the ligand to early or sorting
endosomes. Control experiments confirmed that the sulfo-
namides did not interfere with Tf binding to its receptor
(data not shown). To test whether subsequent steps of
Tf endocytosis were affected, internalization of alexa594-
labeled Tf was followed by fluorescence microscopy. The
results in Figure 9 demonstrate that endocytic uptake of Tf
continued in the presence of 10mM 16D10 (left panel).
Notably, there was no change in the morphology or dis-
tribution of endocytic compartments containing the fluor-
escent probe in cells treated with the compound.
However, a significant decrease in the amount of ligand
internalized was observed relative to control cells treated
with vehicle (DMSO) or the inactive sulfonamide O-1.
Thus, the pattern of alexa594-Tf traffic through the endo-
cytic pathway is normal but the amount of ligand inter-
nalized is dramatically reduced by 16D10.
To evaluate whether reduced uptake is the result of a
reduction in the number of Tf receptors on the plasma
membrane, 125I-Tf binding studieswere performed (Figure 10,
upper panel). Treatment with 10mM 16D10 for 30min
induced a loss of > 60% surface binding sites. Moreover,
the number of surface low density lipoprotein (LDL) recep-
tors was also reduced in cells treated with 16D10 (Figure 10,
lower panel), indicating that the observed effects were
not unique to the Tf receptor. Control experiments also
confirmed that the latter observations did not result from
altered LDL binding in the presence of 16D10 (data not
Figure5: 16F19 and 30N12 inhibit 55Fe uptake from Tf in a
reversible manner. HeLa cells were either first incubated with
2mM 16F19 or 0.5 mM 30N12 for 1 h followed by a 4-h recovery
incubation with 0.5% DMSO after removal of the drug, or cells
were first incubated for 4 h with 0.5% DMSO followed by a 1 h
incubation with sulfonamides. Cells treated under both conditions
were then incubated with 40nM 55Fe-Tf for 1 h. During the 1h
assay, cells continued to be incubated either with DMSO (closed
bars) to test reversibility (closed bars) or with sulfonamide to
directly inhibitory potency in assay (open bars). 55Fe uptake was
normalized to protein content and expressed as percentage
control (cells incubated with 0.5% DMSO in the absence of
sulfonamide). Experiments performed by P.D.B.
Figure 6: Family of sulfonamide inhibitors of membrane
traffic. Based on the structures of 30N12 and 16D19, several
additional compounds were screened for their ability to inhibit
membrane traffic. Dose–response curves for inhibition of 55Fe
uptake from Tf were measured as described for Figure 4. In
addition to 30N12 and 16F19 (5), structures of 16L2, 16D2,
16D10, 23H9 and O-1 are shown along with the relative IC50
values determined for inhibition of Tf-mediated iron uptake. IC50
values were determined as described in Materials and Methods
using GraphPad PRISM3 software. Experiments performed by
J.X.B and P.D.B. with data analysis by T.J.F.N.
Nieland et al.
65
shown). From these combined results, we infer that the sulf-
onamide perturbs the endocytic recycling pathway to induce
receptor down-regulation.
16D10 impairs Tf receptor recycling
A reduction in the amount of receptors on the cell surface
can result from an accelerated rate of endocytosis, a
reduced rate of exocytic return to the cell surface, or a
combination of both perturbations. Experiments measur-
ing the endocytic rate constant by the In/Sur method
(15) indicated that Tf receptor internalization was not
up-regulated by 16D10, aswould be the case if the reduction
in receptors on the cell surface was a consequence of
altered internalization. However, recycling of Tf receptors
back to the cell surface was significantly impaired in the
presence of this compound. In these experiments, the
release of internalized 125I-Tf was monitored in the pre-
sence of 100mM desferrioxamine (an iron chelator) and
3mg/mL unlabeled Tf to prevent ‘treadmilling’ or recapture
of 125I-Tf back into the cells. The rate of 125I-Tf release was
greatly reduced in the presence of 16D10 (Figure 11, panel
A) and from a series of experiments (n¼ 4), a near 10-fold
reduction in the recycling rate constant was determined
(Figure 11, panel B).
Sulfonamides alter endosomal and lysosomal pH
Previous studies have shown that flux of receptors and
membrane components through the recycling pathway is
slowed when the endosomal pH is raised (11,16–18). In
addition, an intracellular retention or accumulation of recyc-
ling receptors is observed, an effect similar to the down-
regulation of surface Tf and LDL receptors induced by
16D10 (Figure 10). We therefore tested whether the sul-
fonamides alkalinized Tf-containing compartments using a
fluorescence ratio imaging method to determine the pH of
recycling endosomes with doubly labeled Rh/Fl-Tf (17).
16D10 promoted an increase in Fl fluorescence, consistent
with a rise in endosomal pH (Figure 12, panels A and B).
Using methylamine to equilibrate cells with buffers of
Figure7: 16D10 sulfonamide does not inhibit NTBI uptake.
The uptake of 55Fe was measured in the absence of Tf by using a
chemical chelate with NTA (1 : 4 ratio) to present the cation to
HeLa cells. To measure nontransferrin bound iron (NTBI) uptake,
cells were preincubated with 50 mM of the indicated compounds
for 30min prior to addition of 2 mM 55FeNTA. After 1 h incubation
at either 4 !C (open bars) or 37 !C (closed bars), uptake was
quenched by placing the cells on ice and incubating with
unlabeled 1mM FeNTA to displace surface-bound iron; lysates
were collected to measure cell-associated radioactivity and
protein to calculate pmol 55Fe/mg cell protein. Shown are the
means of duplicate determinations from a single experiment with
similar results obtained on several occasions. Experiments
performed by J.X.B and P.D.B.
Figure 8: Sulfonamides block
VSV-Gts045 transport from the
Golgi apparatus to the plasma
membrane. Cells were trans-
duced to express VSV-Gts045 and
incubated as described for Figure 2
except that 100mM of 16D10 orO-1
were added before transfer to
32 !C. After 30-min and 2-h
incubation periods, the cells were
fixed with 3% formaldehyde and
images of GFP-tagged VSV-Gts045
were collected using a 40$ lens.
Scale bar¼10 mm. Experiments
performed by Y.F.
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known pH, a standard in-cell calibration curve was con-
structed (Figure 12, panel C). From the values of Rh/Fl
ratios in control vs. 16D10-treated cells, it was determined
that the pH of recycling endosomes was raised from 6.4 to
7.0 in the presence of the sulfonamide. These results are
consistent with the model that receptor down-regulation
and impaired Tf receptor recycling are induced by elevation
of endosomal pH by the sulfonamide. Elevation of endo-
somal pH would also significantly impact the release of
iron from Tf, since dissociation of the metal requires acidic
conditions (8,10,11,16).
To study whether the sulfonamides could also alter lyso-
somal pH, the degradation of a fluid phase endocytic mar-
ker was followed. K562 cells were allowed to internalize
exogenously added avidin-b-galactosidase at 20 !C to load
the early endosomal compartment as previously
described; a subsequent shift of temperature to 37 !C
results in trafficking of this marker enzyme to the lyso-
somes where it is degraded (19). The amount of b-galac-
tosidase remaining after the chase period can be
measured in cell lysates by enzymatic hydrolysis of the
fluorescent substrate 4-methylumbelliferyl-b-D-galactoside.
Agents that are known to raise the lysosomal pH, such as
NH4Cl and the V-ATPase inhibitor bafilomycin A1, prevent
the degradation of b-galactosidase (Figure 13). Similar to
these lysosomotropic agents, addition of 10mM 16D10
also inhibits the loss of b-galactosidase activity, consistent
with the idea that the sulfonamides elevate the pH of the
lysosomes.
Sulfonamides inhibit V-ATPase activity and act as
potent proton ionophores
V-ATPases are required for the maintenance of the pH of
different organelles, including the endosomal, lysosomal
and Golgi compartments (20). Because 16D10 appeared to
raise the pH of compartments in the endocytic pathway,
the V-ATPase is an attractive candidate target for inhibition
by the sulfonamides. To better understand the mechanism
of action of these inhibitors, the effects of 16D2, 16D10
and O-1 on V-ATPase activity were studied biochemically
(Table 1). The active sulfonamides, 16D2 and 16D10, inhib-
ited hydrolysis of ATP by V1-ATPase with IC50 values of 6
and 15 mM, respectively. These values correspond fairly
well with their respective potencies for inhibition of iron
uptake in vivo (Figure 6). Also consistent with the efficacy
of sulfonamide inhibition in vivo, the relatively inactive
compound O-1 inhibited only 30% of ATPase activity at a
concentration of 250mM. The IC50 values for inhibition of
ATP hydrolysis were shifted by an order of magnitude,
however, when the intact V1V0-ATPase was employed in
these assays. This observation suggests that the assem-
bly of the V1 sector onto the V0 domain may somehow
partially protect the enzyme from sulfonamide inhibition,
raising the possibility that the binding site for the sulfo-
namides may be in the stalk region at the V1V0 interface.
The effects of the sulfonamides on the ATP hydrolysis
activity of the V-ATPase were unusual since most specific
inhibitors, such as bafilomycin A1, concanamycin A, and
salicylihalamide A, do not inhibit ATP hydrolysis activity of
dissociated V1 or uncoupled V1V0 complex but instead
inhibit ATP hydrolysis of V-ATPase by blocking the proton
channel (21). To directly investigate the effects of the
sulfonamides on the proton transport function of
V-ATPase, in vitro assays were performed using proteolipo-
somes as previously described (21). During these studies,
16D2 was found to collapse the proton gradient generated
by ATP-driven proton transport by the V-ATPase at a very
low concentration (10 nM) as shown in Figure 14A. Further
investigation using a protein-free liposome system to
measure membrane potential-driven proton conductance
revealed that the two effective sulfonamide compounds
tested (16D2 and 16D10) act as proton ionophores in the
nM range, whereas O-1 is more than a 1000-fold less
potent (Figure 14B). This activity was unexpected and the
potency of the sulfonamides’ effects was quite surprising
since most commonly employed proton ionophores are
effective at ! 1 mM. For example, the activity of the proton
ionophore 1799 (bis-(hexafluoroacetonyl)acetone) at 1mM
Figure9: 16D10 sulfonamide reduces entry of Tf into cells. TRVb-1 cells were pretreated with 10 mM 16D10, O-1 or DMSO for 30min
and then 40mg/mL Alexis594-labeled Tf was added for an additional 30min. Cells were fixed with 3% formaldehyde and fluorescence
images were collected using the same exposure times with a 63$ oil immersion lens. Scale bar¼5 mm. Experiments performed by
T.J.F.N.
Nieland et al.
484 Traffic 2004; 5: 478–492
67
is shown in Figure 14B. Because much higher concentra-
tions of the sulfonamides are required to block intracellular
membrane trafficking in vivo, exactly how these in vitro
ionophore effects correlate with the influence of the com-
pounds on cellular activities remains uncertain. Unfortu-
nately, it is not possible to determine their precise
influence on the V-ATPase proton pump function in vitro
due to the confounding proton ionophore effects.
Discussion
Chemical genetics holds the promise of providing small
molecules to study biological processes in greater detail.
For example, recent screening efforts resulted in the
Figure10: 16D10 sulfonamide promotes down-regulation of
cell surface receptors. Top panel: TRVb-1 cells were
preincubated in serum free media for 90min at 37 !C, then
treated with or without 10 mM 16D10 for 30min at 37 !C. After
cells were chilled on ice, surface 125I-Tf binding was measured as
described under Materials and Methods. Data shown are the
average (#SD) of two experiments. The data are plotted as a
fraction of the 125I-Tf bound to the surface of control cells. Bottom
panel: TVRb-1 cells were grown for 3 days in medium
supplemented with lipoprotein deficient serum to up-regulate
endogenous LDL receptor. On the day of assay, cells were
washed twice in serum-free medium and pretreated with 10 mM
16D10 or DMSO alone for 30min at 37 !C. Cells were then chilled
on ice, and LDL labeled with 125I on the lipoprotein moiety was
added for 1 h on ice at a final concentration of 25 mg/mL. Non-
bound LDL was washed away with phosphate-buffered saline and
cells were lysed in 0.1 N NaOH for 30min at room temperature.
For each sample, an aliquot was counted by LSC and assayed for
protein levels. Data are expressed as LDL receptor levels as a
percentage of control. Note that saturating levels of ligands were
used to measure cell surface binding for Tf and LDL receptors,
3mg/mL and 25mg/mL, respectively. Experiments performed by
T.J.F.N and T.D.C.
Figure11: 16D10 sulfonamide impairs Tf receptor recycling.
Panel A: TRVb-1 cells (treated with or without 16D10) were
incubated with 125I-Tf for 2 h at 37 !C to allow ligand
internalization, then washed and incubated for the indicated
time to allow recycling and release of Tf. The amount of 125I-Tf
remaining as a function of time is shown for control (open circles),
cells treated with 0.5% DMSO (closed triangles) and cells treated
with 10 mM 16D10 (open squares). Panel B: Recycling rate
constant (min%1) was determined from the slope of lines shown
in the middle panel; shown is the mean value (#SD) determined
in four separate experiments. Experiments performed by T.D.C.
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discovery of two new inhibitors (Exo1 and Exo2) of ER-to-
Golgi traffic (4,5). The effects of Exo1 appear similar to
brefeldin A, a well-known fungal inhibitor of Golgi traffic
(22). Unlike brefeldin A, however, its actions do not involve
adenosine diphosphate (ADP)-ribosylation of Bars50 or
inhibition of guanine nucleotide exchange activity of
Golgi-associated ADP-ribosylation factors (ARFs) (4).
Thus, Exo1 is a new chemical tool to help further dissect
the mechanistic elements involved in ER-to-Golgi traffic. In
the present study, we examined these and five additional
compounds for potential effects on the endocytic path-
way. From this analysis, two structurally related com-
pounds, 30N12 and 16F19, were discovered to block
Tf-mediated iron delivery through the endocytic pathway.
Both compounds were previously shown to interfere
with Golgi-to-plasma membrane but not with ER-to-Golgi
traffic (5), suggesting possible influences on membrane
trafficking to the cell surface. 30N12 and 16F19 therefore
became the founding members of a larger class of sulfona-
mide derivatives characterized in this investigation.
Members of the sulfonamide family inhibit endocytic
uptake of iron via Tf–TfR complexes and the transport of
VSVG protein from the Golgi to the plasma membrane in a
dose-dependent and reversible manner. Structural rela-
tionships of this family include aryl groups linked across
the sulfonamide, with a benzyl halide para- to the amide.
While our structure–activity profiling was limited to a small
set of seven compounds, searches of the ChemBridge
DIVERSet E indicate that approximately 30 family mem-
bers are available for study in this chemical library. Among
the sulfonamides we have studied, IC50 values for inhib-
ition of Tf-mediated iron uptake ranged from 0.1mM to
>250mM. Similar values for inhibition of Golgi-to-plasma
membrane traffic were observed, while none of the com-
pounds appeared to block ER-to-Golgi transport.
The functional effects of one sulfonamide, 16D10, were
studied in greater detail. The structure of 16D10 repre-
sents the most significant chemical attributes of the sul-
fonamide family. 16D10 inhibited Tf-mediated iron uptake
with an IC50 !3–8 mM but did not affect NTBI uptake. In
cells treated with 16D10, endosomal pH was elevated
from 6.4 to 7.0. Since release of iron from Tf requires
endosomal acidification (8,10,11,16), dissociation of the
metal would be blocked in the presence of this sulfona-
mide. Therefore, this effect accounts for the observed
inhibition of Tf-mediated iron uptake and provides an explan-
ation for why NTBI uptake is not affected by the com-
pound. The alkalinization of endocytic compartments by
16D10 was also associated with a reduction in the number
of surface Tf receptors due to impaired receptor recycling.
This effect was not specific to the Tf receptor since down-
regulation of the LDL receptor, another constitutively recyc-
ling receptor, was also observed. Previous studies of
recycling endocytic traffic in the presence of pH-disrupting
lysosomotropic agents have shown that Tf uptake is dis-
rupted by alkalinization of intracellular organelles (7,9,23).
Figure12: 16D10 sulfonamide alters endosomal pH. Panel A:
Histogram of the distribution of Rh/Fl ratio of peri-centriolar
recycling compartments of control and 16D10 treated cells.
Compound 16D10 causes an increase in the Fl fluorescence,
resulting in a shift of the distribution to the left. The data are from
a representative experiment and 60 peri-centriolar recycling
compartments from each condition were measured. Panel B:
The average#SEM Rh/Fl ratio of peri-centriolar recycling
compartment from control and 16D10 treated cells (n¼ 60).
Panel C: Estimation of endosomal pH based on the Rh/Fl ratio. A
standard pH curve was constructed by determining the Rh/Fl ratio
in cells whose endosomes were equilibrated to a known pH
(squares). The Rh/Fl ratio measured in control and 16D10 cells can
be converted to pH using this standard curve. The peri-centriolar
endosomes in controls cells have a pH of ! 6.4 and those in cells
treated with compound 16D10 have a pH of !7.0. Experiments
performed by T.D.C.
Nieland et al.
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Alterations in membrane traffic induced by weak bases like
NH4Cl, chloroquine or primaquine, include changes in the
distribution of other recycling receptors aswell. For example,
monensin inhibits dissociation of ligand from the
asialoglycoprotein receptor (24,25) such that lysosomal
degradation is blocked (26). Weak bases also induce a
loss of cell surface asialoglycoprotein receptors, with con-
comitant increases in intracellular pools (24–28). Similar to
our observations that 16D10 promotes down-regulation of
the LDL receptor, monensin also has been reported to block
recycling of this receptor (29). The observation that
16D2 and 16D10 block the loss of endocytosed b-galacto-
sidase activity due to membrane traffic is consistent with
the idea that, very much like these other lysosomotropic
agents, the influence on lumenal pH by these compounds
is not specific to endosomes, since lysosomal protease
activity also appears to be inhibited in cells treated with
the compounds.
Recent pharmacologic advances have provided specific
inhibitors of the vacuolar Hþ-ATPase to study the role of
organelle pH in membrane traffic. Macrolide antibiotics
bafilomycin A1 and concanamycins A and B have been
identified to disrupt V-ATPase activity (30,31), although
their precise mechanism of action is not yet entirely clear
(20). A class of benzolactone enamides has also been
identified to potently and selectively inhibit mammalian
V-ATPase, but they are even less well-characterized (32).
Of these V-ATPase inhibitors, bafilomycin A1 has been
used most extensively in studies of membrane trafficking.
Bafilomycin A1 inhibits the ATPase activity of the intact
V-ATPase by blocking its proton channel (33) and subse-
quently raises the pH of both endosomal (17,18,34), and
Golgi (35,36) compartments. Treatment with bafilomycin
A1 markedly reduces the rate of TfR recycling and pro-
motes receptor down-regulation (17,18,37,38). Similar to
bafilomycin A1, 16D10 also raises endosomal pH to inhibit
Tf-mediated iron uptake, induces receptor down-regulation,
and impairs receptor recycling. It thus follows that the
V-ATPase is a strong candidate target for inhibition by
this compound. This model is also consistent with the fact
that the sulfonamides do not block ER-to-Golgi transport
but do inhibit Golgi-to-plasma membrane traffic of VSV-G
protein (5). A pH gradient exists across the secretory path-
way such that the trans-Golgi and the trans-Golgi network
(TGN) are acidified (20). Similar to our observations of
sulfonamide family members, bafilomycin A1 does not
affect exit of VSV-G protein from the ER, but does cause
its accumulation in the Golgi of virally infected cells (39).
Prodigiosin-25, which uncouples V-ATPase driven proton
transport, also inhibits cell surface transport of VSV-G (40).
Biochemical studies of isolated V-ATPase support the
model that the sulfonamides may act by affecting its func-
tion. However, although the sulfonamides were found to
inhibit hydrolysis of ATP by the V-ATPase in vitro, one
surprise was that the sulfonamides also collapsed the pro-
ton gradient generated by ATP-driven proton transport of
V-ATPase reconstituted in proteoliposomes. Studies using
protein-free liposomes subsequently confirmed that the
sulfonamides can act as proton ionophores. In fact, the
proton ionophore activity of the compounds 16D2 and
16D10 in vitro is at least 100-fold higher than other iono-
phores commonly used in biochemical studies (e.g. 1799,
FCCP, etc.). By comparing in vitro and in vivo data on the
effects of the sulfonamides, however, it becomes appar-
ent that the proton ionophore activity of these compounds
must be ‘neutralized’ by cellular mechanism(s) in vivo. It
seems likely that the 1000-fold concentration difference
observed to elicit effects in vivo vs. in vitro reflects cata-
bolism of the compounds in some manner that may
Figure13: 16D10 prevents lysosomal degradation. K562 cells
were incubated with b-galactosidase at 20 !C for 60min to allow
its internalization by fluid phase into endosomal (prelysosomal)
compartments. After washing, cells were incubated for 30min in
the presence of 10mM 16D10 or 1% DMSO vehicle control, 0.5 mM
bafilomycin A1 (BafA1) or 20mM NH4Cl. The intracellular activity
of internalized b-galactosidase following the chase period reflects
access to lysosomes as is manifested by decreased
b-galactosidase activity due to its proteolytic degradation within
lysosomes. Results of duplicate samples were normalized to the
total amount of activity before the chase period and are expressed
as percentage control (DMSO vehicle treatment). Experiment
performed by T.J.F.N.
Table 1: Inhibition of ATPase activity of the catalytic sector V1 and
the intact V-ATPase by sulfonamide compounds. The ATP hydro-
lysis activity of the dissociated catalytic sector V1 of bovine brain
V-ATPase or the intact enzyme was measured in the presence of
either MgCl2 or CaCl2, respectively. The IC50 of sulfonamides on
the V-ATPase activity was obtained by titration of each compound.
At the concentration of 250 mM, the highest concentration we have
tested, the compound O-1 inhibited less than 50% of either
ATPase activity. Experiments performed by J.W.
IC50 (mM)
Compounds V1 ATPase Intact V-ATPase
16D2 6 27
16D10 15 32
O-1 > 250 > 250
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eliminate or significantly impair their ionophore activity. At
this time, it remains uncertain whether these compounds
act to raise the pH of intracellular compartments directly as
proton ionophores or indirectly through inhibition of
V-ATPase function. They could potentially act through both
mechanisms, and it is also possible that their effectiveness
as proton ionophores differs in different organelles such
that this activity may be more responsible for some cellular
effects than others. With respect to the inhibition of iron
uptake which is thought to occur in endosomes, we note
that the relative potencies of 16D2 and 16D10 for inhibition
of ATP hydrolysis by V1-ATPase in vitro are compatible
with the relative IC50 values measured in vivo, while their
proton ionophore activities at 1000-fold greater concentra-
tions are almost identical in vitro. Thus, the model that the
compounds inhibit ATP hydrolysis and thereby disrupt
V-ATPase function is more compatible with the sum of our
data for inhibition of Tf-mediated iron import.
Although we favor the view that the sulfonamides block
V-ATPase function, it is curious that the IC50 values meas-
ured for inhibition of ATP hydrolysis by the intact V1–V0
complex are significantly higher than for the isolated V1
sector alone. One possible explanation for these results
arises from the inference that the compounds have a
higher affinity to V1 relative to the intact V-ATPase. The
equilibrium between intact V-ATPase and its dissociated
V1 and V0 domains in response to energy utilization and
other cellular events has been well-established in yeast
and insect systems (41,42), and is likely to be true in
mammalian cells as well. In light of our data, the sulfona-
mides may inhibit the V-ATPase primarily by binding to free
V1, which could result from the disassembled inactive
enzyme or which might even prevent V1 from assembly
with V0. Although it can not be ruled out that the sulfona-
mides bind to the catalytic center of the transporter,
wherein the pump’s conformation changes when
assembled with V0, it is more likely that the binding site
for these compounds is within the stalk region at the V1–V0
interface. In this regard, the sulfonamide compounds pro-
vide a particularly attractive tool to further study the struc-
ture, function, and regulation of V-ATPases.
Materials and Methods
Cell culture
BSC1 fibroblasts were cultured and transduced to express
VSV Gts045 as previously described (4). For Tf uptake meas-
urements, HeLa cells were cultured in DMEM supple-
mented with 10% fetal bovine serum (FBS), and grown
to ! 60% confluency in 6-well plates prior to iron uptake
studies. The CHO cell line, TRVb-1, was grown in 24-well
plates with McCoy’s medium containing 5% FBS to meas-
ure recycling and endosomal pH as described below. This
cell line expresses the human Tf receptor but not the
endogenous hamster Tf receptor, and has been exten-
sively used for analysis of Tf receptor endocytic traffic
(43). For 125I-Tf surface binding and alexa-Tf uptake experi-
ments, TVRb-1 cells were maintained in Ham’s F12
medium with 10% FBS.
Small molecule inhibitors
Compounds were purchased from ChemBridge Corp. and
dissolved in DMSO to a final concentration of 10mM and
stored at % 80 !C until use. During the course of this inves-
tigation, we discovered that the potency of the
Figure 14: Proton ionophore activity of sulfonamides. Panel A: Bovine brain V-ATPase was reconstituted into proteoliposomes and
assayed for ATP-driven proton transport activity. Sulfonamide analog 16D2 (10nM) added at the end of the assay was found to collapse the
proton gradient. Panel B: The proton ionophore activity of sulfonamides was measured as membrane potential-driven proton conductance
in a protein-free liposome system. Sulfonamides and 1799 were added at the indicated concentrations. Experiments performed by J.W.
Nieland et al.
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compounds was greatly reduced if serum or bovine serum
albumin was present in the assay medium, presumably
because albumin may act as a scavenger to bind the lipo-
philic compounds, thus reducing their bioavailability.
VSV-Gts045 exocytosis
BSC1 cells transduced with adenovirus to express GFP-
tagged VSV Gts045 were grown overnight at 40 !C in 96-
well clear-bottom plates at a cell density of 10 000/well.
Prior to transfer to 32 !C, compounds were added to the
media at a final concentration of 50mM and cells were
incubated for 1 h at 40 !C. As a control, cells were also
treated with 10mM brefeldin A to completely block trans-
port to the cell surface. After 3 h incubation at 32 !C, cells
were fixed with 3% formaldehyde and stained with the
monoclonal antibody 8G5 to detect GFP-tagged VSV-
Gts045-GFP at the cell surface using secondary goat
antimouse labeled with alexa594. Cell-associated fluores-
cence was measured using an automated fluorescence
microscope (Universal Imaging Corp., Downington, PA)
with triple band-pass filters (excitation wavelengths of
360/490/570 nm; emission wavelengths of 460/530/
625 nm). After subtraction of nonspecific binding of sec-
ondary antisera (measured in the presence of brefeldin A),
the percentage of surface VSV-Gts045 was calculated rela-
tive to the total amount of cell-associated GFP fluores-
cence. This surface/total ratio represents the extent in
transport of GFP-tagged VSV-Gts045 to the cell surface.
Tf-mediated iron uptake
Human apoTf (Sigma Chemical Co., St. Louis, MO) was
loaded with 55Fe as previously described (13). HeLa cells
were washed with serum-free media and incubated with
40 nM 55Fe-Tf at 37 !C with or without inhibitors at the
concentrations shown in the Figure legends. As a control,
cells were incubated with vehicle alone (0.5% DMSO). At
the end of the uptake period, cells were rapidly chilled on
ice, washed with ice-cold phosphate-buffered saline (PBS)
three times, then incubated with 40mg/mL unlabeled Tf to
displace surface-bound 55Fe-Tf for 1 h at 4 !C. Cells were
lysed with 0.1% Triton X-100 containing 0.1% NaOH. Cell-
associated radioactivity was determined by liquid scintilla-
tion counting and cell protein was measured using the
Bradford assay (44) to calculate pmol 55Fe/mg cell protein.
Non-Tf-bound iron uptake
Iron uptake in the absence of Tf was measured using a
chelate of 55Fe with nitrilotriacetic acid (NTA) at a 1 : 4 ratio
(13). HeLa cells were preincubated at 37 !C in serum-free
media with 50mM inhibitor for 30min, then 2mM 55Fe-NTA
was added for 1 h. At the end of the uptake assay, cells
were chilled on ice, washed three times with phosphate-
buffered saline, then incubated with 1mM unlabelled
Fe-NTA on ice to displace any surface-bound iron. Lysates
were prepared and pmol 55Fe/mg cell protein was deter-
mined as described above.
Alexa594-Tf uptake
TRVb-1 cells were first incubated at 37 !C for 2 h in serum-
free Ham’s F12 medium supplemented with 25mM
HEPES (pH7.4) to remove any residual Tf bound to recept-
ors. After preincubation with 10mM 16D10 or vehicle
(0.1% DMSO) in the same medium for 30min at 37 !C,
cells were incubated in the presence of 16D10 or DMSO
for an additional 30min with 40mg/mL alexa594-Tf added
to the media. After internalization of the fluorescent ligand,
cells were washed in PBS containing 2mM CaCl2 and 1mM
MgCl2, fixed for 30min on ice with 4% paraformaldehyde
in PBS. Cells were analyzed for Tf uptake by fluorescence
microscopy using a 63X oil immersion lens.
Down-regulation of cell surface Tf receptors
The effects of inhibitors on cell surface Tf receptors on the
surface were determined by first incubating TRVb-1 cells in
serum-free medium for 2 h at 37 !C in 5% CO2. Com-
pounds or DMSO were added during the final 30min of
this incubation. The cells were transferred to ice for 10min
to inhibit membrane trafficking, washed, and incubated in
HEPES-buffered pH7.2 balanced salt solution (HBSS) con-
taining 3 mg/mL 125I-transferrin to measure surface binding
sites. All data were corrected for nonspecific 125I-Tf bind-
ing, which was measured by incubating cells under the
same conditions except that 600mg/mL unlabeled Tf was
added. After a 2-h incubation on ice, the cells were washed
six times, solubilized and surface-bound radioactivity was
measured by gamma counting.
Down-regulation of cell surface LDL receptors
TVRb-1 cells were grown in 24-well plates for 3days in Ham’s
F12 medium containing 10% new born calf lipoprotein-
deficient serum (a kind gift of Dr. Monty Krieger, MIT)
to up-regulate expression of endogenous LDL receptors.
On the day of the assay, cells (! 40% confluency) were
washed twice in serum-free Ham’s F12 medium supple-
mented with 25mM HEPES, pH7.4, and pretreated with
10mM 16D10 or DMSO (0.1%) for 30min at 37 !C. The
cells were then placed on ice, washed twice to remove
compound, and then incubated for 60min with 25mg/mL
of human LDL labeled with 125I on the apoliprotein moiety
(also generously provided by Dr. Krieger). Unbound 125I-LDL
was washed away with PBS and cells were lysed in 0.1N
NaOH. Cell-associated radioactivity was determined by
liquid scintillation counting and cell protein was meas-
ured using the Bradford assay (44) to calculate the
amount of LDL bound to the cells (ng 125I-LDL/mg cell
protein). Data was corrected for nonspecific binding deter-
mined in the presence of 40- fold excess nonlabeled LDL.
Tf receptor recycling kinetics
The kinetics of Tf receptor recycling in TRVb-1 cells were
measured as previously described (45). Briefly, on the
second day after plating into 24-well plates, cells were
incubated with 3mg/mL 125I-Tf in serum-free McCoy’s
medium for 2 h at 37 !C in 5% CO2. This medium contains
Sulfonamide Inhibitors of Membrane Traffic
72
20mM HEPES and 26mM sodium bicarbonate. Com-
pounds were added at 50mM final concentration during
the last 30min of incubation. In control samples, DMSO
(vehicle) was added to final concentration of 0.5%. At the
end of the incubation period, the cells were washed once
with serum-free McCoy’s medium, washed with a mild
acid wash at pH5 for 2min, and then washed three
times with HBSS. The cells were then incubated in
serum-free McCoy’s media supplemented with 100mM
desferrioxamine and 3mg/mL of unlabeled Tf. The release
of Tf from cells was monitored as a function of time by
collecting the medium and solubilizing cells to measure
125I-Tf released and remaining in cells, respectively. The
recycling rate constant for the Tf receptor was determined
from plots of the natural log of the fraction of cell-
associated Tf vs. time. Nonspecific binding was measured
by incubating cells with 3mg/mL of 125I-Tf and 600mg/mL
unlabeled Tf. All data were corrected for nonspecific 125I-
Tf binding.
Endosomal pH measurements
TRVb-1 cells were plated in McCoy’s 5A medium supple-
mented with 5% FBS on coverslip bottom dishes 2 days
before experiments. On the day of the experiment, the
cells were incubated with 20mg/mL rhodamine/fluorescein-
labeled Tf (Rh/Fl-Tf) for 90min at 37 !C. Compounds or
vehicle (0.5% DMSO) were added at 50mM during the
final 30min of incubation. One dish was incubated for
90min in serum-free McCoy’s 5A medium without any
additions to determine background fluorescence. At the
end of the incubation, samples were washed four times
over 1min with HBSS, transferred to the microscope
stage and imaged live. A field of cells was chosen in the
rhodamine channel, and a rhodamine and fluorescein
images were collected. Images from five fields for each
condition were collected. Samples were examined
sequentially and loading times were staggered to insure
that the incubation periods were constant among the dif-
ferent samples.
To correlate the Rh/Fl ratio with pH values, an in-cell cali-
bration curve was constructed. Cells were incubated with
20 mg/mL Rh/Fl-Tf for 90min, washed four times with
HBSS, and fixed for 5min in 3.7% formaldehyde. Each
sample was transferred to a different pH buffer (6.2, 6.6,
6.8, or 7.2) containing 40mM methylamine. After a 1-h
incubation, during which time the endosome pH equili-
brates with the buffer pH, fluorescein and rhodamine
images were collected from each dish (three fields per
dish).
Images were collected on an Axiovert 200M inverted micro-
scope using a 40$, 1.3 NA oil immersion objective (Carl
Zeiss, Inc., Thornwood, NY), and a cooled CCD-camera
1300-V/HS from Princeton Instruments, Inc. (Monmouth
Junction, NJ). In all experiments the exposure times were
set such that less than 5% of the pixels were saturating in
the brightest samples. Images were processed using
Metamorph image processing software (Universal Ima-
ging Corp.) as described previously (46). The intensity of
the pixels of the endosomes was measured by encircling
the peri-centriolar endosome recycling compartment. The
average pixel intensity was determined and background
corrected by subtracting average pixel intensity from
dishes that were not incubated with Rh/Fl-Tf. The ratio of
rhodamine to fluorescein was calculated per endosomal
recycling compartment and averaged values are presented.
Measurement of endocytosed b-galactosidase activity
K562 cells were washed three times in PBS and sus-
pended in uptake buffer (150mM NaCl, 25mM HEPES,
pH7.4, 1mg/mL dextrose, 1mg/mL bovine serum albumin
[BSA]) with 0.5mg/mL avidin-linked b-galactosidase as
previously described (19). Internalization of the fluid
phase endocytic marker was allowed to proceed for
60min at 20 !C to permit accumulation into early endo-
somes. After extensive washing to remove any noninter-
nalized marker, cells (5$ 106/mL) were resuspended in
uptake buffer without BSA but with vehicle (1% DMSO)
or 10 mM 16D10. For comparison, cells were also treated
with 20mM NH4Cl or 500 nM bafilomycin A1. After contin-
ued incubation at 20 !C for 30min, control cells were
chilled on ice, while a paired sample was warmed to
37 !C to permit traffic to later compartments of the endo-
cytic pathway. After 60min incubation, the latter samples
were also placed on ice, and along with control samples,
cells were washed three times in ice-cold PBS, resus-
pended in hypotonic breaking buffer (20mM HEPES,
pH7.4, 100mM KCl, 85mM sucrose, 20mM EGTA), and
snap-frozen in liquid N2. Samples were stored at % 80 !C
until b-galactosidase activity was measured.
To obtain cell lysates, samples were thawed at room tem-
perature, then placed on ice and vigorously vortexed for
1–2min, then snap-frozen again. This procedure was
repeated two times until > 90% of the cells were broken.
Post-nuclear supernatants were collected upon centrifuga-
tion at 800$ g for 5min at 4 !C. Aliquots of 10mL of the cell
lysates were removed for b-galactosidase assays. Lysates
were solubilized with 1% octyl glucoside and enzyme
assays were performed as previously described using the
fluorogenic substrate 4-methylumbelliferyl-b-D-glactoside
(19). Fluorescence (355 nm excitation; 460 nm emission)
was measured using a SpectraMAX Gemini XS plate
reader (Molecular Devices, Sunnyvale, CA).
Measurement of ATPase activity
ATPase activity was measured as the liberation of 32Pi
from (g-32P)ATP (Amersham) (47). In brief, purified
V-ATPase from bovine brain (21), 1mg protein for each
assay, was first mixed with 2mg phosphatidylserine and
incubated at room temperature for 5min. The ATP hydro-
lysis assay was started by addition of 200mL assay solution
(30mM KCl, 50mM Tris-MES, pH7.0, 3mM MgCl2, and
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3mM [g-32P]ATP (400 cpm/nmol)) in the presence or
absence of sulfonamide compounds at designated con-
centrations and continued for 15min at 37 !C. For ATPase
assay of the dissociated catalytic sector V1 there is no
need to incubate the enzyme with phosphatidylserine
and Ca-ATPase activity was measured instead of Mg-
ATPase activity, by replacing MgCl2 with 3mM CaCl2. The
ATP hydrolysis reaction was terminated by adding 1.0mL
of 1.25 N perchloric acid, and the released 32Pi was
extracted and counted in a Beckman scintillation counter
as described (33).
Reconstitution of V-pump into proteoliposomes and
measurement of proton translocation
The purified bovine brain V-ATPase was reconstituted into
liposomes, which contain phosphatidylcholine, phosphati-
dylethanolamine, phosphatidylserine and cholesterol at a
weight ratio of 40 : 26.5 : 7.5 : 26, by the cholate dilution,
freeze-thaw method (21). In brief, liposomes (200mg) were
added to 1mg of V-ATPase and were well mixed. Glycerol,
Na-cholate, KCl, and MgCl2 were added to the protein–lipid
mixture at final concentrations of 10% (v/v), 1%, 0.15 M
and 2.5mM, respectively. The reconstitution mixture was
incubated at room temperature for 1 h, frozen in liquid N2
for 1min, thawed at room temperature and ready for
assay. Proton translocation was measured using the Acri-
dine orange quenching (48), which was conducted in an
SLM-Aminco DW2C dual wavelength spectrophotometer
and the activity was registered as DA492-540. The mixture
was diluted into 1.5mL of proton pumping assay buffer
(150mM KCl, 10mM Na-tricine, pH7.0, 3mM MgCl2, and
6.7mM Acridine orange) in a spectrophotometer cuvette,
which allows the formation of sealed proteoliposomes.
The reaction was initiated by addition of 1.3mM ATP
(pH7.0) and 1mg/mL valinomycin and continued for
5min. Inhibitors were added into the assay solution either
prior to the start or at the end of the assay.
Measurement of proton ionophore activity
Proton ionophore activity of sulfonamides was examined
by their ability to collapse the proton gradient generated by
the proteoliposomes of V-ATPase as described above, and
by a direct measurement of the membrane potential-driven
proton conductance of these compounds in a protein-
free liposomes system. The membrane potential was
established by loading the liposomes with 150mM KCl
and diluting into a solution containing NaCl instead of KCl,
which will generate a membrane potential, internal negative,
in the presence of valinomycin, a potassium ionophore. This
membrane potential will drive a proton influx if a mechanism
for proton conductance is present, either a proton channel or
a proton ionophore, which has been previously used to study
the proton channel activity of V0 (49). In brief, the liposomes
were reconstituted as described above, except that a buffer
without protein was used instead of V-ATPase. The lipo-
somes were sealed by dilution into 150mM KCl, 10mM
Na-tricine, pH7.0, and 2mMMgCl2, followed by centrifugation
at 100 000$g for 1h to precipitate the sealed liposomes that
were loaded with KCl and suspended in a small volume of the
same buffer. The proton conductance assay was performed
using Acridine orange quenching as described above, except
that the assay solution contains 150mM NaCl in place of KCl.
Specifically, an aliquot of the above sealed liposomes contain-
ing 100mg lipids was added into an assay solution containing
150mM NaCl, 10mM Na-tricine, pH7.0, 2mM MgCl2, 6.7mM
Acridine orange, and 1mM valinomycin, and the compound to
be assayedwas added into the cuvette, after a stable baseline
was established, to measure the proton conductance of the
compound.
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The use of chemical genetics to study cellular transport
The research described in thesis has greatly benefited from the methodology of chemical
genetics to probe the mechanisms of cellular lipid transport and of intracellular vesicular
trafficking. The decision to use this approach finds its origin in the fact that small molecule
inhibitors often act rapidly and reversibly. This makes them ideally suited to study complex
dynamic processes in real-time in a manner that cannot be achieved by genetic methods.
Cellular lipid transport by SR-BI
Chapter II of this thesis describes the design and use of a high throughput small molecule
screen to identify novel chemicals that modulate SR-BI mediated selective lipid uptake. For the
purpose of the screen, HDL was loaded with fluorescent lipid probes to mimic the transfer of
cholesteryl esters. Five compounds, two of which are structurally related, where found to inhibit
selective uptake and they were named BLTs because they Block Lipid Transport. BLTs are
specific for SR-BI and do not interfere with other aspects of membrane biology (endocytosis and
exocytosis), with the integrity of the actin- or microtubule network or, with the exception of
BLT-4, with cholesterol efflux of the unrelated lipid transporter ABCA1. The molecular target(s)
of the BLTs is found within the cell, and it is not a component of the HDL particle.
Unexpectedly, BLTs did not block selective uptake by preventing the binding of HDL to
SR-BI, by down-regulating the surface level of the receptor, or by preventing endocytosis of the
lipoprotein. Instead, they increased the affinity of SR-BI for HDL, indicating that binding and
lipid transport are tightly connected and not separate events. These results confirm the idea that
HDL needs to form a productive complex with the receptor for selective uptake to occur (1, 2).
Under physiological conditions, depletion of lipids from HDL by selective uptake
reduces the size of the lipoprotein. Because SR-BI has a lower affinity for small HDL, this
permits the release of HDL, thereby liberating the receptor for another round of uptake from a
new incoming lipoprotein (1, 3-6). One plausible explanation is that BLTs are inhibitors of the
actual lipid transport step. Accordingly, and in agreement with this model, a consequence of a
BLT imposed block in selective uptake is that HDL does not shrink, resulting in the observed
increase in the affinity of SR-BI for HDL and a decrease in the off-rate of the lipoprotein.
Alternative scenarios, including one in which compounds alter the binding of HDL to SR-BI so
that selective uptake is unable to proceed, cannot be excluded at this moment.
SR-BI mediated cellular cholesterol efflux is less sensitive (higher EC50) for BLT-3, -4
and -5 than the selective uptake pathway. These differences may reflect the chemical
dissimilarities between core cholesteryl-esters and unesterified cholesterol found in the outer
shell of HDL. This possibility was addressed by measuring SR-BI mediated uptake of
radioactive unesterified cholesterol from HDL. These experiments indicate that cholesterol
selective uptake from HDL is more potently blocked by these three BLTs than cellular
cholesterol efflux (but cholesteryl-ether uptake is inhibited with similar efficacy) (not shown).
Thus, the differences in EC50 of BLTs for selective uptake and efflux hint to differences between
the uptake and efflux pathways that can be probed with chemical genetics. One possibility is that
this subset of BLTs interferes differentially with the ability of an unknown protein (‘protein A’)
to assemble into two different complexes, one involved in selective uptake and one that
facilitates cholesterol efflux. Perhaps these BLTs disrupt more potently the ‘uptake complex’
and, hence, the selective uptake pathway. This may result from BLTs having a higher affinity for
the ‘uptake complex’, or from an intrinsic lower stability of the complex that renders it more
prone to collapse upon binding of the small molecules. A (controversial) candidate for this
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complex is the assembly of the cholesterol chaperone caveolin, cyclophilin A and cyclophilin 40,
which is claimed to facilitate selective uptake when it associates with Annexin II (7), and to be
involved in efflux when it associates with HSP56 (8). A variation on this theme is that ‘protein
A’ switches its activity between selective uptake and efflux, depending on a particular post-
translationally modification (e.g. phosphorylation, myristolation), and the compounds could
interfere more potently with the ‘uptake state’ of the protein. Yet another possibility is that the
BLTs bind with different affinities to two related but non-identical proteins involved in uptake
and efflux respectively.
The role of endocytosis in SR-BI mediated selective uptake
It is unclear whether SR-BI mediated selective uptake occurs at the surface, in an
intracellular compartment, or both. Blocking cellular internalization of HDL and LDL by generic
inhibitors for endocytosis did not affect selective uptake, or the subsequent movement of
(fluorescent) lipids into the interior of the cell (Chapter IV). Although it remains a formal
possibility that uncoupling of endocytosis and selective uptake is cell-type dependent, these data
suggest that selective uptake of cholesteryl esters in vivo likely occurs at the cell surface. This
implies that previous reports of internalized HDL are not relevant to lipid transport, but merely
reflects the low levels of (constitutive) endocytosis of SR-BI, perhaps moving to the lysosomal
compartment at the end of its life cycle. This would be consistent with the very low amount of
HDL that is degraded in an SR-BI dependent manner. Alternatively, the internalized SR-BI and
HDL may recycle to the surface in a manner analogous to the transferrin receptor (9, 10).
SR-BII is an alternative splice form of SR-BI, but its physiological role is unknown to
date. SR-BII and SR-BI express different intracellular C-terminal domains, which are 44- and 47
amino acids long respectively (11). This alternative tail allows SR-BII to efficiently internalize
HDL into an intracellular environment that seems to support lipid transfer poorly (12). SR-BI,
SR-BII and HDL are all claimed to enter the same intracellular compartment (9, 10, 12, 13),
making it likely that intracellular selective uptake from HDL internalized by SR-BI is a similar
inefficient process. Amino acid swap analysis between the C-terminal domains of SR-BI and SR-
BII may assist in the elucidation of the underlying endocytic machinery.
Functional comparison between the lipid transporters SR-BI and ABCA1
Small molecules were used to probe for similarities in the mechanism of lipid transport of
SR-BI and the structurally unrelated transporter ABCA1. In addition to its effect on SR-BI
dependent transport, BLT-4 also abolished cholesterol efflux by ABCA1. The effect of BLT-4
was not restricted to a single member of the ABC family as it also inhibits NorA, an ABC
transport protein in Staphylococcus aureus (14), suggesting that the compound targets a
conserved feature in ABC proteins. Conversely, glyburide, a generic inhibitor of the ABC family
(15-25) that blocks ABCA1 mediated cholesterol efflux (22-25), phenocopies the effect of BLTs
on SR-BI. Glyburide prevented SR-BI mediated selective uptake and cholesterol efflux and
increased the affinity of SR-BI for HDL. BLT-4 blocks SR-BI and ABCA1 mediated cholesterol
efflux with similar potency and the same is true for glyburide (but BLT-4 is the more potent of
the two drugs). This suggests that SR-BI and ABCA1 may share similarities in their mechanisms
of lipid transport. Short of the possibility that both compounds directly target SR-BI and
ABCA1, an intriguing possibility is that an ABC transporter protein of unknown identity (‘ABC-
X’) is the rate-limiting step in SR-BI mediated lipid transfer. ABCA1 could not be detected in
our SR-BI expressing cells, making it unlikely that ABCA1 participates in SR-BI activity. In
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fact, it has been proposed that SR-BI and ABCA1 have competing roles, in which SR-BI
promotes the reuptake of cholesterol effluxed to apoA-I by ABCA1 (26).
SR-BI reconstituted in liposomes can mediate selective uptake without the help of other
proteins (27), suggesting that the putative ABC-X is not required for the lipid transfer step, but
rather may modulate it. To date, forty-eight different human ABC proteins have been identified
(28), and the number of ABC transporters that are involved in lipid transport or otherwise affect
cholesterol homeostasis continues to grow. An RNAi-based approach to systematically knock-
down different ABC proteins in SR-BI expressing cells could begin to provide answers.
How could this unknown ABC transporter modulate the activity of SR-BI? ABCA1 is
proposed to create a specific lipid microenvironment to allow docking of apoA-I and subsequent
cholesterol efflux (29, 30). If true, and assuming the hemi-fusion model of SR-BI activity is
correct (2), it can be speculated that hemi-fusion of the outer shell of HDL with the surface
membrane requires rearrangement of the cellular lipid bilayer by ABC-X in a manner similar to
ABCA1, and this may be prevented by BLT-4. It is noteworthy that SR-BI was proposed to
create a similar distinct lipid milieu, but recent genetic mutations in SR-BI have shown that this
is not required for lipid exchange between SR-BI and lipoproteins (31). Thus, while the
inhibitory mechanisms of BLTs-1, -2, -3 and -5 remain obscure, these results suggest that an
ABC protein is the molecular target of BLT-4.
Physiological effect of BLTs
One of the outstanding questions concerns the impact of BLTs on SR-BI related
physiology. Alterations in SR-BI expression in mice have profound effects on cellular
cholesterol homeostasis and lipoprotein metabolism, and the absence of SR-BI increases the risk
for cardiovascular disease and atherosclerosis (32). Indeed, SR-BI expressed in the liver and
steroidogenic tissues is needed to remove cholesteryl-esters from HDL in the final phase of
reverse cholesterol transport. In addition, SR-BI is proposed to reduce the lipid load of
macrophages in the arterial endothelium by facilitating cholesterol efflux to HDL, which
otherwise leads to the formation of foam cells early in the development of an atherosclerotic
lesion. Intuitively, the prediction is that BLTs would chemically phenocopy SR-BI deficiency
and hence promote SR-BI and HDL related pathology. However, inhibition of SR-BI mediated
selective uptake may not be detrimental necessarily. This is exemplified by a collection of
normolipidemic drugs called fibrates which raises HDL levels in patients with the purpose of
reducing the risk of coronary heart disease (33). These fibrates do so in a pleiotropic manner,
including ablation of SR-BI protein expression in the liver (in mice) (34). One obvious but
untested consequence of fibrate treatment is a reduction in selective uptake from HDL in livers,
which is also the predicted outcome of an exposure to BLTs. Moreover, BLTs could abolish the
flux of lipids from (modified LDL) lipoproteins into arterial macrophages caused by local
expression of SR-BI. The, sometimes contradictory, physiological effects of SR-BI can perhaps
be attributed to differences associated with the site(s) of SR-BI expression. In the liver or
steroidogenic tissues (32), SR-BI activity may have anti-atherogenic consequences by facilitating
selective uptake, while in vascular macrophages it may be either pro- (35) or anti-atherogenic
(35-37).
Intracellular vesicular trafficking
The second part of this thesis aimed to characterize molecular regulators of both exocytic
and endocytic traffic. From a diverse set of inhibitors of VSV-G exocytosis (38, 39), a family of
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sulfonamides was found to down-regulate surface expression of transferrin- and LDL-receptors,
which both enter the cell via the clathrin pathway. This observation is explained by a block in
receptor recycling to the surface following internalization, rather than an increase in endocytosis.
Recycling of both receptors is well documented to be sensitive to changes in the endosomal pH
(40), and indeed the sulfonamides increase the pH of the endosomal system.
Changes in acidity of the endosomal compartment can be attributed to, among others,
changes in import of protons by vacuolar proton-translocating ATPases (V-ATPases), in
transport of counter-ions (chloride import and potassium export) and in proton release from the
vesicle (40). In vitro biochemical experiments show that sulfonamides inhibit ATP hydrolysis by
the V1 multi-subunit domain of the V-ATPase, and hence proton import into the endosome
catalyzed by the V0 multi-subunit domain of the pump. ATP hydrolysis by the isolated V1
domain is more potently blocked than ATP hydrolysis by the intact V1V0 complex. This suggests
that allosteric changes are induced in the putative drug-binding site in the V1 domain upon
binding of the two domains. It is possible that the drug-binding site is at the interface of the V1
and V0 domain, within the stalk region, and if true, the sulfonamides potentially could interfere
with the assembly of the two domains into an intact V1V0 complex. In addition, it was found in
protein-free liposomes that the compounds also act as proton ionophores, which may further
contribute to their ability to alter pH homeostasis.
The V-ATPase is also expressed in the Golgi-network, where local control of the pH is
required for proper transit through this secretory compartment (41-44). Therefore, it is likely that
sulfonamides block exit from the Golgi by inhibiting the resident vacuolar ATPase, but this
hypothesis must be formally tested. Collectively, these results reaffirm the role of V-ATPases in
intracellular traffic.
The sulfonamides add to a growing list of proton pump inhibitors. The most famous class
of inhibitors, Bafilomycin A1 and Concanamycin A1 macrolide antibiotics, interferes with
proton flow through the pump by interacting with the c-subunit of the V0 domain, and not with
the V1 domain (45-47) as is the case for sulfonamides. These differences further underscore the
usefulness of these novel drugs in the study of V-ATPase activity and its cell-physiological
importance. Furthermore, the dual activity of sulfonamides as proton pump inhibitors and proton
ionophores has clinical relevance, although substantial improvement in the potency of the drugs
is required. Indeed, macrolide inhibitors of V-ATPases are already being considered as anti-
tumor drugs (48, 49) because many tumors rely on active proton extrusion by surface V-ATPases
to avoid an overload of protons inside the cell (acidosis). Acidosis can be provoked by an influx
of protons from the hypoxic environment (with a lower pH) of the cancer cell. It can also be
caused by acid metabolites produced by the rapidly growing tumor cells (in (50)). The
sulfonamides may serve as lead for the discovery of novel anti-cancer drugs.
Chemical genetics, the next hurdle
The two goals of the chemical genetic approach are to find novel tools that are
instrumental to study complex biological systems, and to discover novel molecular components
involved therein. While the first aim has clearly been met, exemplified for instance by this thesis,
the second one has proven to be much harder.
A variety of methodologies can be exploited to identify the molecular targets for small
molecules such as BLTs. They can be divided into two categories: fishing expeditions and target-
candidate approaches. Biochemical purifications (51) using cell extracts and genetic- and
proteomic profiling screens (52) are an example of the first. However, biochemical
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experimentation has achieved limited success, predominantly because the cellular copy number
of the target is low, or because of the low affinity of the primary ‘hits’, mostly in the micromolar
range. Thus, significant investments in follow-up chemistry and SAR (chemical structure-
activity relation) analysis are required to generate a more potent derivative of the lead
compound. Due to these affinity problems, traditional biochemical approaches, including pull-
downs and gel overlay assays, that rely on a biotinylated compound have lost their appeal. One
solution is to employ photo-crosslinkable derivatives of the compound of interest, and
radioactive tags may be chosen over a bulky biotin group to avoid potential interference with
binding to a target candidate (47). Because of its relatively low EC50, BLT-1 is the most
promising for target identification.
 A number of genetic approaches may be suitable to identify the target of the small
molecule. Collectively, the idea is that by overexpressing or mutating the target (and only the
target), cells can overcome the inhibition imposed by the small molecule. Expression cloning
strategies can be used to screen cDNA libraries for genes that make cells less sensitive to drugs
(this can also be used to increase the copy number of the target in biochemical searches). These
libraries can cover the entire genome, but it deserves consideration to facilitate the search by
using pooled cDNAs or libraries of a more focused nature (e.g. genes suspected to be involved in
lipid metabolism in the case of BLTs). A somewhat cumbersome methodology is to screen
collections of compound-resistant cells created by chemical mutagenesis. Finally, genome-wide
collections of haploinsufficient yeast strains can be assayed for enhanced drug sensitivity (53). A
mirror-image of this principle, genome-wide overexpression screens to search for yeast cells
which confer drug resistance, has recently displayed its use in target identification (54).
Unlike these brute-force fishing expeditions, target-candidate approaches have achieved
some moderate success. This strategy can be based on phenotypic (e.g. (55)), genetic or chemical
criteria. Genetic experimentation may involve manipulations using select dominant-negative or
constitutive-active gene constructs to pinpoint where a small molecule acts in a biological
pathway (56). A chemical variation entails override screens using (biased libraries of) inhibitors
with known targets or with well-defined mechanisms of inhibition. An example of a more
directed chemical strategy is the side-by-side functional comparison of BLTs and glyburide,
which has led to the idea that BLT-4 targets an ABC transporter that modulates SR-BI dependent
lipid transport. Similarly, the characterization of the sulfonamide family combined phenotypic
and chemical criteria. In particular, this line of research was advanced because it was recognized
that the effect on intracellular traffic of this set of drugs was reminiscent of changes in organellar
pH imposed by a class of Vacuolar-ATPase inhibitors known as macrolide antibiotics (42, 57-
61).
To specifically address target identification of BLTs, the in vitro use of recombinant SR-
BI reconstituted in liposomes is very appealing (27). Alternatively, a physical interaction of
BLTs and SR-BI may be detected by ultra-fast gel filtration in combination with mass
spectrometry. Along the same lines, BLT-resistant alleles of SR-BI may be identified by
screening (retroviral) libraries of recombinant mutants of the receptor (62).
It deserves mentioning that sulfonamides were discovered because of their interesting
biological cross-inhibitory effects; they were identified from a panel of structurally unrelated
inhibitors found in a chemical screen for exocytosis to be the only drugs to also interfere with the
related, but dissimilar trafficking process of endocytosis. Target-candidate driven research
culminated in the conclusion that the vacuolar ATPase is a target of the sulfonamides. This
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strategy can be elaborated on by systematically screening chemical libraries in different or
related biological processes. Multi-dimensional chemical profiling can thus select small
molecules for their ability to interfere with multiple (related) phenomena, or in contrast, for their
specificity towards a single phenotype (63, 64). This can serve two purposes; from a chemical
perspective, it establishes a structure-activity relationship for phenotypic or biochemical
perturbations. More importantly, chemical cross-modulation may uncover connections between
biological networks that are related, or, more excitingly, seemingly disparate.
Conclusion
 This thesis has shown the value of chemical genetics to systematically study cell
biology. Small molecule inhibitors of SR-BI mediated selective uptake have dissected
successfully the relationship between lipoprotein binding and selective uptake, between lipid-
import and -export pathways and the role of endocytosis in selective uptake. It opened a new line
of research that explores the collaboration between SR-BI and ABC transporters in lipid
transport.
In the field of vesicular transport, a novel family of sulfonamides has been identified that
links exocytic Golgi trafficking with endocytic receptor recycling by modulating the activity of
vacuolar proton pumps in a manner that previously known V-ATPase inhibitors do not. It is thus
expected that these compounds will be helpful to study the activity of proton pumps and their
role in cellular pH maintenance and vesicular transport. They have a potential use in clinical
settings.
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CHAPTER VII
Samenvatting voor de leek
87
88
Inleiding
 Ons lichaam is een samenleving van miljarden cellen die elk een specifieke functie
uitvoeren, de meeste groepsgewijs in organen. Cellen in het maag-darm stelsel nemen voedsel
op. Cellen van het immuunsysteem staan klaar om vijanden van buiten (virussen, bacteriën en
parasieten) te weerstaan. Hersencellen verwerken en bewaren informatie en besturen het
lichaam. Spiercellen stellen ons in staat om te bewegen.
Een minder bekend voorbeeld van taakverdeling betreft de productie van specifieke
voedings- en bouwstoffen die nodig zijn voor het functioneren van cellen. Hoewel het merendeel
van onze cellen in staat is om  deze stoffen zelf aan te maken, kan het soms gebeuren dat de cel
meer nodig heeft dan hij kan produceren. In dit geval kunnen de benodigde stoffen met behulp
van specifieke oppervlaktereceptoren (‘ontvangers’) uit de omgeving van de cel gehaald worden,
bijvoorbeeld uit het bloed. Sommigen van deze voedings- en bouwstoffen zijn afkomstig uit ons
voedsel, anderen worden uitgescheiden door cellen die zijn gespecialiseerd om deze in al dan
niet grote hoeveelheden te produceren. Het eerste gedeelte van dit proefschrift is gewijd aan de
mechanismen die cellen gebruiken om cholesterol, een bouwstof, op te nemen uit het bloed en
ook weer uit te scheiden.
Om ons lichaam te laten functioneren is communicatie en samenwerking tussen al deze
cellen van groot belang. Cellen kunnen met elkaar communiceren door middel van het
uitscheiden van specifieke (signaal)moleculen, die elk voor een bepaalde boodschap coderen.
Andere cellen hebben specifieke receptoren op hun oppervlakte, die deze signaalmoleculen
kunnen binden (herkennen). Deze interactie kan de cellen doen stimuleren om actie te
ondernemen. Zo kunnen zenuwcellen signaalmoleculen (neurotransmitters) uitscheiden die
spiercellen in onze arm aansporen om een bladzijde in dit proefschrift om te slaan.
Zowel receptoren als signaalmoleculen worden geproduceerd door speciale ‘fabriekjes’
binnenin de cel. Om de receptoren naar het oppervlakte te brengen en om de signaalmoleculen
uit te scheiden, heeft de cel verschillende intracellulaire transportroutes tot zijn beschikking.
Het tweede gedeelte van dit proefschrift beschrijft een studie naar de mechanismen van deze
intracellulaire transportroutes.
Doel van het proefschrift
Dit proefschrift heeft als doel inzicht te verschaffen in (1) hoe cellen cholesterol opnemen
en uitscheiden en (2) hoe intracellulaire transportroutes receptoren naar het cel oppervlakte
brengen en verwijderen. De experimentele basis van dit proefschrift berust op het gebruik van
een nieuwe methode genaamd chemical genetics, ofwel chemische genetica. In chemical
genetics worden collecties van duizenden en duizenden verschillende chemische moleculen
(compounds) op geautomatiseerde wijze getest (gescreend) voor een bepaald, door ons gekozen,
effect op een biologisch proces. Het gebruik van deze compound stelt ons in staat om een beter
inzicht te verkrijgen in dat proces, zoals later zal worden toegelicht.
Cholesterolmetabolisme en de relatie tot hart- en vaatziekten
Cellen kunnen niet zonder cholesterol. Als bouwstof is het een onlosmakelijk onderdeel
van de celwanden (celmembranen), die te vergelijken zijn met de muren van huizen. Cholesterol
word ook gebruikt om signaalstoffen en nutriënten te maken, zoals (steroïde) hormonen en
vitaminen. Al onze cellen kunnen zelf cholesterol maken door een opeenvolging aan
enzymatische reacties. Wanneer de cel onder bepaalde omstandigheden zelf niet voldoende
cholesterol aanmaakt, moet dit worden opgenomen vanuit de omgeving, het bloed. Dit
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cholesterol is afkomstig uit de lever, die uitermate geschikt is om grote hoeveelheden cholesterol
te maken. Omdat cholesterol een ‘vettig molecuul’ is dat niet in het bloed oplosbaar is, wordt het
in het bloed getransporteerd door lipoproteïnen, pakketjes van eiwitten en vetten die wél
cholesterol kunnen binden. Er zijn verschillende klassen van lipoproteïnen, die worden
onderscheiden aan de hand van hun samenstelling van eiwitten en vetten. Belangrijke
lipoproteïnen zijn VLDL (very low-density lipoproteïn) , LDL (low-density lipoproteïn), HDL
(high-density lipoproteïn) en chylomycronen. De lever verpakt het cholesterol in VLDL
lipoproteïnen, die na uitscheiding in het bloed worden omgezet in LDLs. Het bloed transporteert
de LDLs naar cellen die een tekort hebben aan cholesterol, die vervolgens via speciale LDL-
receptoren het cholesterol op kunnen nemen. Een te grote cellulaire cholesterolopname van LDL
vergroot het risico voor hart- en vaatziekten, zoals later beschreven zal worden. Om deze
overmaat aan cholesterol kwijt te raken, hebben een beperkt aantal cellen het vermogen
ontwikkeld om cholesterol af te breken. Een meer gebruikte oplossing is om het teveel aan
cholesterol uit te scheiden aan een speciale klasse van lipoproteïnen in het bloed, de HDLs.
Hart- en vaatziekten ontstaan onder speciale omstandigheden. Ontstekingsreacties in de
wanden van het vaatstelsel kunnen leiden tot de activatie van bepaalde cellen, macrofagen
genoemd, die gespecialiseerd zijn om dit soort beschadigingen te herstellen. Helaas leiden deze
omstandigheden er ook toe dat deze macrofagen grote hoeveelheden cholesterol van een
(gemodificeerde) vorm van LDL gaan opnemen, waardoor de cellen als het ware in een grote
vetmassa veranderen. Dit wordt verder verergerd door kalkafzetting. LDL word ook wel slecht
cholesterol genoemd omdat deze vetmassa een vernauwing van de (slag)aderen teweeg kan
brengen, wat de bloedstroom ernstig kan belemmeren. Indien dit gebeurt in een kransslagader,
leid dit ertoe dat het hart minder bloed, en dus minder zuurstof ontvangt (dit heet
slagaderverkalking of atherosclerose), met als mogelijke consequentie dat een gedeelte van het
hart afsterft. Dit word een hartinfact genoemd. Een grote hoeveelheid LDL in het bloed verhoogt
dus de kans op hart- en vaatziekten.
Omdat HDL overtollig cholesterol kan verwijderen van de macrophagen en andere
cellen, speelt het een belangrijke rol in de voorkóming van hart-en vaatziekten, zoals beschreven
zal worden in de volgende paragraaf. HDL word daarom ook wel goed cholesterol genoemd.
Opname en uitscheiding van cholesterol door cellen
Het eerste gedeelte van dit proefschrift betreft een studie naar de mechanismen die cellen
gebruiken om cholesterol op te nemen vanuit de lipoproteïnen in het bloed, en hoe ze dat weer
kunnen uitscheiden. Een methode die cellen kunnen gebruiken om cholesterol op te nemen en
waar we veel van afweten, heet receptor-gemediëerde endocytose. Cellen hebben specifieke
receptoren aan hun oppervlakte die (LDL) lipoproteïnen kunnen binden, en ze vervolgens naar
binnen brengen (internaliseren of endocyteren). Binnen in de cel word het LDL afgebroken,
waardoor het cholesterol vrijkomt voor gebruik. Een andere methode van cellulaire
cholesterolopname, waar we veel minder van afweten, maakt gebruik van receptoren die
functioneren als transporter. Deze receptoren binden lipoproteïnen aan het celoppervlak en
transporteren vervolgens het cholesterol van de lipoproteïnen naar de cel. In tegenstelling tot
receptor-gemediëerde endocytose worden de lipoproteïnen niet opgenomen in de cel en hoeven
deze ook niet afgebroken te worden om het cholesterol vrij te maken. Sommige transporters
kunnen ook een teveel aan cholesterol uit de cel pompen naar de lipoproteïnen, de omgekeerde
weg dus. Het eerste onderwerp van dit proefschrift betreft experimenteel onderzoek naar de
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mechanismen van cholesterol transport van twee transporters, te weten SR-BI (Scavenger
Receptor, klasse B, type I) en ABCA1 (ATP-Binding Cassette A1) transporters.
De relatie tussen SR-BI, ABCA1 en HDL
De voorlopers van HDL worden, net als de voorlopers van LDL (VLDL), gevormd en
uitgescheiden door de lever. Alleen indien deze zich ontwikkelen tot het rijpe HDL is dit in staat
om cholesterol te op te nemen vanuit cellen. Een onmisbare rol hierin wordt vervuld door de
ABCA1 transporter in de lever. ABCA1 transporteert een kleine hoeveelheid cholesterol en
andere vetten naar de HDL-voorlopers, en alleen dan kunnen deze zich verder in het bloed
ontwikkelen tot de rijpe vorm.  Het bloed transporteert de rijpe HDLs door het lichaam, onder
meer naar cellen met een schadelijke hoeveelheid cholesterol (macrofagen etc.). Door cholesterol
te pompen naar het HDL kunnen zij hun cholesterol niveau verlagen. HDL wordt daarom ook
wel goed cholesterol genoemd omdat dit de kans op hart- en vaatziekten verlaagt. Er zijn
aanwijzingen dat een van de ABC transporters (er zijn achtenveertig verschillende ABC-
transporters bekend in het menselijk lichaam) cholesterol pompt naar het HDL, maar dit is
waarschijnlijk niet ABCA1.
Nadat het HDL cholesterol heeft ontvangen vanuit een cel, kan het via het bloed weer
terechtkomen in de lever, of in de steroïdogene organen (bijnieren, ovaria, testes). Deze vier
organen hebben de andere transporter, SR-BI, aan het celoppervlak. SR-BI bindt HDL (het rijpe
HDL, niet de voorlopers), en transporteert cholesterol uit HDL naar de cellen van deze organen
in een proces dat selectieve opname heet, omdat alleen het cholesterol
1 
(en andere vetten) van
HDL word opgenomen. In tegenstelling tot de opname van cholesterol via receptor-gemedieerde
endocytose van LDL vindt er gedurende selectieve opname geen afbraak plaats van HDL binnen
in de cel, maar blijft het intact achter in het bloed. Het HDL kan vervolgens hergebruikt worden
om cholesterol op te nemen van cellen nadat het door het bloed naar de juiste plek is gebracht.
 De steroïdogene organen gebruiken cholesterol om steroïde hormonen te maken, zoals
geslachtshormonen. De lever gebruikt het voor andere doeleinden, bijvoorbeeld om galzuren te
maken die na uitscheiding in de darmen dienen om vetten uit het voedsel op te nemen. De lever
kan cholesterol ook opslaan, of uitscheiden in VLDL dat na omzetting tot LDL het cholesterol
kan vervoeren naar cellen die het kunnen gebruiken als bouwstof etc., zoals eerder beschreven.
Behalve dat SR-BI cholesterol kan transporteren van HDL naar de cel, kan SR-BI ook
cholesterol de andere kant uit pompen: van de cel naar het HDL. Echter, de fysiologische
relevantie hiervan is tot op heden onbekend.
SR-BI, ABCA1 en HDL beschermen ons dus tegen bepaalde hart- en vaatziekten door
hun rol in transport van cholesterol van cellen (zoals macrofagen) naar de lever of steroïdogene
organen. Dit komt bijvoorbeeld tot uiting in Tangiers’ syndroom, waarbij patiënten lijden aan
vele cholesterolgerelateerde afwijkingen omdat zij door (overerfelijke) genetische mutaties in
ABCA1 geen functionele cholesteroltransporters hebben, en dus ook geen HDL. Dit resulteert in
een toename in de hoeveelheid cholesterol in veel cellen, met alle gevolgen vandien. Dit betekent
dat niet alleen de hoeveelheid vet in ons voedsel een risicofactor is voor hart- en vaatziekten (dit
                                                 
1
 voor de cholesterol aficionados: cellen gebruiken ABC-transporters om hun (overmaat aan) cholesterol naar HDL
te transporteren. In de bloedsomloop word dit cholesterol omgezet in cholesterol-esters door enzymen gebonden aan
HDL. Deze cholesteryl-esters worden via SR-BI gemediëerde selectieve opname door de lever en steroïdogene
organen opgenomen. Om het voor deze samenvatting eenvoudig  te houden worden cholesterol en cholesteryl-esters
onder dezelfde noemer (cholesterol) gebracht.
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verhoogt namelijk de hoeveelheid cholesterol in het bloed), maar dat ook overerfelijke
afwijkingen een belangrijk deel bijdragen.
Chemical genetics
Een klassieke methode om de biologie van een cel te bestuderen berust op genetische
manipulatie van kandidaat-genen die er van verdacht worden een belangrijke rol te spelen in het
biologische gedrag (van een cel). Voorbeelden hiervan zijn het aanbrengen van mutaties in de
genen, of het verwijderen of toevoegen van genen aan het DNA van de cel. Indien deze
manipulaties het biologische proces verstoren, is dat een goede indicatie dat deze genen
inderdaad betrokken zijn bij het normale verloop van dat proces. Het voordeel van deze
genetische benadering is dat de identiteit en (vaak) de functie van het gen bekend is, we kiezen
immers zelf welke genen we willen bestuderen. Dit stelt ons direct in staat een link te leggen
tussen het gen, zijn functie en zijn rol in de biologie. Echter, er bestaat een kans dat het door ons
gekozen gen geen rol heeft, hetgeen ons noodzaakt weer van vooraf aan te beginnen om een
nieuw kandidaat-gen te vinden. Een ander nadeel is dat we van te voren een idee moeten hebben
welke genen belangrijk zouden kunnen zijn. Hoewel tegenwoordig de techniek ons in staat stelt
om systematisch vele van de ongeveer dertigduizend bekende genen gelijktijdig te screenen, is
dit overduidelijk een zeer bewerkelijk proces. Problemen kunnen ook ontstaan doordat de
geïntroduceerde genetische manipulaties niet alleen de kandidaat-genen veranderen (primaire
gevolgen), maar ook het algehele gedrag van de cel kan beïnvloeden. Dit zijn vaak ongewenste
en secundaire gevolgen van het feit dat de cel allerlei veranderingen kan ondergaan omdat het
problemen heeft met de opgelegde genetische veranderingen. Het is dus van groot belang om een
goed onderscheid te maken tussen de primaire gevolgen van de genetische manipulatie en de
secundaire consequenties.
Om deze problemen te voorkomen is er voor dit proefschrift gebruik gemaakt van een
nieuwe benadering, die chemical genetics
2
 heet, om cholesterol transport en intracellulair
transport te bestuderen. Het concept van chemical genetics is het geautomatiseerd screenen van
collecties van duizenden en duizenden verschillende chemische moleculen, compounds, op hun
eigenschap om een biologisch proces te remmen of te stimuleren. Dit kan bijvoorbeeld gebeuren
indien de compounds binden aan een (onbekend) genproduct (bijvoorbeeld een eiwit of een
vetmolecuul) dat betrokken is bij cholesteroltransport, waardoor dat genproduct zijn normale
functie niet meer kan uitvoeren.
 De twee doelstellingen die ten grondslag liggen aan chemical genetics zijn (1) deze
nieuw ontdekte chemische moleculen te gebruiken als gereedschap om (cel)biologie te
                                                 
2
 Er zijn twee varianten van chemical genetics. In één aanpak worden collecties van compounds gescreend voor hun
eigenschap om de activiteit van een geisoleert genproduct te beïnvloeden. De keuze voor het genproduct kan
berusten op het feit dat het er van verdacht word een rol te spelen in de ontwikkeling van een ziekte. Deze methode,
ook wel pharmacologie genoemd, word veelal door pharmaceutische bedrijven gebruikt om nieuwe medicijnen te
ontwikkelen. Hoewel het voordeel van deze methode is dat we weten aan welk genproduct het compound bindt (dat
genproduct hebben we immers zelf gekozen!), blijft het een gok of het compound ook daadwerkelijk in staat is om
de ziekte te beïnvloeden. Zo kan het gebeuren dat het compound niet door ons lichaam of onze cellen kan worden
opgenomen, of het kan worden afgebroken in het bloed. Het is ook mogelijk dat het binden van het compound aan
het genproduct helemaal geen effect heeft op de ontwikkeling van de ziekte. Deze problemen kunnen voorkomen
worden door de screen als het ware om te draaien, door compounds te selecteren voor hun effect op het (al dan niet
ziektegerelateerde) gedrag van de cel of een organisme. Vervolgens kunnen we dan bijvoorbeeld gaan zoeken aan
welk genproduct het compound bind, of waarom het compound het gedrag van de cel verandert. Deze manier van
screenen word ook wel forward chemical genetics genoemd. Voor het gemak word in deze Nederlandse
samenvatting gerefereerd naar chemical genetics terwijl er eigenlijk forward chemical genetics wordt bedoeld.
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bestuderen en (2) om (nieuwe) genen (of genproducten) te vinden die betrokken zijn bij dat
proces. Dit laatste kan bijvoorbeeld door de compound radioactief te maken en vervolgens te
kijken aan wat voor genproducten het bindt in de cel. Omdat het effect van deze chemische
moleculen vaak binnen een paar minuten zichtbaar is, dit in tegenstelling tot genetische
manipulaties die dagen kunnen duren, is de kans dat deze compounds secundaire, ongewenste,
activiteiten in de cel induceren bijzonder klein. Een ander voordeel is dat de compounds
geselecteerd worden omdát ze een bepaald gewenst effect hebben op de biologie. Dit in
tegenstelling tot de klassieke genetische methode, waarbij vaak (vele) kandidaat-genen
gemuteerd moeten worden in de hoop dat ze een effect hebben.
Chemical genetic screening van cholesterol transport door SR-BI
Het eerste gedeelte van dit proefschrift bestudeert het mechanisme waarmee SR-BI
cholesterol transporteert tussen cellen en lipoproteïnen. Hoofdstuk II beschrijft de ontwikkeling
van een chemical genetic screen om compounds te vinden die interfereren met SR-BI
gemediëerde selectieve opname van cholesterol. In deze screen zijn vijf compounds gevonden,
die BLTs gedoopt zijn omdat zij transport van lipiden (vetten, cholesterol) blokkeren (Block
Lipid Transport). De verwachting was dat de BLTs selectieve opname zouden blokkeren omdat
ze de binding van HDL aan SR-BI zouden voorkomen en/of het aantal SR-BI transporters aan
het celoppervlak zouden reduceren. Geen van beide was echter het geval. In tegenstelling, het is
gebleken dat wanneer cellen behandeld worden met BLTs, het HDL beter (‘steviger’) bind aan
SR-BI. Om dit te verklaren moet we SR-BI gemediëerde selectieve opname zoals dat gebeurt
onder normale omstandigheden beter ‘onder de loep nemen’. De eerste stap is de binding van
HDL aan SR-BI, gevolgd door SR-BI gemediëert cholesteroltransport van HDL naar de cellen.
Dit reduceert het formaat van HDL, en omdat SR-BI niet goed in staat is om deze kleinere HDL
lipoproteïnen te binden, resulteert dit in het loskomen van HDL. Dit stelt SR-BI in staat om een
nieuw HDL lipoproteïn te binden, om zo opnieuw de cyclus van selectieve opname te beginnen.
Volgens dit model zou een inhibitie van cholesteroltransport door BLTs voorkomen dat het
formaat van HDL gereduceerd wordt, resulterend in dat SR-BI het HDL ‘steviger’ bindt en het
vervolgens niet zo makkelijk kan loslaten. Dit is inderdaad wat we hebben waargenomen. Het
dient echter vermeld te worden, dat we het op dit moment het omgekeerde scenario niet geheel
kunnen uitsluiten: dat BLTs de HDL binding veranderen en als gevolg daarvan selectieve
opname geblokkeerd wordt.
Voor selectieve opname zijn twee componenten nodig, te weten cellen met SR-BI aan
hun oppervlak, en een bron van cholesterol, het HDL. Het is gebleken dat BLTs een effect
uitoefenen op de cellen, en niet op het HDL, om selectieve opname te remmen. Dit betekent dat
het onbekende genproduct(en) dat eventueel door de compounds gebonden zou worden zich in
de cel bevindt en niet in het HDL.
De BLTs remmen niet alleen selectieve opname (cholesterol transport van HDL naar
cellen) maar ook SR-BI gemediëerde uitscheiding (export) van cholesterol van de cel naar HDL.
Selectieve opname is gevoeliger voor BLTs dan SR-BI gemediëerde cholesterol-export van
cellen naar HDL. Hieruit hebben we de hypothese afgeleid dat het mechanisme van selectieve
opname en cholesterol-export niet geheel identiek is, maar dat er bepaalde verschillen zijn. De
verwachting is we een beter inzicht in (de verschillen tussen) selectieve opname en cholesterol-
export kunnen verkrijgen door een systematisch gebruik van de BLTs.
93
Waar in de cel vindt SR-BI gemediëerde selectieve opname plaats?
Er zijn twee verschillende gedachten over waar SR-BI gemediëerde selectieve opname
zou kunnen plaatsvinden: (1) aan het celoppervlak, alwaar HDL binding aan SR-BI gevolgt zou
worden door cholesteroltransport en vervolgens in het loskomen van HDL van de receptor en (2)
ergens binnen in de cel. In het laatste geval is het idee dat SR-BI en HDL allebei door de cel
worden geïnternaliseerd en naar een (onbekende) locatie in de cel worden gebracht waar de
selectieve opname plaats zou vinden. Hierna zouden de receptor en lipoproteïn weer samen naar
het celopervlak worden vervoerd, alwaar het HDL word losgelaten door SR-BI. Het verschil met
cholesterolopname van LDL via LDL-receptor-gemediëerde endocytose  is dat er in dit scenario
geen afbraak van HDL binnen in de cel nodig is om cholesterol te transporteren.
Het gebruik van BLTs en remmers van cellulaire internalisatie (van SR-BI en HDL) heeft
geleid tot de conclusie dat SR-BI gemediëerde selectieve opname daadwerkelijk aan het
celoppervlak plaatsvindt en niet binnen in de cel.
Een functionele vergelijking van SR-BI en ABCA1 met betrekking tot cholesteroltransport
Hoewel zowel SR-BI als ABCA1 in zijn staat om cholesterol te transporteren van cellen
naar lipoproteïnen, bestaan er grote structurele verschillen tussen de twee transporters.
Bovendien transporteren ze cholesterol naar verschillende lipoproteïnen (rijpe HDLs voor SR-
BI, voorlopers van HDL voor ABCA1) en kan ABCA1 geen selectieve opname mediëeren.
Hoewel men zou denken dat dan ook de mechanismen van cholesteroltransport van SR-BI en
ABCA1 verschillend zouden zijn, lijkt het tegenovergestelde waar te zijn. Het is gebleken dat
een van de SR-BI inhibitors, BLT-4, in staat is om cholesteroltransport door de ABCA1
transporter te blokkeren. We hebben ook aangetoond dat een remmer van ABCA1, genaamd
glyburide, ook SR-BI gemediëerde cholesteroltransport kan blokkeren. Dit heeft geleid tot de
hypothese dat cholesterol transport door SR-BI gemoduleerd word door een (onbekende) ABC
transporter. Er zijn achtenveertig verschillende ABC-transporters bekend en een aantal is in staat
om ofwel cholesterol te transporteren dan wel een effect uit te oefenen op de cellulaire of
organismale cholesterolbalans. Deze hypothese kan in principe getest worden met bepaalde
genetische methoden die ons in staat stellen om doelbewust specifieke ABC-genen uit te
schakelen in de cel en vervolgens te kijken of dit het cholesteroltransport door SR-BI beïnvloedt.
Chemical genetic screening van intracellulair transport
In Hoofdstuk V van het proefschrift wordt chemical genetics gebruikt om intracellulair
(‘binnen in de cel’) transport  te bestuderen. Cellen in ons lichaam communiceren door
uitscheiding van signaalmoleculen, die gebonden worden door receptoren aan het oppervlakte
van andere cellen (in sommige gevallen kan dit ook gebeuren door de cel die het
signaalmolecuul uitscheid). Deze interactie resulteert in een passende reactie, een verandering in
het gedrag van de cel. Het is dus van groot belang dat de cel nauwkeurig reguleert hóe het
reageert op signaalmoleculen omdat een verkeerde of niet goed gedoseerde reactie schadelijk kan
zijn voor de cel zelf, of voor andere cellen of organen van het organisme.
Cellen gebruiken ook (andere) receptoren om nutriënten en bouwstoffen op te nemen
vanuit hun omgeving, zoals daar is het bloed. Wederom moet dit goed gecontroleerd worden
omdat een te grote opname van bijvoorbeeld cholesterol, een bouwstof, schadelijk kan zijn
getuige de al eerder beschreven ontwikkeling van bepaalde hart- en vaatziekten.
Receptoren, signaalmoleculen, nutriënten, (voorlopers van) lipoproteïnen en vele andere
moleculen worden binnen in de cel gemaakt in speciale ‘fabriekjes’. Om deze vervolgens naar de
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het celoppervlak te brengen, dan wel uit te scheiden, heeft de cel diverse intracellulaire
transportroutes tot zijn beschikking, te vergelijken met ‘autobanen door de cel’. Dit
transportproces heet exocytose, ofwel buitenwaards transport. Vergelijkbare transportroutes
worden ook gebruikt om receptoren en eventueel gebonden moleculen (lipoproteïnen,
signaalmoleculen etc.) van het celoppervlak te verwijderen en naar binnen te vervoeren
(endocytose of binnenwaards transport). Door regulatie van transportroutes kan de cel
nauwkeurig bepalen hoeveel signaalmoleculen, nutriënten en lipoproteïnen uit worden
gescheiden en hoeveel receptoren aan het oppervlak worden gebracht, of in het inwendige
worden opgenomen (eventueel met gebonden signaalmoleculen, nutriënten of lipoproteïnen).
Regulatie van transportroutes draagt dus voor een belangrijk deel er aan bij dat de cel zich op de
juiste wijze gedraagt, correct zijn functie uitoefent en de juiste hoeveelheid voedings- en
bouwstoffen tot zich neemt.
Hoewel er grote verschillen zijn tussen  de mechanismen van endocytose en exocytose,
zijn er wel degelijk ook overeenkomsten. Zo zijn er genproducten die een belangrijke rol spelen
bij de regulatie van beide transportroutes. Met behulp van chemical genetics worden in
hoofdstuk V van dit proefschrift genproducten gekarakteriseerd die betrokken zijn bij zowel
endocytose als exocytose. Het primaire doel van dit onderzoek is een beter inzicht te verschaffen
in intracellulaire transportroutes. Het Kirchhausen Laboratorium op Harvard Medical School
heeft in een chemical genetic screen (een andere screen dan beschreven voor SR-BI) een aantal
compounds gevonden die exocytose remmen. We hebben gevonden dat behandeling van cellen
met één van deze compounds ook kan leiden tot blokkade van endocytose. Dit heeft geleid tot de
ontdekking van een nieuwe groep van remmers van de Vacuolar-ATPase protonpomp, oftewel
V-ATPase, die gekenmerkt word door een bepaalde chemische groep genaamd sulfonamide. Het
blijkt dat het blokkeren van deze V-ATPase leidt tot een verhoging van de zuurgraad (de pH) van
organellen
3
 die betrokken zijn bij ofwel exocytose dan wel endocytose. In het algemeen kunnen
organellen alleen hun functie uitoefenen indien ze de juiste zuurgraad handhaven (pH
homeostasis). De V-ATPase speelt hierin een belangrijke rol, omdat het ervoor zorgt dat de juiste
hoeveelheid zure protonen in de organellen wordt gepompt. De sulfonamides remmen dit
pompen van protonen. Hierdoor worden de organellen minder zuur, hetgeen resulteert in een
blokkade van zowel endocytose als exocytose. De uitgevoerde experimenten bevestigen de
belangrijke rol die de V-ATPase en pH homeostasis spelen in de regulatie van intracellulaire
transportroutes.
Er waren al compounds (macrolide antibiotica) bekend die in staat zijn de V-ATPase te
blokkeren, maar deze doen dat op een andere wijze. De verwachting is dus dat het gebruik van
de sulfonamides zal leiden tot een groter inzicht in de werking van V-ATPase protonpompen en
hun rol in de regulatie van intracellulaire transportroutes en pH homeostasis.
Er word gedacht dat macrolide antibiotica gebruikt zouden kunnen worden als medicijn
tegen tumoren. Vele tumoren hebben de V-ATPase aan het celoppervlak om een schadelijke
overmaat aan intracellulaire zure afbraakproducten (protonen) kwijt te raken die onder andere
gevormd worden als gevolg van het snelle metabolisme van de snelgroeiende tumoren. Een
voorspelling is dat de sulfonamides de protonpomp van de tumor zouden kunnen blokkeren,
                                                 
3
 Zoals ons lichaam is opgebouwd uit organen die ieder een specifieke functie hebben, zo zijn onze cellen ook
opgebouwd uit diverse onderdelen, de organellen. Deze organellen hebben elk een specifieke taak, zoals het
genereren van energie, het bewaren van genetische informatie of het uitscheiden van signaalmoleculen,
lipoproteïnen en vele andere moleculen.
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waardoor deze de overtollige protonen niet kwijt kan en dus niet (goed) in staat is te om
overleven. Het is dus niet ondenkbeeldig dat in de toekomst sulfonamides, of verwante
chemische moleculen, een rol kunnen vervullen in de ontwikkeling van nieuwe medicijnen die
gebruikt kunnen worden tegen tumoren.
Conclusie
De doelstelling van dit proefschrift was om inzicht te verschaffen in twee verschillende
aspecten van cellulair transport. Er is gebruik gemaakt van een nieuwe experimentele
benadering, chemical genetics, om nieuwe chemische moleculen te identificeren die gebruikt
kunnen worden om celbiologie te bestuderen op een wijze die niet met genetische methoden
mogelijk is.
In het eerste gedeelte van het proefschrift werd bestudeerd hoe cellen hun
cholesterolbalans kunnen bewaren via de SR-BI gemediëerde selectieve opname en export van
cholesterol van en naar lipoproteïnen. Zowel de lipoproteïnen als de SR-BI transporter zijn van
uitermate groot belang in onze defensie tegen hart- en vaatziekten. Deze studie heeft geleid tot
nieuwe inzichten in de mechanismen van SR-BI gemediëerde selectieve opname,
cholesterolexport en binding van lipoproteïnen aan de receptor. Verder onderzoek heeft geleid
tot de hypothese dat een ABC-transporter een rol zou kunnen spelen bij SR-BI gemediëert
cholesteroltransport. Tenslottte hebben experimenten aangetoond dat cholesteroltransport door
SR-BI plaatsvind aan het celoppervlakte, en niet binnen in de cel.
Het tweede gedeelte van dit proefschrift betreft een moleculaire karakterisatie van de
overeenkomsten tussen cellulaire endocytose en -exocytose, met als doel om een groter inzicht te
ontwikkelen in intracellulaire transportmechanismen. We hebben een nieuwe groep van
sulfonamide remmers ontdekt die de V-ATPase protonpomp blokkeren, waardoor de zuurgraad
van een aantal organellen die betrokken zijn bij intracellulair transport wordt verhoogd. Dit leidt
tot een blokkade van zowel endocytose als exocytose. Deze sulfonamides hebben een potentiële
toepassing in de strijd tegen bepaalde tumoren.
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